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Abstract
The development and evaluation of a gamma-ray imaging system for dosimetry of Molecular
Radiotherapy (MRT) is presented. MRT is a cancer treatment that aims to deliver high ra-
diation doses to targeted tumour or disease sites, with minimal dose to surrounding healthy
tissue. This is achieved through the administration of radiopharmaceuticals, typically with
a fixed activity or adjusted for patient weight or body surface area. These activities are of-
ten several gigabecquerels (GBq). The administered radionuclide decays via the emission of
charged particles which damage the cancerous or diseased cells, ideally alongside gamma rays
that can be used to image the distribution of the radiopharmaceutical. The absorbed dose
in regions of interest can then be calculated by extracting activity from these images. How-
ever, the energy resolution, spatial resolution and count rate performance of current clinical
gamma-ray imaging systems result in inaccurate activity calculations. The Dosimetric Imag-
ing with Cadmium Zinc Telluride (DEPICT) project aims to overcome these performance
limitations through the development of an optimised gamma camera system, configured with
a 3D printed tungsten collimator and Cadmium Zinc Telluride (CZT) detectors. This thesis
focuses on the optimisation of the DEPICT system for 131I, which is used for MRT treatment
of the thyroid. This will provide improved verification of these treatments and information
that allows subsequent personalisation of the otherwise generic treatment plans. A pixelated
CZT detector was selected because of its excellent energy resolution and spatial resolution.
The DEPICT CZT detector was characterised and an experimental study undertaken to opti-
mise the energy resolution and throughput of gamma rays. The optimum energy resolution at
364.5 keV was shown to be 2.94% for a maximum count rate of 160 kcps. A 3D printed high-
energy parallel-hole tungsten collimator suitable for imaging the 364.5 keV gamma rays from
131I was developed. Experimental data were acquired with medical phantoms to determine
the imaging capability DEPICT, as accurate area delineation is necessary for measurements
of activity within a region of interest. The spatial resolution of DEPICT was shown to be
ii
2 mm, which is superior to 13.4 mm for clinical systems that are configured with high-energy
collimators. Methodology for quantifying the sizes of artefacts in an image are described.
The experimental performance of DEPICT for imaging 131I distributed in a thyroid phantom
was shown to surpass that of a clinical Siemens gamma camera. It was possible to identify
regions of interest in the DEPICT thyroid phantom image that were not visible in the clinical
image, due to the improved spatial and energy resolution. Quantification of the activity in
vials containing 131I has been achieved using DEPICT to within 9% of the known activity for
data acquired with 1 vial and 3% for data with 3 vials. Distributed sources have also been vi-
sualised in 3D using tomography, to show the capability of accurately reconstructing volumes
of interest. The future of MRT relies on the development of innovative radiopharmaceuticals.
The radionuclides 177Lu, 111In, 223Ra and 227Th are being increasingly considered in MRT
and have been investigated in this thesis through acquisition of experimental gamma-ray
spectra. Monte-Carlo simulations have been developed so that modifications to the DEPICT
system can be recommended for imaging radionuclides other than 131I.
iii
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Chapter 1
Introduction
Molecular Radiotherapy (MRT) is a cancer treatment technique that involves the internal
administration of radiopharmaceuticals to deliver high absorbed doses to targeted tumour
tissue, whilst minimising the dose to surrounding healthy tissue. Although MRT has been
used clinically for around 75 years, there are no standardised dosimetry practises to calculate
the absorbed dose delivered to tumour or benign disease targets, or the surrounding organs
at risk from the administered activity. Current MRT treatment plans are undesirably generic
as the administered activity is often fixed for a given procedure or scaled according to the
weight or body surface area of the patient [1]. However, the uptake and retention of the MRT
therapeutic agents and hence the absorbed dose can vary by up to two orders of magnitude
between patients [2, 3], due to the wide range of biokinetics and disease status. The outcome
of the treatment is therefore somewhat uncertain and can lead to unnecessary expense.
The archetypal example of MRT is the radioiodine (131I) treatment of thyroid cancer and
diseases. The efficacy of MRT is evaluated through knowledge of absorbed dose and this is
ideally calculated through accurate real-time quantitative imaging of the 131I distribution in
the patient. Single Photon Emission Computed Tomography (SPECT) is the modality that
is used to image the 364.5 keV gamma rays emitted by 131I. Uncertainties arise however, as
clinical diagnostic SPECT systems are not optimised for imaging the high activities adminis-
tered in 131I MRT (typically 1.1 – 7.4 GBq) and therefore suffer from count rate saturation.
A further inadequacy of these systems for dosimetry is the image quality arising from poor
spatial and energy resolution of the collimated detector system, and from the scattering of the
gamma rays as they leave the body of the patient or interact within the collimator. Therefore,
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a custom gamma-ray imaging system has been developed to overcome these limitations. The
detector system discussed in this thesis is based on Cadmium Zinc Telluride (CZT) room
temperature semiconductor detectors with Application Specific Integrated Circuit (ASIC)
readout. The good energy resolution of CZT will facilitate excellent scatter correction and
the detector pixelation will allow high count rate operation and improved spatial resolution
compared to current clinical gamma cameras used in SPECT. The detector is coupled to
a high-resolution, low-efficiency parallel-hole collimator that is optimised for imaging the
high-energy gamma rays from 131I. This custom-designed collimator will improve count rate
saturation and overcome some of the factors that degrade image quality. The collimated
detector system will be used to accurately calculate cumulated activity and absorbed dose
estimations. Development of this optimised system will tend towards a future of personalised
patient treatment based on absorbed dose measurements, and potentially make MRT a more
safe and effective treatment modality. The benefit to society will be improved treatment ef-
ficacy, increased patient throughput and vital funds being saved within the National Health
Service.
There are currently a small number of CZT-based commercial SPECT products globally; the
GE Healthcare Discovery NM 530C [4] and the Spectrum Dynamics Medical D-SPECTR© [5]
for cardiac imaging, the mobile declipseR© SPECT imaging probe by SurgicEye [6], the CMR
Naviscan LumaGEM molecular breast imaging system [7] and the whole body Molecular
Dynamics Valiance X12 [8]. All of these systems are optimised for diagnostic imaging of low
energy gamma rays such as 99mTc (140.5 keV) and 123I (159 keV), and are therefore not
suitable for 131I imaging. There is currently no dedicated system for dosimetry in MRT.
1.1 The DEPICT Project
The Dosimetric Imaging with Cadmium Zinc Telluride (DEPICT) project is a collaboration
between The University of Liverpool, The Royal Marsden Hospital, The Royal Liverpool and
Broadgreen University Hospital and the commercial partner Kromek. This collaboration al-
lows an multidisciplinary team of physicists, clinical medical physicists and engineers to work
together with the aim of developing a gamma-ray imaging system that will facilitate quan-
titative dosimetry in MRT. There are four main interlinking work packages in the DEPICT
project:
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• Optimisation of a CZT detector for 131I MRT applications.
• Development of a custom-designed high-energy collimator for imaging 131I.
• Evaluation of the system using medical phantoms.
• Implementation of appropriate SPECT reconstruction algorithms to visualise radionu-
clide distributions in 3-dimensions and obtain quantitative activity information for dose
calculations.
1.2 Thesis Overview
An in-depth discussion on the Monte-Carlo modelling for developing the custom-designed
collimator is outside the scope of this thesis. The main objectives of the work of this thesis
were to:
• Optimise and characterise a CZT detector for MRT applications.
• Obtain planar images with the CZT detector and custom-designed high-energy parallel-
hole collimator with high activities of 131I.
• Extract quantitative activity information from planar images.
• Perform tomographic reconstruction to obtain 3-dimensional (3D) activity distribution.
• Evaluate the feasibility of using the detector system with radionuclides other than 131I.
Chapter 2 details a literature review of MRT treatment and the process of performing dosime-
try for MRT. Chapter 3 describes the principles of gamma-ray interactions with matter, gives
an overview of SPECT, outlines the fundamentals of CZT semiconductor detectors and con-
cludes by discussing the factors affecting activity quantification. Chapter 4 describes the
methodology used to characterise and optimise the CZT detector for MRT applications, and
Chapter 5 investigates the imaging capability of the optimised CZT detector with a variety
of phantoms filled with 131I. The methods to perform planar activity quantification and 3D
reconstruction are discussed in Chapter 6. Finally, the feasibility of using the CZT detector
system for treatments with radionuclides other than radioiodine is explored in Chapter 7.
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Molecular Radiotherapy
Cancer is a disease caused by the uncontrolled division of abnormal cells that have the ability
to invade surrounding tissues, form a malignant primary tumour and spread to other organs
(metastasise). There are several treatment options for cancer including surgery, chemother-
apy, radiotherapy, immunotherapy and hormone therapy, which can be used for curative,
palliative or adjuvant purposes. Although a combination of the available therapies is usually
employed, surgery is often the first treatment option if a tumour can be removed from the
body. Radiotherapy and chemotherapy may be used separately or together to shrink the tu-
mour before surgery, or used post-operatively to treat residual or metastasised tumour cells.
Chemotherapy uses anti-cancer drugs to kill cancer cells, whereas radiotherapy delivers high
doses of radiation to the tumour volume. Both aim to stop or slow the proliferation of cancer
cells.
There are two ways to deliver radiotherapy; external and internal, as highlighted in Figure
2.1. External beam radiotherapy (EBRT) is the most common method of delivering radia-
tion to a tumour, and involves directing a beam of high-energy photons (gamma or x-rays)
or charged particles (electrons or protons) at the area to be treated. In EBRT, the source
of radiation is generally a linear accelerator and the shape of the beam can be dynamically
adjusted to optimise the dose to the tumour volume. Brachytherapy and MRT are two types
of internal radiotherapy. MRT is also known as radionuclide therapy or targeted radionuclide
therapy. Brachytherapy involves the administration of sealed radioactive sources, whereas
MRT utilises unsealed sources to impart a radiation dose. Both EBRT and MRT aim to
deliver a high radiation dose to tumour tissue whilst minimising the dose to the surrounding
healthy tissue.
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Chemotherapy
Cancer treatment
External beam 
radiotherapy
Brachytherapy 
(sealed source)
Molecular radiotherapy 
(unsealed source)
External Internal
Radiotherapy
Figure 2.1: Diagram highlighting common cancer treatment modalities.
MRT is a systemic therapy that involves the internal administration of unsealed radiopharma-
ceuticals, either orally or intravenously. The administration of these radiopharmaceuticals
is minimally invasive and the duration of treatment is shorter than that of chemotherapy
[9]. The radiopharmaceuticals incorporate a radioactive tracer atom, with appropriate phys-
ical characteristics to impart a radiation dose, coupled to a larger pharmaceutically-active
molecule that has a relative specificity for tumour tissue, for delivery to the target tissue
[10]. As it is a systemic treatment, the radioactive material can travel throughout the body
to reach the primary tumour site and distant metastases [11]. MRT is advantageous in the
treatment of systemic malignancy such as bone metastases, as whole body irradiation using
EBRT is impossible. MRT has therefore become one of the most preferred types of cancer
treatment for specific clinical applications due to its selective ability.
2.1 Radionuclides in Molecular Radiotherapy
There are many radiopharmaceuticals used in MRT, to address a variety of clinical needs.
The radionuclide coupled to the pharmaceutical will have been selected because it possesses
the necessary physical properties for use in therapeutic nuclear medicine. The most important
property for a therapeutic radionuclide is to decay via particle emission, therefore radionu-
clides that emit charged particles such as alpha (α) or beta (β−) particles are used in MRT.
These decay processes are discussed in more detail in Sections 2.1.1 and 2.1.2. The emission
of charged particles with a high linear energy transfer (LET) that deliver localised cytotoxic
ionising radiation can lead to double strand breaks in the DNA. This irreversible damage in-
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hibits further proliferation of these tumour cells. α particles have an LET of ∼100 keV/µm,
with ∼0.2 keV/µm for β− particles [12]. A unique feature of these radionuclides is that they
can exert a ‘bystander’ effect, unlike the drugs and toxins administered in chemotherapy
which kill only the directly targeted cells. Radiation-induced bystander effects are defined as
biological responses occurring in cells that are not traversed by an ionizing radiation track
i.e. the responses take place in unirradiated cells. Therefore, adjacent tumour cells can po-
tentially be destroyed even if they are not targeted by the radiopharmaceutical [13].
α and β− particles have different physical and nuclear properties so a radionuclide can be
chosen with appropriate characteristics to match the tumour type. For example, the range of
α particles in tissue is about 50 – 100 µm, compared to a few mm travelled by a β− particle
[14]. Therefore, the size of the tumour or tissue mass being treated can be matched with a
radionuclide that emits charged particles with the appropriate effective radiation range. The
short range of these charged particles means that high activities can be administered that
concentrate in small volumes, reducing the radiation dose to surrounding healthy tissue.
2.1.1 Alpha Decay
The spontaneous emission of a helium ion from a nucleus is known as α decay, with the
parent nucleus losing both mass and charge in order to become stable. The decay process is
illustrated in Figure 2.2 and expressed as
A
ZX → A−4Z−2Y + 42α, (2.1)
where A is the atomic mass number, and X and Y are the parent and daughter nuclei. As
the atomic number Z has changed, the parent and daughter nuclei are different chemical
elements. α particles are emitted with discrete energies that range between 4 and 10 MeV
[15] and provide a highly targeted treatment due to their high LET and short range. They
are more likely to cause double-strand breaks in the DNA of cancer cells than other types
of radiation and double-strand breaks are effective at causing cell death as they are more
resistant to normal repair [16].
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Figure 2.2: Schematic illustrating the emission of a 42He nucleus (α particle).
2.1.2 Beta Decay
The emission of β− particles (fast energetic electrons) from unstable neutron-rich radionu-
clides causes damage to cancer cells. In β− decay, a neutron within the unstable nucleus
transforms into a proton and a β− particle and an electron antineutrino (ν¯e) are emitted.
This is expressed in Equation 2.2 and illustrated in Figure 2.3.
A
ZX → AZ+1Y + β− + ν¯e (2.2)
The emission of a β− particle results in the atomic number Z increasing by one, while
the atomic mass number A remains the same. The energy of the emitted β− particle is
not discrete, but a continuum. Energy conservation is maintained by the emission of the
antineutrino ν¯e. Antineutrinos are elementary particles that have an extremely small mass,
are uncharged and only weakly interact with matter. Thus, only the β− particle causes any
significant ionisation. The maximum energy (or end-point energy of the β−) is the energy
expected according to the mass-energy relationship and is typically a few MeV. The average
β− energy is only about a third of this.
β  decay Electron (β
-) Antineutrino (νe)
X Y
A
Z
A
Z+1
Figure 2.3: β− decay schematic illustrating the emission of an energetic electron (β− particle) and an
electron antineutrino (ν¯e).
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2.1.3 Gamma Decay
In addition to charged particle decay, an excited nucleus can also decay via the emission
of gamma (γ) radiation. In γ decay, the radionuclide loses energy by transitioning from an
excited state to a lower energy state in the same nucleus. The energy difference between the
initial and final states may appear in the form of an uncharged γ ray, as illustrated in Figure
2.4. As the atomic mass number A remains the same, the emission of a γ ray does not change
the element:
A
ZX
∗ → AZX + γ, (2.3)
where X∗ is an excited state of nucleus X. The energy of the emitted γ ray is discrete and
characteristic of the excited nucleus. It can vary from a few eV to around 8 MeV. γ rays
are only weakly ionising but highly penetrating when compared to α and β particles. They
therefore do not cause significant damage to cancer cells, but if emitted from the body can
be imaged.
γ decay
X* X γ
Figure 2.4: Schematic illustrating the emission of a γ ray from a nucleus in an excited state, X∗.
2.1.4 Further Criteria for Therapeutic Radionuclide Selection
Alongside undergoing charged particle decay, other properties that determine the suitability
of a radionuclide for MRT include:
• Radionuclide half-life
The period of time required for the activity level of a radionuclide to reduce to half
its initial value is known as the physical half-life t1/2phys. The half-life of the chosen
radionuclide should be long enough such that a sufficient radiation dose is delivered to
the tumour before physical decay and biological excretion. However, the half-life should
also be short enough that the activity has decayed to minimal levels to allow the patient
to be discharged from hospital within a reasonable time. The type of tumour, method
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of administration, uptake mechanism and time for transportation from the production
site should be taken into account. A t1/2phys of around 1 – 14 days is deemed to be
optimum [12].
• Radionuclide decay products
The daughter radionuclide decay product should ideally be stable, or decay with low-
energy emissions and have a short half-life to avoid the patient receiving an unnecessary
radiation dose.
• Radionuclide purity
Radionuclides used for MRT should have a high grade of chemical purity and should
either be carrier-free (every atom is that of the chosen radionuclide/undiluted with a
stable isotope carrier) or with a very high specific activity (activity per unit mass).
• Gamma emissions
The emission of γ radiation, alongside charged particles, provides the ability to track the
biodistribution of activity in the body with a gamma camera for personalised dosimetry
calculations. This will be discussed in further detail in Section 2.1.6.
• Economic factors
Large-scale, cost-effective production feasibility will decide on the success of a radionu-
clide for therapy.
• Chemical Properties
The radionuclide must be non-toxic and when coupled to an appropriate pharmaceuti-
cal, stable in vivo.
2.1.5 Suitable Radionuclides for MRT
Table 2.1 highlights radionuclides deemed suitable for MRT, given the previous requirements.
This table is not exhaustive but lists the radionuclides that are frequently detailed in liter-
ature. It illustrates the type of decay, the radionuclide, the energy of the principal charged
particle emitted (end-point energy if β− emitter), the energy of the principal γ ray (if any
emitted) and the physical half-life t1/2phys. The radionuclides highlighted in bold are approved
by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK equivalent
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of the Food and Drug Administration (FDA), or the European Medicines Agency (EMA)
[17] and can therefore be used clinically in the UK. 223Ra dichloride (trade name Xofigo),
89Sr chloride (trade name Metastron) and 153Sm (trade name Quadramet) are all used as
a palliative treatment for the relief of cancer-induced bone pain and 90Y treats liver can-
cer. For the treatment of thyroid cancer and benign thyroid diseases, 131I is administered
as sodium iodide 131I-NaI. 131I can also be coupled to the tracer metaiodobenzylguanidine
(mIBG) for the management of neuroendocrine tumours (NETs), particularly neuroblastoma
[18]. The radionuclide 177Lu (trade name Lutathera) was approved by the EMA in 2017 and
is also used in the treatment of NETs [19]. A multicentre clinical trial assessing the use of
177Lu for prostate cancer is currently ongoing, with an estimated completion date of 2020 [20].
2.1.6 Theranostics
In many β− emitting MRT radionuclides, the β− decay populates an excited state of the
daughter nucleus which leads to the emission of de-excitation γ rays alongside the β− particles.
If they escape the body, the emitted γ rays can be detected by a gamma camera to track
the biodistribution of radioactivity in the body and perform dosimetry. This decay chain
has been utilised in the recent concept of ‘theranostics’ (also known as ‘theragnostics’) [24].
Theranostics refers to an integrated approach to therapy and diagnosis using appropriate
combinations of radionuclides and molecular targeting pharmaceuticals [25]. There are two
approaches to theranostics. In the first method, a radionuclide is selected that simultaneously
emits charged particles for therapy and γ rays for imaging such as 131I, 153Sm and 177Lu, and
allows real-time monitoring of the treatment. The second method involves administering pairs
of radionuclides, in which one is a γ-ray or positron emitter for imaging with SPECT or PET,
and the other is a therapeutic particle emitter. An example would be the imaging/therapeutic
pair of 111In/90Y [26], where each nuclide is bound to the DOTATATE pharmaceutical [27]
and administered simultaneously. The radionuclide 131I is the theranostic of interest in this
thesis.
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CHAPTER 2. Molecular Radiotherapy
2.2 Radioiodine Thyroid Treatment
The archetypal example of MRT is the radioiodine, 131I, treatment of malignant and benign
thyroid diseases and this is the radionuclide of interest for the DEPICT project. Since the
1940s [28], it has been used extensively for treatment of thyroid diseases. Out of the 37
known isotopes of iodine, four are used as tracers and therapeutic agents in medicine. These
are 123I, 124I, 125I, and 131I, with the two most commonly used isotopes being 123I and 131I.
123I has a half-life t1/2phys of 13.2 hours and decays via electron capture to
123Te, emitting γ
radiation (159 keV). This makes it a suitable isotope for diagnostic imaging as the γ ray is
of ideal energy to be detected by a gamma camera, as discussed in Section 3.1. It causes less
internal damage to the patient as a lower radiation dose is received than if the isotope also
emitted particulate radiation. 131I has a physical half-life t1/2phys of 8.04 days and decays
via both β− and γ-decay modes. Therefore, it is suitable for use as a theranostic for therapy
and imaging. The primary emissions of 131I highlighted in red in Figure 2.5a are β− particles
with an end-point energy of 606.3 keV (Pβ = 89.9%), average energy of 192.6 keV and mean
path length of ∼1 mm in soft tissue and 364.5 keV γ rays (Pγ = 81.7%). The main decay
product of 131I is stable 131Xe. The continuous beta spectrum is shown in Figure 2.5b.
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Figure 2.5: (a) 131I decay scheme with the primary β− and γ emissions highlighted in red. Only the
major transitions are shown. The full decay scheme is shown in Appendix A.1 and (b) the continuous
β particle energy spectrum for 131I decay [29].
In MRT practice across 26 countries in Europe in 2016, approximately 72% of all therapies
involved 131I [30]. There are a broad range of administered 131I activities, but many agree
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on the limits [31, 32, 33]. Following thyroidectomy (removal of all, or part of the thyroid
gland), activities of 131I in the range 1.1 – 3.7 GBq (30 – 100 mCi) are prescribed for post-
operative ablation of thyroid bed remnants. In patients with thyroid cancer and lymph node
metastases, generally higher activities of up to 5.5 GBq (150 mCi) are administered, and this
increases to 7.4 GBq (200 mCi) for the treatment of distant metastases.
2.3 Dosimetry of Molecular Radiotherapy
Dosimetry is the process of relating the administered activity to the absorbed radiation dose
of an organ or whole body. In EBRT, it is possible to precisely calculate the absorbed dose
from the point at which the radiation enters the body to the tumour target. MRT however,
relies on the accumulation of radiopharmaceuticals in the target tissue, that deliver a low and
continuously decreasing dose. This accumulation depends on the physiological mechanisms
that govern the distribution of the radiopharmaceutical in the body [34]. The calculation of
radiation energy deposited by radionuclides in the body during MRT is known as internal
radiation dosimetry (IRD). Performing IRD would ideally follow a number of simplified steps:
• Quantitative imaging of the patient at multiple times post administration of the
radiopharmaceutical.
• Modelling the distribution of activity within the patient over time from these images.
• Converting this cumulative activity in different volumes into an absorbed dose.
2.3.1 The MIRD Schema
The MIRD Schema, proposed by the Medical Internal Radiation Dose (MIRD) Committee of
the Society of Nuclear Medicine, is the most widely used methodology for providing guidance
on how to calculate the mean absorbed dose from distributed sources of radioactivity in
MRT [35, 36]. The mean absorbed dose is often used to quantify the efficacy of a therapeutic
procedure. The MIRD Schema assumes the body is composed of source s and target t organs.
Source organs are organs in which the radiopharmaceutical is localised, whereas target organs
are those that are irradiated by a source organ. A proportion of the emitted energy will be
absorbed in other organs, and some will escape the body completely. The absorbed dose is
defined as the energy absorbed per unit mass and is calculated through the knowledge of the
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CHAPTER 2. Molecular Radiotherapy
cumulated source activity A˜s (Bq·sec or µCi·hr) in organ s over the time interval of interest
t1 to t2 by
A˜s =
∫ t2
t1
As(t)dt. (2.4)
The mean absorbed dose D¯(t← s) (in Gy or Rad) to a target organ t from a source organ s
is then defined by the MIRD schema as,
D¯(t← s) = A˜s
mt
∑
i
∆iφi(t← s)
= A˜s
∑
i
∆iΦi(t← s),
(2.5)
where mt is the mass of the target organ (kg) and ∆i (Gy·kg/Bq·s) is the equilibrium absorbed
dose constant, which is the mean energy emitted per nuclear transition for radiation type
i. The absorbed fraction and the specific absorbed fraction of energy for target organ t for
particles i emitted by source organ s are represented by φ(t← s) and Φ(t← s) respectively.
For a given radionuclide and specific source-target organ combination in a mathematical
model, the quantity
∑
i ∆iΦi(t ← s) is constant. The MIRD Schema simplifies these values
and refers to them as S factors, defined as the mean absorbed dose in the target per unit
cumulated activity (Gy/Bq · sec or rad/µCi · hr),
S(t← s) =
∑
i
∆iΦi(t← s). (2.6)
This S factor allows simplification of the mean absorbed dose formula, Equation 2.5, to
D¯(t← s) = A˜s S(t← s). (2.7)
There are generally a number of source organs, therefore the total dose to the target organ
is the sum of the absorbed doses from all source organs. The estimation of mean absorbed
dose is thus dependent upon two types of information: time-dependent biokinetic factors
(incorporated within A˜) and time-independent physical factors (represented within S ) [37].
The biokinetic factors incorporate characteristics of uptake and retention of activity in the
regions of interest, and include consideration of the physical and biological decay of the
radiopharmaceutical. The physical S factor considers the types and energies of the radiations
emitted, size and shape of the source and target organs, and the composition of the absorbing
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and intervening media. Tables of S factors are available for many situations of interest in
nuclear medicine [38].
2.3.2 Limitations in Molecular Radiotherapy Dosimetry
There are three main limitations in MRT dosimetry. The first limitation is the MIRD Schema
assumes a homogeneous distribution of radioactivity in the target tissue, whereas in reality
there is a non-uniform activity distribution due to variations in pharmacokinetics (delivery,
uptake, site-specific binding and clearance) [39]. Inhomogeneous radiation distributions may
also arise as the tumour can shrink during treatment, increasing the complexity of dosimetry
in MRT. In addition, the MIRD specific absorbed fractions [40] assume a monoenergetic γ-ray
source, which is not the reality for many radionuclides. 131I is not a monoenergetic source
as it emits γ rays with energies 80.2 keV (2.6%), 284.3 keV (6.1%), 364.5 keV (81.7%) and
636.9 (7.2%), although not all of these are shown on the simplified decay scheme in Figure
2.5b.
The second limitation is the use of generic S factors. A MIRD total-body phantom was
developed for Monte-Carlo calculations of specific absorbed fractions for photons of 12 ener-
gies from 10 keV to 4 MeV [40]. The MIRD phantom was designed to represent a reference
adult and consisted of three principal sections: an elliptical cylinder representing the arms,
torso and hips; two truncated circular cones representing the legs and feet, and an elliptical
cylinder representing the head and neck, with an overall mass of approximately 70 kg. The
sizes and shapes of the internal volumes resembling the organs and tissues of an average per-
son are defined by mathematical equations. Monte-Carlo methods are subsequently used to
determine absorbed fractions because of the complicated geometric configurations that must
be considered. Problems with S factors arise when dosimetry needs to be performed on a
patient not resembling the ‘reference man’ phantom. S factors that are based on a standard
anthropomorphic phantom make assumptions about anatomy (standard weights, sizes and
distance between source and target organs) and radiopharmaceutical distribution (uniformity
of source and uptake) that aren’t necessarily valid in individual patients. Although more so-
phisticated and anatomically accurate phantoms have been developed over the years [41],
there is an obvious need for patient specific S factors as the space between source and target
organs, and size and weight of organs will differ between patients.
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Finally, limitations arise in dosimetry calculation as there are uncertainties in measuring
radioactivity over time in a patient. As shown in Equation 2.4, the first step for calculating
the mean absorbed dose is determining the cumulated source activity. This is determined by
imaging the patient at certain time points following administration of the radiopharmaceutical
and converting image counts into activity, to calculate a time-activity curve (TAC). The TAC
is described by
A˜s = A0
∫ ∞
0
e
− ln(2)t
t1/2eff dt, (2.8)
where t1/2eff is the effective half-life. The effective half-life t1/2eff is the period of time re-
quired for the radioactivity level to reduce to half the initial level, due to radioactive de-
cay (physical half-life t1/2phys) and biological elimination (biological half-life t1/2biol) where
1
t1/2eff
= 1t1/2phys
+ 1t1/2biol
. The effective half-life of 131I is approximately one week. The
cumulated activity is then given by integrating the TAC over a number of days. Figure
2.6a illustrates an ideal TAC showing the rapid uptake of the radiopharmaceutical and then
exponential decay due to the physical and biological effects. In reality, a TAC similar to
Figure 2.6b is obtained. Due to dead time in current gamma cameras, discussed in detail
in Section 3.4.4, there is often a limit placed on the earliest imaging time point of a day or
two post administration of gigabecquerels of activity. In addition, ideally a minimum of 5
points would be acquired for the TAC, however in reality only 2 or 3 images are acquired
with each patient. This limit on the earliest imaging point, along with only obtaining a few
measurements of the activity, makes extrapolation to the initial administered activity very
challenging. Often, straight lines are drawn across to both the y- and x-axes from the first
and last time points respectively, and the cumulative activity is then obtained from the area
created by these lines. This leads to large uncertainties in the calculation of cumulated source
activity.
It is therefore very evident that with such large uncertainties in both the values of A˜s and
S, that this will lead to errors in the value of absorbed dose D¯. Due to this lack of accurate
dosimetry protocols, current MRT treatment plans are undesirably generic, in which the ad-
ministered activity is often fixed for a given procedure or scaled according to the weight or
body surface area of the patient [1]. MRT is typically prescribed to patients on the basis of
16
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Figure 2.6: (a) Ideal time-activity curve and (b) an example time-activity curve from The Royal
Marsden Hospital where only three images were collected following the administration of the radio-
pharmaceutical.
the maximum activity of the therapeutic radiopharmaceutical that has been shown in clinical
trials to minimise the incidence of damage to critical normal tissues to an acceptable fraction
of the trial population (typically 5%). This implies the other 95% potentially could have
received a higher activity, and therefore a more effective treatment [42]. For the same initial
administered activity, the absorbed dose to the normal tissue has been found to vary by up
to an order of magnitude [43], and by up to two orders of magnitude between patients for
absorbed dose to the target tissue [2, 3] due to differences in uptake and retention of the
therapeutic agent. Therefore, treatments could be improved dramatically by measurement
of absorbed dose to the critical tissues on an individual patient basis. A recent EU directive
2013/59/EURATOM Article 56 also states, ‘For all medical exposure of patients for radio-
therapy purposes, exposures of target volumes shall be individually planned and their delivery
appropriately verified’. Personalised treatment planning and verification is clearly essential
and needs to replace these simplified MIRD internal dosimetry models, to produce better
and more reliable outcomes. MRT will then move from being largely a last-resort palliative
treatment, to a frontline cancer therapy.
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Nuclear Medicine
Since the discovery of x-rays by Wilhelm Ro¨ntgen in 1895 [44], electromagnetic radiation
has been used in medical imaging for non-invasive investigations of the internal structures of
the body. Nuclear medicine is a branch of medical imaging that involves the administration
of radioactive material for both diagnostic and therapeutic purposes. It differs from other
imaging modalities such as x-ray Computed Tomography (CT), as the physiological func-
tions of the body are investigated rather than the anatomical structure. Nuclear medicine
imaging modalities include Positron Emission Tomography (PET) and Single Photon Emis-
sion Computed Tomography (SPECT), which are used to visualise the 3D distribution of the
radioactive material in the body. Positron emitting radionuclides are administered in PET,
from which two annihilation photons are detected. For SPECT γ-ray emitting radionuclides
are utilised and this modality can therefore be used to image the γ rays emitted during 131I
MRT.
3.1 Single Photon Emission Computed Tomography
Modern SPECT systems are based on the gamma camera principle by Hal Anger [45] and
the main components are a collimator, scintillation crystals (typically thallium doped sodium
iodide NaI(Tl)) and photomultiplier tubes (PMTs), illustrated in Figure 3.1. γ rays emitted
from the body of a patient interact with the scintillation crystal, causing fluorescence and
the emission of visible light that is detected by the PMTs. The light is then converted into
electrical signals that are processed by readout electronics and sent to a computer to produce
an image. One of the basic problems suffered in 2D (or planar) gamma camera imaging is
that internal information can be lost due to overlying or underlying organs. 3D imaging is
18
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Collimator
Scintillation Crystal
Light Guide
Photomultipler Tubes
Electronics
Patient administered 
with γ-ray 
emitting radionuclide
Figure 3.1: Schematic diagram of γ rays emitted from the body of a patient. One γ ray passes through
the collimator to the detector and one is absorbed by the collimator.
required for accurate quantification of the 3D radionuclide distribution within the body, and
this is achieved by reconstructing 2D images (projections) collected at multiple angles around
the body. There are typically two gamma cameras mounted on a rotating gantry, reducing
the scan time over a single gamma camera by acquiring two images simulataneously. The
most common method of data acquisition is known as ‘step and shoot’, where images are
obtained at predefined angular positions over a 360◦ rotation around the patient. Typically,
120 projections are acquired at 3◦ increments with a total scan time of around 20 – 30
minutes [46]. 3D radionuclide distributions are then reconstructed from these 2D projections
and should accurately correspond to the activity distribution within the patient. SPECT
systems are optimised for imaging the low-energy radionuclide 99mTc, with its photopeak at
140.5 keV. 99mTc is the most commonly used radionuclide in medicine and provides diagnostic
information. NaI(Tl) scintillator detectors are most commonly used in SPECT as large crystal
sizes can be produced relatively inexpensively, giving good efficiency in the 50 – 250 keV range.
Typically, NaI(Tl) crystals are between 6.4 mm to 12.7 mm thick, with 9.5 mm thick crystals
suitable for imaging 99mTc.
19
CHAPTER 3. Nuclear Medicine
3.2 Gamma Ray Interactions with Matter
In order to image γ rays using SPECT, they must pass through a collimator and inter-
act within the radiation detectors positioned around the patient. γ rays are massless and
chargeless, and therefore transfer energy to charged electrons in the detection material dur-
ing ionisation or excitation to create a signal in the radiation detector. In spectroscopic
detectors, the electrical signal produced has an amplitude that is proportional to the energy
deposited in the detecting medium. There are three primary interaction mechanisms that a
γ ray can undergo; photoelectric absorption, Compton scattering and pair production. The
work in this thesis focuses on γ rays with energies of less than 400 keV and the detector
material of interest for the DEPICT project is CZT, which has an effective atomic number
Zeff ∼50. Photoelectric absorption and Compton scattering are therefore the only possible
interaction processes, as shown by the dotted grey diagonal lines in Figure 3.2. It can be
seen in Figure 3.2 by the red circle that Compton scatter interactions are slightly dominant
in this material for 364.5 keV 131I γ rays. Above approximately Z = 60, the photoelectric
effect dominates at 364.5 keV. The DEPICT collimator discussed in Section 5.1 is made of
tungsten. Tungsten has Z = 74 and it can be seen by the blue diamond in Figure 3.2 that
the photoelectric effect dominates at this atomic number with 364.5 keV 131I γ rays. This
effect is utilised by gamma camera collimators to preferentially absorb γ rays not travelling
in the desired direction and will be discussed in detail in Section 3.3.
Photoelectric absorption is the process in which a γ ray interacts with a bound atomic elec-
tron, transferring all of its energy to the electron as illustrated in Figure 3.3a. A photoelectron
e− is subsequently emitted from the atom with kinetic energy
Ee− = Eγ − Eb, (3.1)
where Eγ is the original γ-ray energy and Eb represents the binding energy of the photoelec-
tron in its original shell. This process leaves the atom in an ionised state with a vacancy in
one of its bound shells. Rearrangement of the electrons from other higher lying shells filling
the inner shell vacancy can cause the emission of one or more characteristic x-ray photons.
These x-rays are typically reabsorbed close to the original site, but can also be emitted from
the material.
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CZT 131I
Tungsten 131I
Figure 3.2: A plot showing the probability of a γ ray interacting via photoelectric absorption, Compton
scattering or pair production as a function of γ-ray energy (E = hv) and absorber atomic number,
Z [47]. Dotted grey lines highlight the interaction mechanisms of interest in this work. Although
pair production is included here, γ rays emitted from therapeutic radionuclides (Table 2.1) never
reach the minimum energy required (1022 keV) for pair production. The blue diamond highlights the
dominant interaction effect at the atomic number of tungsten (Z = 74) and the red circle highlights
the dominant effect for CZT (Zeff ∼50) for 131I 364.5 keV γ rays.
Compton scattering occurs when an incident γ ray is deflected by a weakly bound atomic
electron, transferring a fraction of its energy to the electron, shown in Figure 3.3b. The
equation that relates the incident γ-ray energy Eγ , scattering angle θ, and energy of the
scattered γ ray Eγ′ is
Eγ′ =
Eγ
1 +
Eγ
m0c2
(1− cos θ)
, (3.2)
where m0c
2 is the rest-mass energy of the electron (0.511 MeV). The γ ray cannot deposit all
of its energy during Compton scattering. The maximum energy is transferred to the electron
when the incident γ ray is scattered through an angle of 180◦, and for the 364.5 keV γ ray
from 131I, the maximum energy that can be transferred to an electron is 214.3 keV. The
probability of Compton scattering increases with electron density (number of electrons per
unit mass) and therefore increases linearly with atomic number Z.
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Figure 3.3: A schematic illustration of (a) photoelectric absorption and (b) Compton scattering.
3.3 Collimators
Collimators form the primary layer of the gamma camera and are essential for image for-
mation. In the absence of a collimator, no relationship can be formed between the position
at which a γ ray interacts within the detector and from where the γ ray was emitted from
within the patient. As γ rays are uncharged and cannot be focused, collimators operate via
the principle of absorptive collimation. This is the principle that γ rays not travelling in the
desired direction are absorbed by the collimator before reaching the detector, as shown in Fig-
ure 3.4a. Materials of high atomic number Z and high density ρ are required for the collimator
to increase the likelihood of absorbing γ rays, as in the energy range of interest in SPECT
(∼100 – 400 keV γ rays), photoelectric absorption increases with increasing Z, as shown in
Figure 3.2. Collimators are therefore typically made of lead (Z = 82, ρ = 11.34 g/cm3) or
tungsten (Z = 74, ρ = 19.24 g/cm3).
There are four basic collimator types used with a gamma camera: pinhole, parallel-hole,
diverging and converging. Pinhole collimators are cone-shaped with a single pinhole at the
apex that generates a magnified, inverted image of the organ of interest, whereas parallel-
hole collimators have a large array of holes parallel to one another and perpendicular to the
detector face. Diverging and converging collimators have multiple holes that either diverge
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Figure 3.4: Parallel-hole collimator schematics illustrating (a) absorption of a γ ray by the septa,
detected γ ray following a straight line trajectory from patient to detector, and a γ ray undergoing
septal penetration before being detected, and (b) hole length L, hole diameter d, septa thickness t,
and distance from object to collimator x.
or converge with respect to the detector face, allowing minimisation or magnification of an
organ or interest, respectively. The most common type and the collimator of interest for the
DEPICT project is the parallel-hole collimator. Parallel-hole collimators are defined by hole
length L, hole diameter d and septa thickness t, where septa are the high Z material walls
between the collimator holes, illustrated in Figure 3.4b. A direct projection of the radionu-
clide distribution in the object being imaged is formed on the detector crystal. Parallel-hole
collimators can have various geometries for use with a range of medical radionuclides with
different γ-ray energies. A low-energy collimator is used for γ-ray energies less than 140 keV,
a medium-energy for less than 260 keV and a high-energy for less than 400 keV [48]. Imaging
the 364.5 keV γ rays following 131I MRT requires the use of a high-energy collimator, and a
typical clinical high-energy parallel-hole collimator has hexagonal holes with L = 59.7 mm,
d = 4.0 mm and t = 2 mm [49].
Collimator spatial resolution Rcoll depends on L, d and the distance from the object being
imaged to the collimator x:
Rcoll ≈ d
L
(L+ x). (3.3)
The collimator spatial resolution increases as a function of x, therefore the image quality
degrades with increasing distance to the object being imaged. This is due to collimator holes
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not being infinitely long or thin, so γ rays that are travelling close to perpendicular to the
crystal can be accepted and included in the image. This results in a blurring of the image.
It also increases with d, indicating smaller collimator holes improve the resolution. The total
spatial resolution of the system Rsys is a combination of both the intrinsic detector spatial
resolution Rint, which will be discussed later, and the collimator spatial resolution Rcoll:
Rsys =
√
R2int +R
2
coll. (3.4)
The collimator is usually the limiting factor in gamma camera system spatial resolution as the
collimator spatial resolution is typically worse than the intrinsic detector spatial resolution.
For example, the GE Healthcare Infinia HawkeyeR© SPECT system configured with a high-
energy parallel-hole collimator and standard 9.5 mm-thick crystals has an intrinsic spatial
resolution of 3.8 mm FWHM, and a system spatial resolution at 10 cm of 12 mm FWHM
[50]. In diagnostic SPECT, administered activities range from a few MBq up to ∼900 MBq
[51, 52], therefore collimators are often designed to maximise detection efficiency to ensure
sufficient statistics are produced for a high quality image. This is achieved by increasing
the hole size to allow more γ rays through. However, the corresponding decrease in septal
thickness can lead to γ rays either passing through the septa material before being detected or
being scattered and detected with a reduced energy. This is known as septal penetration and
is shown in Figure 3.4a. Septal penetration results in decreased image contrast, degradation
of spatial resolution and increased image artefacts, leading to difficulties in accurate activity
distribution quantification [53]. The transmission of γ rays through an absorber material
such as the collimator septa is described by the exponential equation:
I(x) = I(0) e−(µx) (3.5)
where I(x) is the intensity of γ rays transmitted through thickness x of the absorber material,
I(0) is the intensity recorded with no absorber material present, and µ is the linear attenuation
coefficient of the absorber material. For 364.5 keV γ rays, the linear attenuation coefficient
of lead is 3.12 cm−1 [54] therefore when using a high-energy parallel-hole collimator with
a typical septal thickness of 1.8 mm, 57% of the γ rays would pass through the septa of
a lead collimator (with the possibility of then being attenuated by further septa). Septal
penetration degrades the final image as this incomplete attenuation decreases the signal-to-
noise ratio resulting in a loss of image contrast. A reasonably small level of septal penetration
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is accepted, around 5% [55], to allow for adequate detection efficiency.
3.4 Detector Properties
Once the γ rays have passed through the collimator, they interact with the detector. There
are several properties that are important for a γ-ray detector to be used in SPECT. The
following sections provide a description of these performance characteristics.
3.4.1 Energy Resolution
Energy resolution is a measure of the ability to precisely determine the energy deposited in
the detector. The intrinsic energy resolution of a radiation detector ∆Ei is given by the full
width at half maximum (FWHM) of a photopeak E0 (the peak formed when a γ ray deposits
all of its energy in the detector). The FWHM of a photopeak is influenced by three terms:
(∆Ei)
2 = (∆Es)
2 + (∆Ecol)
2 + (∆Eel)
2. (3.6)
The first term (∆Es)
2 is due to the statistics associated with the charge production process
in the detector, and arises because the charge is generated by discrete charge carriers:
(∆Es)
2 = (2.35)2(F.Eγ .), (3.7)
where F is the Fano factor, which accounts for deviation of the observed statistical fluctua-
tions in the number of charge carriers from pure Poisson statistics, Eγ is the γ-ray energy,
and  is the average energy required to produce a pair of charge carriers. The second term
(∆Ecol)
2 and the third term (∆Eel)
2 correspond to the contribution to the energy resolution
from incomplete charge collection and electronic noise, respectively. The contribution from
electronic noise Eel is independent of the γ-ray energy and determined largely by the detector
capacitance and front-end electronics. In SPECT, γ-ray events are selected for imaging from
the γ-ray spectrum only if their energy falls within a user specified energy window, which is
typically around the photopeak of interest. A smaller photopeak FWHM indicates superior
energy resolution and allows for narrow energy windows to be set around a γ-ray energy
of interest. This reduces the number of scattered events included in the image, increasing
the signal-to-noise ratio. In turn, this improves delineation of tumour volumes which is an
important aim of the DEPICT project.
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3.4.2 Spatial Resolution
The spatial resolution of a gamma camera quantifies how well a detector system can localise
a γ-ray interaction within the detector crystal. It is related to the dimensions of the read-out
segments, be it the pixel size or strip pitch. The position sensitivity of pixelated detectors
is of interest in this work and will be expanded upon in Section 3.5.3. The intrinsic spatial
resolution depends on the detector crystal and electronics however the total system resolution
has to also take into account the properties of the collimator, discussed in more detail in
Section 3.3. Being able to determine the origin of a γ ray is essential in SPECT for accurate
measurements of the activity within a patient.
3.4.3 Detection Efficiency
The probability that a γ ray will interact in the detector and produce a signal is known as
the detector efficiency. There are several methods to describe efficiency including absolute
abs and intrinsic int, which are defined as
abs =
Number of γ rays recorded
Number of γ rays emitted by the source
(3.8)
and
int =
Number of γ rays recorded
Number of γ rays incident on the detector
. (3.9)
The number of γ rays recorded can refer to either the total number of γ rays detected, or
those contained within the photopeak. The absolute efficiency, unlike the intrinsic efficiency,
depends on the solid angle subtended by the detector. The relative efficiency of a detector
can also be quoted and compares the absolute efficiency of the detector to a 76 x 76 mm
NaI(Tl) detector, irradiated by a 60Co (1332 keV γ ray) source at 25 cm from the detector
face (abs = 1.2 x 10
−3 cps/Bq). A highly efficient detector is usually desirable in diagnostic
procedures to reduce the time required for patient imaging. This is not as essential for
imaging following MRT as very high activities are administered.
3.4.4 Dead time
At high count rates there is an increased likelihood of two γ rays interacting in the detector
crystal within the response time of the detector. These events can be lost because of the
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short but finite time interval required to process each recorded event. The minimum time
separation is known as the dead time τ of the system. The detector itself can induce an
intrinsic dead time, alongside contributions from the electronics, and readout and storage of
the event information. There are two types of dead time; paralysable and non-paralysable,
illustrated in Figure 3.5. In a non-paralysable detector, an event that occurs during the dead
time is lost but has no effect on subsequently occurring events. However, in a paralysable
detector an interaction that occurs during the dead time would not be counted and extends
the dead time.
Non-paralysable
Time
Events in detector
τ
Paralysable
τ τ
τ
τ τ τ
Figure 3.5: Illustration showing non-paralysable and paralysable models of dead time τ for radiation
detectors.
For each model of dead time, the measured m count rate of a γ-ray detector can be related
to the true, or incident, count rate n and the detector dead time τ . For the non-paralysable
model, this relationship is expressed by
m =
n
1 + nτ
. (3.10)
The equation expressing the relationship between m, n and τ for the paralysable model is
m = ne−nτ . (3.11)
Derivations for Equations 3.10 and 3.11 can be found in [47]. A plot of measured count rate
m versus the true count rate n is shown in Figure 3.6 for both models, alongside a dashed
black line showing m = n; the count rate response of an ideal detector.
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Figure 3.6: Variation of the measured rate m as a function of the true rate n for the two models of
dead time [47].
Figure 3.6 shows that at low counting rates, the two models predict similar behaviour; at
high count rate the models begin to diverge. At the high count rates associated with MRT,
dead time losses may be extreme and can mean that the detected count rate can no longer
be accurately corrected to the administered activity. A detector that can function at high
count rates and has minimal dead time is therefore required for use in the DEPICT project.
3.5 Semiconductor Detectors
Semiconductor detectors are the most recent class of radiation detectors to have been de-
veloped, and many report on their suitability for use in nuclear medicine imaging systems
[56, 57, 58, 59]. Compared to scintillator based cameras that first convert incident γ rays to
visible light that is then subsequently detected by PMTs and converted into an electronic
signal, semiconductors directly convert the absorbed γ ray into an electronic current. This
improves the detectors energy resolution and spatial resolution through direct conversion
of the energy and location of the detected γ ray [60]. The following sections describe the
principles of semiconductors for use as radiation detectors.
3.5.1 Band Structure
Semiconductor materials have crystalline structures in which electrons are confined to energy
bands and the material properties depend on the structure of these bands. The two bands
are the valence and conduction bands. Electrons in the valence band are bound to specific
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lattice sites within the crystal, whereas electrons in the conduction band are free to migrate
through the crystal structure. An energy band gap Eg separates the two bands. The structure
of the bands dictates whether a material acts as an insulator, semiconductor or conductor,
illustrated in Figure 3.7.
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Figure 3.7: Schematic illustration of insulator, semiconductor and conductor energy band gaps.
Insulators have the largest energy band gap, with a minimum gap of 5 eV between the valence
and conduction bands. They have a completely filled valence band and empty conduction
band, meaning all the electrons are bound and the energy generated by thermal excitations
is insufficient to promote electrons from the valence band. Semiconductors have a band
structure similar to insulators, but a smaller band gap of ∼1 eV between the top of the
valence band and the bottom of the conduction band allows thermal excitation of electrons.
When a valence electron is excited into the conduction band, a positively charged vacancy is
left in the valence band, called a hole. The excited electron and hole are known as electron-
hole pairs and are the charge carriers in semiconductors. In conductors, the conduction band
and valence band overlap, and there is no band gap. Intrinsic semiconductors have equal
numbers of excited electrons n and holes p; n = p. Figure 3.7b and Figure 3.7c highlight
the difference in p- and n-type semiconductors. Extra electron energy levels called donor
levels sit beneath the conduction band in n-type, and extra hole energy levels sit above the
valence band in p-type semiconductors. These extra electrons and holes are known as dopant
impurities. Dopant impurities that add excess electrons n > p to the material are called
donors, and those that lack electrons (or add holes) n < p are called acceptors. In n-type
semiconductors, the electrons outnumber the holes and are therefore named majority carriers
and the holes are the minority carriers. The converse applies in in p-type semiconductors.
These donor impurities are often intentionally added during fabrication to alter the electrical
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properties of the semiconductor material as a higher concentration of charge carriers increases
conductivity.
3.5.2 Charge Carriers
When incident γ rays interact with the detection material, energy can be transferred to an
electron in the valence band exciting it to the conduction band, which creates an electron-hole
pair. The excited electrons are now mobile and can flow through the material. Neighbouring
electrons can subsequently fill the vacant hole in the valence band, leaving a new hole in its
original position that can also then be filled by an electron. This filling of holes gives the
impression of the holes migrating through the material. A large number of electron-hole pairs
are created. The number of electron-hole pairs N created is dependent upon the energy of
the incident γ ray Eγ and the ionisation energy pair of the detection material, as shown in
Equation 3.12.
N =
Eγ
pair
(3.12)
The ionisation energy pair is the average energy required to produce one electron-hole pair.
On average, 3 – 5 eV is required to produce an electron-hole pair in a semiconductor. By
comparison, approximately 100 eV is required to produce a photoelectron from a PMT in a
typical scintillator detector.
If the semiconductor crystal is placed between two electrodes and a potential difference is
applied, an electric field E is produced. When ionising radiation interacts within the semi-
conductor crystal and electron-hole pairs are created, the negatively charged electrons and
positively charged holes then migrate to the oppositely charged electrode where an electrical
signal is induced on the contacts and read out. The motion of a charge carrier through the
crystal can be influenced by diffusion and magnetic and electric fields, and the strength of
this influence is characterised by the carrier mobility. Electron mobility is denoted µe and
hole mobility is µh (cm
2/V·s). The velocity v of a charge carrier can be expressed as:
υe,h = µe,hE (3.13)
Holes have reduced mobility, typically orders of magnitude smaller than electrons, as they
cannot move as freely in the valence band and have a greater effective mass. The charge
30
CHAPTER 3. Nuclear Medicine
transport properties of a semiconductor are also characterised by the electron and hole life-
times, denoted τe and τh respectively. The charge carrier lifetime refers to the average time
taken for a minority charge carrier (either electron or hole) to either become ‘trapped’ or
to recombine with a charge carrier of the opposite charge. The presence of impurities, ir-
regularities (e.g. dislocations) and structural defects (e.g. vacancies) in the crystal act as
trapping centres. Often the charge carrier mobility and lifetime properties are expressed as a
single parameter, denoted as either the electron µeτe or hole µhτh (cm
2/V) mobility lifetime
product, and are key parameters in the development of radiation detectors.
3.5.3 Position Sensitivity
Position sensitivity can be achieved by segmenting or pixelating the negative (cathode) or
positive (anode) electrodes. For radionuclide imaging, the segmentation is often in the form
of square pixels. The electron-hole pairs that have been created travel along the electric
field lines and induce a signal on the closest electrode. Pixelated detectors allow increased
spatial resolution compared to planar detectors, and this effect improves as the pixel size
decreases due to the small pixel effect [61]. The pixelated electrodes are bonded to a readout
integrated circuit that reads out each pixel individually. Detectors using pixelated electrodes
have several advantages including smaller leakage current, lower electronic noise, and lower
capacitance per pixel electrode. Detectors with a pixel pitch of a few hundred µm have been
reported [62, 63]. One drawback of pixelated detectors is that the device can suffer from
charge sharing problems between pixels [64]. This occurs when the pixel size is decreased to
be comparable in size to the electron charge cloud created when a γ ray interacts. The charge
may be shared between multiple pixels or lost in the gap between the pixels, degrading the
spatial resolution.
3.5.4 Cadmium Telluride and Cadmium Zinc Telluride
The two best semiconductors are generally considered to be silicon (Si) and germanium (Ge),
with excellent resolution and charge transport properties. However, the low stopping power
of Si means it is inefficient at detecting γ rays with energy over a few tens of keV [65], and the
small band gap of Ge (0.66 eV at room temperature) mean cryogenic cooling is required to
reduce thermal excitations. Therefore, room temperature semiconductors with high atomic
numbers and a wide band gap have long been investigated for use as γ-ray detectors for
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nuclear medicine. The most attractive semiconductors for use in gamma cameras include
Cadmium Telluride (CdTe) and Cadmium Zinc Telluride (Cd1−xZnxTe where x = 0.1 – 0.2,
or CZT). CdTe has been studied as an x-ray and γ-ray detector since the 1960’s [66] and has
been evaluated for medical applications since the 1970’s [67]. CdTe combines high atomic
numbers of 48 (Cd) and 52 (Te) giving a high quantum efficiency suitable for detecting γ
rays typically in the 10 – 500 keV range [68]. CdTe and CZT are compound semiconductors,
semiconductors that are composed of at least two chemical elements, with densities of 5.85
and 5.78 g/cm3, respectively [68]. II-VI semiconductor compounds are composed of a metal
from either Group 2 or 12 of the periodic table (the alkaline earth metals and Group 12
elements) and a non-metal from Group 16 (formerly called group VI). Cadmium and zinc are
elements from Group 12 of the periodic table, while tellurium is Group 16. II-VI compound
semiconductors generally have a wide band gap compared to Si and Ge and can therefore
operate at room temperature without excessive thermally generated electronic noise.
CZT is one of the most promising materials for semiconductor detectors in nuclear medicine.
It is formed by alloying CdTe with ZnTe, and is found to be better than CdTe for spectro-
scopic applications. Alloying CdTe with ZnTe increases the band gap from ∼1.45 eV in CdTe
to around 1.6 eV in CZT [69]. CdTe can also suffer from noise due to leakage current, a small
current that flows as there is not infinite resistance, degrading the energy resolution. This
increase in band gap alongside the high electrical resistivity of CZT (ρ = 109 – 1011 Ωcm) [68]
overcomes this. CZT crystals can be grown to larger sizes at a reduced but still expensive
cost compared to CdTe and therefore CZT detectors are deemed more desirable than CdTe.
The number of impurities or defects increases with increasing size of the crystals, therefore
multiple small crystals are often tiled together in an array to increase the detection surface
area. Good detection efficiency for γ rays above 300 keV requires the detectors to be 5 – 10
mm-thick. The ionisation energy is ∼5 eV for CZT, compared to around 100 eV in typical
scintillator detectors meaning more charge carriers are produced from the primary ionisation
event and the statistical fluctuation signal response is reduced. As shown by Equation 3.6 in
Section 3.4.1, a reduction in ∆Es improves the energy resolution of the detector.
The excellent statistics concerning charge carrier numbers are counterbalanced by effects
that prevent complete charge collection. CZT detectors that are pixelated have boundaries
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where signal collection is weaker than in the pixel centre. Compound semiconductors such
as CZT are also characterised by poor charge transport properties due charge trapping and
recombination, leading to incomplete charge collection. Typical values for mobility lifetime
products in CZT materials are µhτh = 10
−6 – 10−4 cm2/V and µeτe = 10−3 – 10−2 cm2/V
[70]. As the CZT crystal thickness increases, a considerable amount of charge is lost due to
the low mobility, long drift times and short lifetime of the charge carriers. Loss of signal at
pixel boundaries and by hole trapping reduces the detectors charge collection efficiency, and
the effect of this is characteristic tailing on the low energy side of the photopeak. Equation
3.6 illustrates a larger ∆Ecol degrades the detectors spectroscopic performance.
3.5.5 Ohmic Contacts
CZT crystals are fabricated with very thin metalised electrode geometries deposited on the
detector surfaces to extract the electrical signals. Due to their high resisitivity and low
leakage currents (< 10 nA at room temperature), CZT detectors are usually fabricated with
ohmic contacts [70]. High work-function metals such as gold or platinum will form ohmic
(charge injecting) contacts on p-type semiconductors, whereas low work-function metals such
as indium will form ohmic contacts on n-type semiconductors. Ohmic contacts form an
electrical junction between the metal and semiconductor that has a linear current-voltage (I -
V) relationship, following Ohm’s law [71]. A low resistivity would lead to high bulk leakage
current, potentially greater than the current produced from radiation events in the detector.
To overcome this, blocking contacts must be used. An example of a blocking contact is that
produced from a p-n junction, typical in Si and Ge. The metal electrodes can be applied
through either thermal evaporation, sputtering or electroless deposition [72]. The contacts
are then bonded to readout electronics to read and process the electrical signals.
3.5.6 Application Specific Integrated Circuits
Application Specific Integrated Circuits (ASICs) have been developed to read out and process
electrical signals from pixelated CZT radiation detectors [73, 74]. ASICs process information
such as the amplitude and timing of the signal that is produced when charge is induced
on either the cathode or pixelated anode. They contain a preamplifier that is designed to
amplify the small output pulses (mV) from semiconductor detectors and match impedance
between the detector and pulse processing electronics. The preamplifier must also operate
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in a linear fashion; that is, the amplitude of the signal out must be directly proportional to
the amount of charge delivered to it by the detector. This preserves the relationship between
pulse amplitude and energy of the incident γ ray and is achieved by using a charge sensitive
preamplifier. The charge Q is collected on a capacitor Ci. The charge pulse is then integrated
onto a second capacitor Cf and discharged via a feedback resistor Rf . The output voltage
from the preamplifier has amplitude Vout:
Vout =
Q
Cf
. (3.14)
The output pulse from a preamplifer is characterised by a fast rise time (a few µs) and long
exponential decay time (typically 50 – 100 µs). The rise time is determined by the charge
collection time in the detector, while the decay time is determined by the time constant
(τ = RfCf ) of the shaping circuit. As long as τ is long compared to the duration of the input
pulse, the output voltage is proportional to the total integrated charge in the pulse. The pulse
is then processed by an shaping amplifier. The shaping amplifier further amplifies the still
relatively small pulses from the preamplifier to a sufficient amplitude (V), and subsequently
shapes it into a Gaussian-shaped pulse. This removes the long pulse tail that can cause
pulses to pile up on the tail from a preceding pulse. The PMTs used to process the signals in
conventional gamma cameras occupy considerable volume and must be surrounded by lead.
Semiconductors that are read out by ASICs eliminate the need for PMTs and therefore have
considerable advantages in weight and manoeuvrability for use in a SPECT system.
3.6 SPECT Activity Quantification
As detailed in Section 2.3, accurate measurements of the activity distribution within a well-
defined volume are essential for performing patient dosimetry, leading to to the need for
absolute quantification with SPECT [75]. Ideally this would be achieved by: imaging the
volume of interest within the patient using SPECT, correcting for the factors that degrade the
image, obtaining a measured count rate distribution within the volume and finally calibrating
this to obtain a measured activity distribution, as illustrated in Figure 3.8. This process would
be repeated at multiple time points to obtain a time-activity curve and a value of cumulative
activity.
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Figure 3.8: Illustration of a simplified image formation chain, reproduced from [76].
The following sections describe the factors that degrade SPECT image quality and lead to
loss of true activity information.
Attenuation
Attenuation, the loss of γ rays due to absorption or scattering, will prevent γ rays from
leaving the body and reaching the detector leading to an underestimation of the activity
within the body. The reduction in the number of detected γ rays varies with the thickness
and the nature of the material through which the γ rays must travel before being imaged. The
amount of attenuation is also energy dependent, with greatest attenuation occurring at lower
γ-ray energies. The linear attenuation coefficient of soft tissue is 0.11 cm−1 at 364.5 keV,
therefore Equation 3.5 shows γ rays that are emitted from a depth of 2 cm (the approximate
thickness of tissue covering the thyroid gland is 1 – 3 cm [77]) would have a probability of 80%
of emerging from the body in their original direction. For 99mTc where the linear attenuation
coefficient is 0.15 cm−1, this falls to 74%. The aim of attenuation correction is to recover the
lost events.
Scatter
Unlike attenuation correction where the aim is to recover the attenuated events to determine
activity, the aim of scatter correction is to remove the scattered events to improve image
quality. Compton scattering is the dominant interaction process in soft tissue (Zeff = 7.4) for
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γ rays with energy between 40 keV to 10 MeV. γ rays that are scattered either whilst leaving
the body of the patient or within the collimator do not represent the true position in which
the γ ray originated in the body, compromising the ability to obtain a precise map of the
radioactivity distribution. If a γ ray scatters in the body or collimator, it cannot deposit all
its original energy in the detector. Therefore, an energy window can be used to remove these
scattered events. Typical scintillator SPECT systems have an energy resolution of ∼10%
[78], therefore during imaging an energy window of width 15% – 20% centred around the
photopeak is recommended [79]. Only these events within the energy window will be used
for imaging. An example 131I energy spectrum with a 20% (328 – 400 keV) energy window
is illustrated in Figure 3.9a. Although it is important to have an adequately wide energy
window to avoid excessive count losses, γ rays that are Compton scattered through small
angles within the body can also be recorded within the photopeak window, degrading the
signal-to-noise ratio. This is a more significant problem with 140.5 keV γ rays, compared to
364.5 keV, as for an energy window of 20% (127 – 155 keV) γ rays scattered up to 50◦ will fall
into the energy detection window and will be accepted. For 364.5 keV, only γ rays scattered
up to 30◦ will be accepted into a 20% energy window. However, multiple Compton scattering
processes are more likely at higher energies, and these scattered events may also be accepted
into the 131I energy window. Improved detector energy resolution is required to discriminate
photopeak events from unwanted scatter. Down-scatter is also an issue if the nuclide emits γ
rays higher in energy than the γ ray of interest and is a problem with 131I due to the presence
of 637 keV (7.2%) and 723 keV (1.8%) γ rays. Scattering degrades the signal-to-noise ratio
and hence the contrast in the image, as the Compton scattered γ rays will give an increased
background signal that is closer to that of the absorbed γ rays. As CZT has better energy
resolution compared to NaI(Tl) scintillator detectors, a smaller energy window can be set.
Figure 3.9b shows a 131I spectrum acquired with a CZT detector and a 5% energy window
(355 – 375 keV) highlighted around the 364.5 keV photopeak.
Partial Volume and Motion
Partial volume effects occur when the region of interest (e.g. tumour) is smaller than ap-
proximately twice the FWHM of the spatial resolution. Objects smaller than the resolution
volume will have all their counts detected, but over a larger volume than their true size.
The counts will be ‘spread out’, thus the recorded concentration of activity will be lower
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Figure 3.9: 131I γ-ray spectra acquired with (a) a NaI(Tl) scintillator gamma camera with 20% (±
10%) energy window around the 364.5 keV photopeak and an energy threshold set at 25 keV and (b)
a CZT detector with 5% (± 2.5%) energy window around the 364.5 keV photopeak and an energy
threshold of 220 keV.
than the actual concentration. Improvements in the spatial resolution of a system can help
avoid partial volume effects. Patient movement during data acquisition due to respiratory or
cardiac motion can cause aretefacts in the reconstructed 3D image of the organ. This can be
corrected for with sufficiently long scanning times and a large number of projection images
acquired during the SPECT scan.
3.6.1 Limitations for 131I Imaging
Further problems arise with obtaining accurate quantitative activity information following
therapeutic applications such as MRT, as current gamma cameras are optimised for diag-
nostic imaging with low-energy radionuclides such as 99mTc, not high-energy therapeutic
radionuclides such as 131I. At high energies, the performance of gamma cameras with stan-
dard 9.5 mm-thick NaI(Tl) crystals is limited by decreasing detection efficiency as well as
increasing collimator septal penetration. Alongside this, poor image quality arising from poor
system spatial resolution and energy resolution leads to uncertainties in volume delineation
and errors in the measured values of activity. As SPECT systems are also optimised for imag-
ing following the administration of activities up to a maximum of ∼900 MBq in diagnostic
procedures, they suffer from count rate saturation when imaging following therapy. The ef-
fects of dead time on quantitative SPECT with commercial systems have been reported with
therapeutic activities of 2 – 6 GBq of 131I [80], and this is an issue as typical adminsitered
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activities of 131I in MRT can be up to 7.4 GBq. 131I has multiple high-energy γ-ray emissions
that will also contribute to dead time, even when they are outside the acquisition energy
window [81]. As mentioned in Section 2.3.2, often when imaging after the administration of
several gigabecquerels of activity there is a limit placed on the earliest imaging time point
of around a couple of days after injection due to the effects of camera dead time [82]. This
means an accurate initial calculation of the activity distribution cannot be performed. Quan-
titative activity information is therefore lost due to this dead time leading to uncertainties
in absorbed dose calculations.
3.6.2 Reconstruction Algorithms
The final stage in SPECT imaging is the implementation of a reconstruction algorithm to
achieve 3D images from the acquired 2D projection images. In general, there are two groups
of reconstruction methods used to obtained a 3D radiation distribution from 2D projection
images: iterative and analytic methods. The most conventional method and an example of an
analytic technique is Filtered Back Projection (FBP). However for quantitative studies, iter-
ative methods such as Ordered Subset Expectation Maximisation (OSEM) [83] or Maximum
Likelihood Expectation Maximisation (MLEM) [84] are required. These methods include
explicit corrections for the factors detailed in Section 3.6 that degrade the quantitative accu-
ratry of a SPECT image. Most iterative algorithms fit into the general model following the
image (projection) acquisition process of: generating a simple initial guess of the image, esti-
mating a set of projection data from the initial estimate using a mathematical process called
forward projection (it is in this step where corrections can be made) and comparison of the
resulting projection with measured projection data, with the difference between the two used
to update the estimated image. The iterative process is repeated until a condition predefined
by the algorithm is satisfied and the final image is generated that closely matches the true
distribution in the 3D structure [85, 86]. Iterative reconstruction methods have been found
to offer both superior image quality [87] and potentially quantification [88] compared to FBP,
at the expense of being more computationally intensive. OSEM is a simple modification of
the MLEM algorithm and works by breaking up the full set of projection data into a series of
mutually exclusive subsets and applying the algorithm to each subset sequentially [72]. This
is often achieved in far fewer iterations compared to MLEM. Due to its speed, the OSEM
algorithm has quickly become the reconstruction method of choice in nuclear medicine [89].
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CZT Detector Characterisation
Pixelated CZT has been shown to possess superior qualities, including improved energy reso-
lution and position resolution, compared to the scintillator detectors typically used in clinical
gamma cameras [90] [91]. A pixelated CZT detector was therefore selected for use in the
DEPICT project for investigating the feasibility of obtaining quantitative activity informa-
tion following MRT. This chapter will discuss the DEPICT CZT detector characterisation
involving investigations into the following:
• Electronic noise
• Operating voltage
• Linearity
• Stability
• Peaking time
• Dead time
Optimisation of these performance parameters will allow the detector to meet the high γ-ray
throughput and good energy resolution requirements of the DEPICT project.
4.1 DEPICT CZT Detector
The DMatrix Nuclear Imager [92], manufactured by eV Products, is a fully integrated, γ-ray
counting, pixelated, 12-bit energy discriminating CZT detector. Its end-user applications in-
clude gamma spectroscopy for nuclear security and as a SPECT demonstrator in the medical
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industry. The CZT detectors and associated electronics are encased in aluminium, shown in
Figure 4.1a, to allow shielding from visible light that would otherwise induce noise. The fun-
damental building block of the DMatrix, shown in Figure 4.1b, is an array of four (2 x 2) CZT
detector modules each coupled to an ASIC (to process and read out the signals), analogue-
to-digital converters (ADCs) and an aggregator field programmable gate array (FPGA). The
design enables large field of view scaling by tiling multiple 2 x 2 modules. Each individual
CZT crystal is 22 x 22 x 5 mm with 11 x 11 pixels at 2 mm pitch, illustrated in Figure 4.1c,
allowing high count rate operation. Highlighted in grey are two pixels that are exessively
noisy in the DEPICT CZT detector, and therefore were manually switched off for all data
collection. Each ASIC, which is based on the H3D ASIC [93], has 128 anode channels (121
used) for anode pixels and 2 cathode channels (1 used) which perform charge amplification
and shaping, and provide energy and timing information. The anode and cathode channels
utilise charge sensitive preamplifiers1 with adaptive reset, a 5th order unipolar shaping ampli-
fier, baseline stabiliser and discriminator with trimming. After shaping, the analogue outputs
of the ASIC are digitised. The 2 x 2 modules communicate with the aggregator FPGA over
a low-voltage differential signaling (LVDS) tether where data are formed into packets. These
packets are received by a PC where the DMatrix Application Programming Interface (API)
decodes them, and presents the end-user with list-mode data. These data include the de-
tector module number, individual pixel number, uncalibrated γ-ray energy and time stamp.
Software was written in MATLAB [94] that produces a user-friendly graphical user interface
(GUI) that allows the raw list-mode data to be input alongside a calibration file. Individual
γ-ray spectra (calibrated or uncalibrated) can then be viewed for each pixel, alongside a ‘sum’
spectrum produced by binning all single pixel events into one spectrum. In addition, the data
can be viewed as a 2-dimensional intensity map or ‘pixel map’, where each square pixel has
a colour assigned to it, depending on the total counts in the individual pixel spectra. For the
2 x 2 detector configuration, Gigabit Ethernet is sufficient for communication with a PC. A
carbon fibre window covers the active area of the detector at a height of 1.36 cm from the
closest face of the detector, and this can be removed to allow a mechanical collimator to be
mounted.
1Rise time ∼ 50 ns
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Figure 4.1: Photograph of (a) DMatrix Nuclear Imager external housing, (b) DMatrix fundamental
building block with four individual CZT detector modules, ASICS, ADCs and an FPGA and (c)
illustration of the pixelation of the CZT crystals.
4.2 Detector Characterisation
Measurements were undertaken to optimise and evaluate the performance of the DEPICT
CZT detector for MRT applications, by determining settings that facilitate good energy res-
olution and high γ-ray throughput. Good energy resolution is required to discriminate γ rays
that are scattered as they are emitted from the body and within the collimator before reach-
ing the detector face. High throughput is essential due to the high activities of radionuclides
administered in MRT. The DMatrix ‘basic sparsified photon collection mode’ was used, which
entails only collecting data from the anode channels that exceed a user-defined threshold. For
a pixel to trigger data readout, its voltage pulse height must be greater than the threshold
set in mV for that pixel, which is adjustable by a 10-bit DAC. A global threshold sets the
same value for all pixels, and a threshold of 380 mV was applied that was calculated to be
equivalent to ∼15 keV. The threshold was used to remove electronic noise contributions at
low energy, and characteristic low-energy x-rays.
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4.2.1 Electronic Noise
An internal digital test pulser was used to estimate the electronic noise contribution to the
total energy resolution, allowing noise contributions from charge production and collection
to be excluded. Pulser circuitry is internal to the ASIC and charge is injected to the front of
the preamplifier. A typical pulser peak from a single pixel is shown in Figure 4.2. The pulser
amplitude is controlled by a 10-bit DAC in the ASIC. A test pulse of amplitude 185 mV was
induced for 60 seconds, allowing a peak in each pixel to be produced with approximately
20,000 gross counts. Data were collected and the position and FWHM of the pulser peak
were noted in four typical pixels from each of the four detector modules. This allowed an
average FWHM for each individual module to be calculated. The average FWHM over all
the detector modules was then calculated to be 3.32 ± 0.22 keV. Electronic noise of around
3 keV in pixelated CZT detectors have been reported in [63, 95].
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Figure 4.2: Example pulser peak from a single detector pixel.
4.2.2 Energy Resolution as a Function of Operating Voltage
Measurements were made at bias voltages between 300 V to 1000 V, in steps of 100 V, to
determine the voltage that produced the best energy resolution of an 131I 364.5 keV pho-
topeak. A skewed Gaussian fit is required for calculation of the FWHM due to low-energy
tailing on the photopeak, which is characteristic of incomplete charge collection in the CZT
detector due to hole trapping [96, 97]. The least-squares peak-fitting programme GF3 [98]
was utilised to apply a skewed Gaussian fit to the photopeak. Figure 4.3 shows 131I photo-
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Figure 4.3: Example GF3 fit to skewed 131I photopeak generated from a DEPICT detector pixel at
600 V.
peak data generated from a DEPICT detector pixel at 600 V in black, and the fit illustrated
by the smooth red line.
Photopeak centroid positions and FWHM values were measured in ADC channel numbers at
each bias voltage. The data plotted in Figure 4.4 show the FWHM (%) of a photopeak from
a single pixel, and from the sum spectra produced by binning all single pixel events in one
spectrum. The FWHM (%) was calculated using Equation 4.1.
FWHM (%) = 100× FWHM (ADC channels)
photopeak centroid position (ADC channel)
(4.1)
The results presented in Figure 4.4 demonstrate that as the voltage is increased from 300 V
to 600 V, the FWHM (%) for a single pixel decreases from 7.8% to 2.9%, due to improved
charge collection. However, as the bias voltage is increased above 600 V, the FWHM (%)
degrades due to increasing leakage current. Although the FWHM measured at each bias
voltage is larger than the summed pixel spectra, decreasing from 10.3% to 6.5% across 300
to 600 V, the trend is reproduced with the best energy resolution again being achieved at
600 V. The operating voltage of 600 V was therefore selected as the optimum and will be set
for all future measurements.
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Figure 4.4: FWHM (%) calculated for a 131I photopeak produced in a single pixel (blue) and from
summing all individual pixel spectra (red) as a function of bias voltage.
4.2.3 Detector Linearity
Data were acquired with 241Am (59.5 keV γ ray, 179.5 kBq), 133Ba (81, 356 keV γ rays,
138.9 kBq), 57Co (122 kev γ ray, 343.3 kBq) and 139Ce (165.9 keV γ ray, 26.4 kBq) point
sources and an 131I (364.5 keV γ ray, ∼8 MBq) distributed source to determine if the detec-
tor and associated electronics were linear in energy response and to apply any corrections, if
necessary. The energy range provided by these sources [99, 100] corresponds to the energy
region of interest for the DEPICT project (< 364.5 keV). The gain on the anode channel can
be set to one of four values in the ASIC; 20, 40, 60 and 120 mV/fC, so these were investigated
to optimise the use of the dynamic range. The sources were sequentially placed 4 cm from
the carbon fibre window for 600 seconds at each gain setting.
Figure 4.5 shows the ADC channel number of the measured photopeak centroid plotted as a
function of known γ-ray energy for all acquired data sets. The 20 mV/fC setting was found
to decrease the dynamic range such that with the global threshold applied, no spectrum
could be collected for these sources. Therefore, data were only acquired at the three higher
settings. It can be seen that the energy response is linear below 364.5 keV for all three gain
settings. A linear calibration can therefore applied across the energy range. A calibration file
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Figure 4.5: Measured ADC channel number of various photopeak centroids as a function of known
γ-ray energy.
was created using the MATLAB GUI. The user input list-mode data acquired with sources
known to have γ emissions across the energy region of interest (241Am - 60 keV and 133Ba -
81, 277, 302, 356 and 384 keV). The user was then able to match the uncalibrated channel
number to the known γ-ray energy. A text file was then output with two columns of values;
the first column contained values of m, and the second values of c, to convert every channel
into an a value of keV using y = mx + c. Figure 4.5 shows the intercept at ADC channel
500, which is due to a known baseline offset of 230 mV in the pulses and is highlighted in
Figure 4.8. The dynamic range is known to be approximately 2 V from this baseline and
the total range consists of 4096 channels. The 120 mV/fC setting is optimum in this energy
region as the data best fills the dynamic range and will be used for all measurements.
The deviation (%) of the measured ADC channel from the ADC channel calculated from the
linear fit for the 120 mV/fC data is plotted in Figure 4.6. The equation of the linear fit for
the 120 mV/fC data in Figure 4.5 is y = 6.43x+509.2. The measured ADC channel numbers
for all energies are within ± 0.5% of the calculated ADC channel numbers. The maximum
energy that can be resolved at this gain setting has been calculated to be 558 keV, however it
is unlikely that the detector would have suitable efficiency at detecting γ-ray energies above
364.5 keV due to the 5 mm crystal thickness.
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Figure 4.6: Deviation (%) of measured photopeak ADC channel from ADC channel calculated from
the linear fit at the chosen gain setting of 120 mV/fC.
4.2.4 Detector Stability
A medical imaging detector is required to behave consistently throughout the day in a hospi-
tal, as patient images need to be reproducible and comparable. Data were therefore acquired
to investigate the stability of the detector by measuring the position of a 133Ba photopeak
(ADC channel number) and FWHM (%) as a function of temperature. 133Ba is often used a
surrogate for 131I as it emits a 356 keV γ ray, which is comparable in energy to the 364.5 keV
131I γ ray. It also has a much longer half-life (10.51 years compared to 8.02 days) making it
practical for experimental data collection. The DMatrix software provides a reading of the
temperature of each detector module. The detector was switched on and the average temper-
ature of the four detector modules was noted. The detector was left switched on, increasing
the temperature of the detector over time, and a 133Ba energy spectrum was acquired at
various temperatures. The FWHM (%) of a 133Ba photopeak and the photopeak centroid
position (ADC channel number) as a function of temperature is plotted in Figures 4.7a and
4.7b.
It was found that both the FWHM (%) and photopeak centroid position increased with
increasing temperature. The FWHM (%) increased from 2.94% to 3.66% with a 10◦C increase
in temperature and the photopeak centroid position increased by 20 channels, corresponding
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Figure 4.7: (a) FWHM (%) of 133Ba photopeak as a function of temperature (b) ADC channel number
of 133Ba as a function of temperature.
to ∼3 keV. An increase in temperature decreases the band gap, allowing more electrons to
become excited from the valence band to the conduction band. This increase in the number of
electrons N shifts the photopeak position to a higher ADC channel as the number of electrons
N produced is directly proportional to incident γ-ray energy. The equation FWHM = 2.35σ
where σ =
√
N shows that the energy resolution is also directly proportional to the number of
electrons N produced. Therefore, at higher temperatures, the energy resolution will degrade.
In addition this decrease in band gap will allow thermal excitation of electrons that will induce
a signal when a γ ray has not actually interacted within the detector crystal, increasing the
noise in the detector and decreasing the signal-to-noise ratio. The detector’s internal cooling
fans were therefore switched on for all data collection to reduce this photopeak shift and
improve the energy resolution. The temperature variation measured over 3 hours with the
fans on was 0.4 ◦C.
4.2.5 Peaking Time
To determine the energy of an incident γ ray, the voltage pulse produced by the detector
must be shaped. The amount of shaping depends on the time allowed for a shaped pulse to
reach its maximum amplitude, known as the peaking time. If the pulse width is too large,
there will be pile-up of successive pulses. Reducing the peaking time allows the first pulse to
return to the baseline before a second pulse arrives, but if the peaking time is shorter than
the charge induction time on the anode pixel, the signal will be shaped before the full charge
has registered, resulting in ballistic deficit. Four peaking time values can be set by the user in
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Figure 4.8: Shaped pulses at peaking times of 0.25, 0.50, 1.0 and 2.0 µs. The 230 mV offset of the
pulses from the baseline is evident.
the ASIC; 0.25, 0.50, 1.0 and 2.0 µs. Figure 4.8 illustrates the shaped pulse produced at each
peaking time. The signals were acquired by connecting the detector an oscilloscope, allowing
analogue signals to be directly monitored, bypassing the D-Matrix readout electronics. The
pulse width increases with increasing peaking time. The 230 mV baseline offset of the pulses
is evident.
The energy spectra acquired at each peaking time are shown in Figures 4.9a-d. The energy
resolution (FWHM %) of the 131I 364.5 keV photopeak from a single pixel was measured
to be 8.66 ± 0.05%, 2.94 ± 0.02% and 4.56 ± 0.21% at peaking times of 0.25, 0.50, and
1.0 µs respectively. At 2.0 µs peaking time, the photopeak was no longer resolvable. It is
known that lowering the threshold helps to recover the spectrum at the longer peaking time,
although this is not desirable for the high count rate application of DEPICT. The best energy
resolution of 2.94 ± 0.02% was observed at a peaking time of 0.50 µs, therefore this setting
will be used for subsequent measurements. In Figure 4.9b, the photopeak centroids are la-
belled. The 80.2 keV (Pγ = 2.6%), 284.3 keV (Pγ = 6.1%) and 364.5 keV (Pγ = 81.7%)
131I
photopeaks are clearly identified. There are multiple unresolvable low-energy x-rays with
energies between 29.5 – 34.5 keV, and a combined intensity of approximately 4.86%. For
comparison, the typical energy resolution for NaI(Tl) scintillator detectors currently used
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Figure 4.9: Example 131I energy spectra acquired at peaking times of (a) 0.25 µs, (b) 0.50 µs, (c)
1.0 µs and (d) 2.0 µs. Figure 4.9 has the photopeak centroids labelled.
in SPECT systems is approximately 10% FWHM at 364.5 keV. The superior CZT detector
energy resolution will facilitate improved scatter correction over scintillator SPECT systems,
improving quantitative imaging and volume delineation, which are key aims of the DEPICT
project.
The setup parameters of bias voltage and peaking time have been selected so far to optimise
energy resolution for discrimination of scattered γ rays. However, the DEPICT project also
requires the detector to operate with high γ-ray throughput, due to the high activities of
nuclides administered in MRT. This could potentially be achieved by reducing the peaking
time. Therefore, the γ-ray throughput was compared at peaking times of 0.25 and 0.50 µs.
The detector was exposed to a 3.54 MBq 133Ba point source for measurement periods of
300 seconds, at a range of distances from 0 cm (on the carbon fibre window) to 14 cm, to
vary the incident count rate. The incident count rate was calculated using the activity of the
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source, the time taken for data collection and a solid angle Ω correction for a square detector
shown in Equations 4.2 and 4.3, at each distance.
Ω = (1− fs) · 4 · arcsin (sin2 α) (4.2)
where
α = arctan
( w
2d
)
(4.3)
and where fs is a pre-factor to account for any physical shadowing of the detector area
by ancillary windows, w is the active width of the detector and d is the distance from the
detector to the source [101]. A 133Ba point source was used for this measurement due to the
uncertainties that would arise in the solid angle correction to be applied to the 131I distributed
source. The measured count rate was determined from the total counts in the sum spectra at
each source distance, and is shown as a function of the incident count rate for data acquired
at peaking times of 0.25 and 0.50 µs in Figure 4.10. The error on the measured γ-ray count
rate is statistical, whereas the error on the incident count rate takes into account geometrical
uncertainties. The results show reducing the peaking time to 0.25 µs slightly decreased the
γ-ray throughput, which may be due to ballistic deficit effects. Since the peaking time is not
the limiting factor for throughput, the detector can be operated at 0.50 µs to ensure best
spectroscopic performance.
4.2.6 Dead Time
The dead time of a SPECT system has always been a main limitation for quantitative imaging
in MRT and it is therefore essential to minimise this where possible. 131I is a complex
gamma emitter as it emits γ rays both lower and higher in energy than the main 364.5 keV
photopeak, shown in Figure A.1, that will all contribute to dead time. If large count losses
occur due to dead time, the scaling from measured counts to activity by a calibration factor
will underestimate the activity and the absorbed dose to the patient [34]. Figure 4.10 shows
the measured count rate versus incident count rate for the DEPICT detector when exposed to
a 133Ba source. The data have a non-linear relationship and appears to be entering a plateau
region, indicating the detector behaviour follows a non-paralysable model for dead time. In
order to confirm that the detector does follow a non-paralysable model, it is necessary to
calculate the detector dead time τ . To calculate τ , the minimum time interval that two
consecutive counts must be separated in order to be recorded as two different events, the
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Figure 4.10: Measured γ-ray count rate as a function of incident γ-ray count rate at peaking times of
0.25 and 0.50 µs.
two-source method [47] was used. Two 133Ba point sources with activities 3.54 MBq and
0.95 MBq were used at the optimised peaking time of 0.50 µs, to calculate the detector
dead time. The two-source method is based on observing the counting rate from two sources
individually and in combination. Because the counting losses are non-linear, the observed
rate due to the combined sources will be less than the sum of the rates due to the two sources
counted individually, and the dead time can be calculated from the discrepancy. The count
rates and hence the system dead time was measured with the sources placed at 8 cm above
the carbon fibre window. Each measurement was acquired for 600 seconds. A background
measurement with both sources removed was also acquired. The dead time τ of the system
can be calculated from the following equation:
τ =
X(1−√1− Z)
Y
(4.4)
where
X ≡ m1m2 −mbm12, (4.5)
Y ≡ m1m2(m12 +mb)−mbm12(m1 +m2), (4.6)
Z ≡ Y (m1 +m2 −m12 −mb)
X2
, (4.7)
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and where m1 = measured count rate of source 1, m2 = measured count rate of source
2, m12 = measured count rate of sources 1 and 2 combined and mb is a measure of the
background counts. The values for m1, m2, m12, mb and τ are shown in Table 4.1. The dead
time τ was calculated to be 4.87 ± 0.18 µs.
m1 (cps) m2 (cps) m12 (cps) mb (cps) τ (µs) Error (µs)
6.43 x 104 2.36 x 104 7.59 x 104 3.29 x 101 4.87 0.18
Table 4.1: Values used for calculation of dead time τ .
If the detector is non-paralysable, it is known the system will approach an asymptote for a
measured count rate of 1/τ , which represents the situation in which the device essentially
just completes one dead time period before starting another. In the paralysable case, the
measured count rate reaches a maximum value at an incident count rate of 1/τ , before the
measured count rate starts to decrease with increasing incident count rate, as illustrated in
Figure 3.6. For the DEPICT system, 1/τ is equal to just over 205 kcps. Above an incident
count rate of 205 kcps, the data do not fall off (decrease with increasing incident count rate)
confirming it follows a non-paralysable model. The measured count rate will tend towards
an asymptotic value of 205 kcps. Using Equation 3.10, it was determined that a measured
count rate of 205 kcps would be reached at 30,000 kcps for a dead time τ of 4.87 µs. When
the detector enters a plateau region and there is no unique correlation between the measured
and incident count rate, it is not possible to apply corrections. Therefore, a measured count
rate of 160 kcps was chosen as the maximum operating count rate as it is still possible to
correlate to the incident count rate. This maximum operating count rate will used in the
design of a high-energy parallel-hole collimator for the DEPICT system. The development
of the collimator is discussed in Section 5.1.
4.3 Summary of Characterisation Measurements
The characterisation measurements undertaken in this chapter ensure the detector has been
optimised for therapeutic imaging. Internal cooling fans were switched on and a reverse
bias voltage of 600 V, gain setting of 120 mV/fC, peaking time of 0.5 µs were selected to
give optimum energy resolution and γ-ray throughput. The detector was characterised as
following a non-paralysable dead time model and the dead time was calculated to be 4.87 µs.
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Often, characterisation of pixelated detectors involve an investigation into charge sharing.
That is, measurement of the proportion of charge that gets shared between neighbouring
pixels, degrading the spatial resolution. Data were acquired to ascertain the charge sharing
suffered in the DEPICT detector, however a 241Am source was used. The energy of the γ
rays emitted by 241Am (60 keV) is much lower than that of 131I and therefore the value of
the charge that gets shared would not be representative of that when using the detector for
radioiodine MRT and is therefore not included here. The methodology followed has however
been included in Appendix A.2 for completeness.
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Phantom Imaging
A medical imaging system with good image quality is essential for patient dosimetry. A
clear image with contrast between regions with different activity uptake is needed for area
delineation and calculation of activity within a region of interest. Medical imaging phantoms
are used to evaluate the performance of imaging systems, such as clinical gamma cameras.
Phantoms can be designed for testing detector performance characteristics, such as system
spatial resolution. Alternatively, they can be made to resemble organs or anatomical features
with materials that mimic the attenuating properties of human tissue. In order to evaluate the
imaging capability of the DEPICT system, data were acquired with 131I at various activities
and with a mix of phantoms. Table 5.3 summarises the aims of the imaging tests performed
in this chapter and the type of phantom used to achieve each aim. The custom designed
DEPICT collimator will also be described in this chapter as it is used to produce images
of line, Jaszczack and thyroid phantoms. In this chapter, data were also acquired with a
Siemens Intevo gamma camera at The Royal Marsden Hospital, to allow comparison of some
phantom data sets acquired with DEPICT.
Aim Phantom
Acquire a matrix of uniformity factors Uniformity
Determine system spatial resolution Line
Perform area delineation Jaszczak
Acquire a thyroid image and resolve features of differing activity Thyroid
Table 5.1: Experimental aims with associated phantom type.
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5.1 Custom-Designed Parallel-Hole Collimator
As detailed in Section 3.3, collimators are an integral part of a γ-ray imaging system and are
essential for image formation. A custom-designed high-energy parallel-hole collimator was
developed to couple to the DEPICT detector, optimised for imaging 131I 364.5 keV γ rays. It
was designed using Geant4 based Architecture for Medicine Oriented Simulation (GAMOS)
[102]. Although the Monte-Carlo optimisation study of this parallel-hole collimator was not
the work of this thesis, its final design will be discussed here. Hole length and diameter,
and collimator material were varied in the GAMOS Monte-Carlo simulations in order to op-
timise collimator design given the detectors maximum operating count rate of 160 kcps and
typical 131I administered activity of 3.7 – 7.4 GBq. The collimator was designed to have a
low efficiency, in order to eliminate dead time issues arising from high count rates used in
MRT. In the GAMOS simulations, the length of the circular collimator holes L was varied
between 30 – 65 mm and the hole diameter d between 0.6 – 1.4 mm. The final parallel-hole
collimator design parameters were: L = 55 mm, d = 0.6 mm and septa thickness t = 1.4 mm.
The long collimator holes with small diameter enable high-resolution images to be acquired,
whilst reducing the efficiency, and the thick septa reduced septal penetration. Tungsten and
lead were both studied for the collimator material. Although both were deemed to be suit-
able material for the collimator, tungsten was chosen as the final collimator material due
to its high density (19.25 g/cm3 compared to 11.34 g/cm3 for lead) and as lead is a haz-
ardous material that is difficult to machine due to its softness. The DEPICT collimator was
manufactured by M&I Materials [103] via selective laser melting (SLM), a form of additive
manufacturing. The process utilises a high powered laser to fuse successive layers of tungsten
powder until a complex component is built in a configuration specified by a CAD file. A case
study of the collaboration between M&I Materials and the University of Liverpool is found in
[104]. Applications of tungsten collimators have been proposed for high-energy 131I imaging
in [105, 106], with the attenuation and manufacturing accuracy of SLM tungsten discussed
in [107]. Figures 5.1a and 5.1b show photographs of the collimator design. The 15.5 mm
solid tungsten edge of the collimator reduces the number of γ rays interacting with the CZT
detector from outside the field of view (FOV). CAD images of the top, bottom and cross
sectional views of the collimator are shown in Appendix B.1.
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(a) (b)
Figure 5.1: Photographs of the high-energy parallel-hole DEPICT collimator.
To verify the collimated system did not suffer from dead time at therapeutic activity levels,
the count rate detected in DEPICT as a function of activity was experimentally investigated
in this thesis work. A 25 mm inner diameter vial was filled with 131I of activities varying from
0.1 – 3.5 GBq. The count rate measured at each activity was calculated by dividing the total
counts from the acquired sum spectra across all four modules of DEPICT by the acquisition
time. The activities of the 131I vial were measured by a dose calibrator, with an uncertainty of
± 3%. The energy threshold was set at 220 keV to reduce unwanted measurement of x-rays
and low-energy γ rays that would otherwise contribute to the dead time. The results are
shown in Figure 5.2. It can be seen the count rate increases linearly as a function of activity,
indicating no measurable dead time. This result demonstrates the system can be used to
calculate the activity uptake in localised regions up to 3.5 GBq. DEPICT therefore meets
the design criteria of being able to operate at therapeutic activities, beyond the capabilities
of some conventional gamma cameras, as discussed in Section 3.6.1. Unless otherwise stated,
all future measurements will be acquired with the DEPICT collimator.
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Figure 5.2: System count rate as a function of activity indicating the detector does not enter dead
time up to ∼3.5 GBq with the DEPICT high-energy parallel-hole collimator.
5.2 Uniformity Phantom
It has been shown that the total count rate measured in DEPICT is directly proportional to
the activity of 131I, up to at least 3.5 GBq. However, localised variations in measured count
rate have not yet been investigated. Knowledge and correction of any detector count rate
non-uniformities are essential as these would otherwise lead to inaccurate measurements of
activity within a region of interest, and hence of the absorbed dose calculated. To correct for
non-uniformities, a matrix of uniformity correction factors was created. This was achieved
using a flood field phantom, illustrated in Figure 5.3. A photograph of the phantom above the
DEPICT detector is shown in Appendix B.3. The phantom was designed in the work of this
thesis to have a fillable cavity that is 50 x 50 mm in area and 5 mm in height. The phantom
was filled with 21.0 ± 0.8 MBq of 131I in 12.5 ml and placed 5 cm from the detector face. Data
were collected with and without the collimator for 24 hours and 300 seconds, respectively, at
Thode Royal Liverpool University Hospital. The long acquisition time when the collimator is
present in these measurements is required to collect sufficient statistics because the collimator
is designed to operate for activities a factor of 100 higher. A matrix of detected counts per
pixel was generated from the data, creating uniformity maps. It is expected that the number
of γ rays incident on each pixel is equal, within statistical uncertainties accounting for the
radioactive decays of
√
N , therefore any further variation in the number of detected counts
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Fillable Cavity Height - 5 mm
Total Phantom Height - 8 mm
Fillable Cavity Length and Width - 50 mm
Total Phantom Length and Width - 60 mm
PTFE Screw Seals
Figure 5.3: Schematic of the uniformity phantom designed to irradiate the detector for normalisation.
would be due to pixel-to-pixel variations or collimator effects. The matrix of detected counts
acquired with and without the collimator were gated on γ-ray events with energies between
355 – 375 keV as all data acquired with 131I will be energy gated with this window. For the
uncollimated uniformity maps, the counts in each pixel were divided by the maximum pixel
count of 7149. For the collimated uniformity map, the maximum pixel count was 287. This
scales the uniformity maps for the uncollimated and collimated data between 0 and 1, as
shown in Figures 5.4b and 5.4b respectively, to give appropriate uniformity factors for each
pixel. For the uncollimated data in Figure 5.4a, it can be seen there is variation in detected
photopeak counts across the system. There are reduced counts in pixels at the edges of
each of the four detector modules. This is due to γ rays passing through the physical gaps
between the detector modules and therefore not interacting within the pixels and can also
be attributed to degraded charge collection in edge pixels [97]. In addition, environmental
effects such as light can also degrade the performance of edge pixels. There is also a region
of reduced counts corresponding to ∼0.7 normalised counts in detector module 2 from pixel
(12, 8) to (16,12). This is due to that detector module being slightly misaligned with respect
to the other three modules, increasing the gap. This misalignment is shown in Appendix B.2.
It is particularly important to uniformity correct the data when using the collimator as the
reduction in counts due to module misalignment is exacerbated, as seen in Figure 5.4b. This
is due to the collimator holes no longer exactly aligning with the CZT pixels. Figure 5.5
shows a histogram of the pixel counts from the data in Figure 5.4b. Ideally, the histogram
would be normally distributed around the mean number of counts in the pixels, however the
plot shows tailing on the lower count side, highlighting that a number of pixels have reduced
counts, beyond those expected from statistical fluctuations. Uniformity correction of future
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Figure 5.4: Uniformity factor pixel maps for the DEPICT detector (a) without and (b) with the
collimator coupled to the detector.
data sets will involved dividing each pixel by its associated pixel uniformity factor. In pixels
where its uniformity factor is nearly or equal to 1, such as in the middle of the detector
modules, the counts will not be modified to a great extent. However, module edge pixels
with a low uniformity factor will have their counts increased to bring them in line with inner
module pixels.
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Figure 5.5: Histogram of counts acquired when the collimated system is uniformly irradiated and
events are gated on energy between 355 – 375 keV. There are increased low pixel counts because of
collimator-module misalignment.
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5.3 Line Phantom
Line phantoms were used to investigate the DEPICT system spatial resolution with and
without scatter material between the phantom and the collimated detector [108]. The data
for these measurements were acquired at The Royal Liverpool University Hospital. The sys-
tem spatial resolution measures the ability of the system to determine the origin of a γ ray
on an x-y plane and is therefore a widely used measure of image quality. It is important
to take account of the Compton scattering contribution as the γ rays will have to travel
through the neck of the patient in thyroid MRT before they can be detected externally. The
system spatial resolution of the Siemens Intevo gamma camera used to acquire data in this
chapter is 13.4 mm with its associated high-energy parallel-hole collimator, measured at a
source-to-collimator distance of 10 cm. Thus, clinical systems such as this can only be used
to determine the 3D spatial distribution of activity in volumes that are large relative to this
dimension. For the calculation of system spatial resolution for DEPICT, the test equipment
consisted of two line phantoms (capillary tubes) with an inner diameter of 1 mm placed 1.6
cm apart. The capillary tubes were ∼40 mm in length, filled with 30 MBq of 131I and sealed
at both ends. The liquid radionuclide filled approximately 30 mm of the capillary tubes. The
tubes were positioned 10 cm from the face of the collimator along the axis of measurement
in both x- and y-directions. No material was placed between the collimator face and the
capillary tubes for the first acquisition. Figure 5.6a shows a photograph of the capillary
tubes with respect to one another. Before data acquisition, the capillary tube labelled (1)
was repositioned so the liquid 131I was in line with that of tube (2). The system spatial
resolution is then obtained from a line spread function. A line spread function (LSF) is the
profile of measured counts as a function of position across a line source. To create the LSF,
the data in the pixel intensity maps were summed parallel to the direction of the capillary
tubes over widths of 22 mm (pixels 6 to 16 in both x- and y-directions) to get a value for
each point in the LSF over 11 pixels. This is illustrated for the x-direction in Figure 5.6b.
Calculating the average count over 11 pixels and using two capillary tubes allowed data from
pixels in all four detector modules to be included in each LSF, giving a spatial resolution that
is representative of the whole detector. The pixel intensity maps were uniformity corrected
using the uniformity factors in Figure 5.4b. Due to the logistics of acquiring data at a work-
ing hospital, the data collection times of the four data sets (capillary tubes placed in x- and
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(a) (b)
Figure 5.6: (a) Photograph of the 1 mm inner diameter capillary tubes used to measure the system
spatial resolution in y-position and (b) a schematic illustrating how the data were summed to form
line spread functions for capillary tubes in the x-position where the black arrows show the range of
pixels summed. In reality, all counts in pixels from x = 6 to x =16 were summed for a given y-pixel,
but for ease of understanding only 6 arrows are shown.
y-positions, with and without scattering material) were not comparable. The range of data
acquisition times was 21 – 24 hours. Therefore, the counts in each image were normalised
when producing the LSFs for accurate comparison.
Figures 5.7a and 5.7c show the pixel intensity maps produced with the capillary tubes placed
in x- and y-positions, respectively. The pixel maps are gated on γ rays with energy between
355 – 375 keV. Figure 5.7a shows two areas of high counts that are one pixel in width in
the y-direction and approximately 15 pixels in length in the x-direction. The capillary tube
placed at y = 15 appears to contain more activity than the tube at y = 7, as each pixel
contains ∼4000 counts, compared to ∼3000 counts indicating the two capillary tubes may
not contain equal activities. Figure 5.7c shows the same two areas of uptake of 1 pixel wide
and 15 pixels in length. The capillary tube with slightly reduced activity is now positioned
at x = 16. For this capillary tube, pixels y = 4 to y = 11 have reduced counts compared
to those from y = 12 to y = 18. The top half of this capillary tube is positioned over
module 2 where there are known to be reduced counts, seen in Figure 5.4b. Although the
data has been uniformity corrected, Figure 5.7c shows the uniformity correction has not
adequately correctly the counts within this module. The uniformity map would be improved
with increased statistics as currently the average pixel count is approximately 200, giving a
low value of 0.002 cps per pixel.
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Figure 5.7: (a) Capillary tubes with no scatter material in x-position and (b) summed LSF for data
shown in (a). (c) Capillary tubes with no scatter material in y-position and (d) summed LSF for data
shown in (c).
System spatial resolution is typically measured and expressed as the FWHM of the LSF,
with the FWHM equal to the minimum separation required by two line sources if they are
to be just resolved. As the DEPICT detector is pixelated, the LSF counts are histogrammed
into well defined bins. Therefore, it is not appropriate to calculate the FWHM of the LSF
using a standard Gaussian fit. For calculation of the DEPICT system spatial resolution, the
percentage of counts in the peak pixel bin were compared to those of its two nearest neigh-
bours to assess the spread of counts from imaging a 1 mm inner diameter capillary tube.
Firstly, the average normalised background counts were determined and subtracted from all
pixel bins. The normalised background count for the x-position data was 0.055, and 0.058
for the y-position data. Then, comparison of the background subtracted counts in the LSF
peak pixel bin with those in the pixel bins either side of the peak bin was performed. Table
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5.2 shows the peak bin pixel number, the two nearest neighbour pixel bin numbers and the
background subtracted relative counts (%) in each bin with respect to the summed counts of
the three bins.
Capillary tubes in x-position
y pixel number % y pixel number %
Pixel 6 0 Pixel 14 7.48
Pixel 7 87.14 Pixel 15 92.45
Pixel 8 12.95 Pixel 16 0.07
Capillary tubes in y-position
x pixel number % x pixel number %
Pixel 7 10.99 Pixel 15 21.40
Pixel 8 88.73 Pixel 16 77.68
Pixel 9 0.28 Pixel 17 0.92
Table 5.2: Comparison of counts within the peak pixel bin to two nearest neighbour bins for the two
capillary tubes in both x- and y-positions. The % value shows the ratio of the counts within that
pixel bin to the sum of the three pixel bins, following background subtraction.
Table 5.2 shows that for the two capillary tubes in the x-direction and two in the y-direction,
the majority of the counts fall within one pixel with a much smaller percentage of counts in
the pixel bins either side of the peak bin. For the x-position, 87% and 92% of the counts for
both capillary tubes lie within one pixel. For the y-position, the values are 89% and 78%.
The ratio of peak bin counts to the sum of the peak and nearest neighbours counts is likely
poorer for the capillary tube at x = 16 due to the uniformity correction not adequately recov-
ering lost counts. Given that the majority of the counts lie within one pixel width, the system
spatial resolution of DEPICT at 10 cm was concluded to be 2 mm. Discrete detectors such as
the DEPICT CZT detector have their spatial resolution governed by the size of the pixel ele-
ments. Therefore, although the size of the object being imaged is less than 2 mm, this is not
discernible as the minimum bin size in the pixel size. It is possible to manufacture CZT detec-
tors with smaller pixel size but this adds complexity and cost in the readout and processing
of the data due to the increased number of pixels and sharing of charge across multiple pixels.
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Figure 5.8: (a) Capillary tubes with scatter material in x-position and (b) summed LSF for data
shown in (a). (c) Capillary tubes with scatter material in y-position and (d) summed LSF for data
shown in (c).
To evaluate the spatial resolution in a more realistic context to clinical implementation, a
10 cm thick acrylic scattering block (Zeff = 6.47 [109]) was placed between the capillary tubes
and the collimator [108]. A photograph of the setup is shown in Appendix B.5. This is to
replicate the scattering effect when the radioactive source is in the body of a patient. With an
effective atomic number Zeff for soft tissue of 7.4, Figure 3.2 shows Compton scattering is the
dominant interaction in tissue for the γ rays emitted from 131I and will therefore contribute
significantly. Figures 5.8a and 5.8c show the pixel intensity maps produced with the capillary
tubes placed in x and y-positions with 10 cm of scatter material. It can be seen in Figures
5.8a and 5.8c that, as expected, there is significantly increased background in comparison to
the data acquired with no scattering material. There are however, still two areas of increased
counts of 1 pixel width corresponding to the two capillary tubes in each image. Figures 5.8b
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Capillary tubes in x-position
x pixel number % x pixel number %
Pixel 7 3.07 Pixel 15 3.44
Pixel 8 91.82 Pixel 16 93.87
Pixel 9 5.11 Pixel 17 2.81
Capillary tubes in y-position
y pixel number % y pixel number %
Pixel 6 14.02 Pixel 14 17.66
Pixel 7 86.08 Pixel 15 80.81
Pixel 8 0 Pixel 16 1.52
Table 5.3: Comparison of counts within peak pixel bin to two nearest neighbour bins with scatter
material present. The % value shows the ratio of the counts within that pixel bin to the sum of the
three pixel bins, following background subtraction.
and 5.8d show the LSFs calculated for the summed data acquired with the capillary tubes in
x- and y-positions with scatter material. The normalised average background counts are 0.25
and 0.25, respectively, for the x- and y-position data. Following background subtraction, the
ratio of peak pixel bin counts and nearest neighbour counts to the sum of peak and nearest
neighbour counts for each LSF were calculated and are shown in Table 5.3.
The percentage of counts within the peak bins compared to the sum of the peak and nearest
neighbour bins are all over 80%, shown in Table 5.3. Although the number of background
counts has increased, the spatial resolution has not degraded with the inclusion of scatter-
ing material. In clinical gamma camera systems, the FWHM is known to degrade with the
inclusion of scattering material, however very little difference is observed in DEPICT. It is
expected that this is because the DEPICT collimator offers such high resolution that any
differences are at a negligible level, at the scale of one pixel width. The system spatial res-
olution is equal to the minimum distance that two line phantoms must be separated by in
space to appear as separate objects in the image. With DEPICT, as long as two objects are
greater than 2 mm (1 pixel width) apart, they will be distinguishable from one another.
A useful measure of the relative number of γ rays being detected via the photoelectric inter-
action is the peak-to-total ratio, defined as the ratio of number of counts in the photopeak
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Figure 5.9: Summed energy spectra for capillary tubes in x-position with scatter (blue line) and
without scatter (black line) material.
to the total number of counts in the spectrum. The peak-to-total ratio was calculated from
the sum spectra acquired with the capillary tubes in the x-position and compared for the
data collected with and without scatter material between the detector and the sources. The
total normalised counts between 250 – 400 keV, the energy region shown in Figure 5.9, were
calculated and compared to the the photopeak counts, with energy between 355 – 375 keV.
For the data acquired without scatter material, the peak-to-total was calculated as 14.7%.
For the scatter data, the peak-to-total decreased to 12.5%. As expected, the peak-to-total
has therefore slightly degraded due to the inclusion of scattering material. Having a lower
peak-to-total ratio is undesirable as it is indicative of increased scattering contribution, which
degrades the contrast in an image, however the excellent energy resolution of DEPICT sys-
tem in comparison to NaI scintillation based systems will facilitate high quality vetoing of
scattered events. The DEPICT system spatial resolution of 2 mm at 10 cm is significantly
better compared to clinical gamma cameras with a resolution of 13.4 mm. Improvement in
spatial resolution reduces partial volume effects, improves the detectability of small struc-
tures and provides precise anatomical localisation of radiotracer uptake, leading to improved
dose estimates.
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5.4 Jaszczak Phantom
The Jaszczak phantom [110] is a perspex body that contains various inserts for vials of
differing size. It is routinely used to assess the imaging performance of gamma cameras,
including image contrast and spatial resolution. Perspex is known as a tissue equivalent
material as it has a linear attenuation coefficient at 364.5 keV of 1.26 cm−1 and is comparable
that of soft tissue (1.09 cm−1 at 364.5 keV) [54]. One such phantom was constructed at the
University of Liverpool for the DEPICT project and is shown photographed in Figure 5.10a.
It can be seen that there are 12 inserts; 3 of which are 10 mm in diameter, 3 are 11 mm, 3
are 12.4 mm and 3 are 16.4 mm. Three vials of length 50 mm and inner diameter 10 mm
were filled with aqueous 131I and placed into the Jaszczak phantom. The positions of the
vials, labelled as 1, 2 and 3 in Figure 5.10a, corresponding to central positions above pixel
numbers (11, 8), (6, 17) and (16, 17) and the phantom was placed 10 cm from the detector,
as shown in Figure 5.10b. Vials 1, 2 and 3 contained solutions of activity 1.142 ± 0.03 GBq,
1.042 ± 0.03 GBq and 1.189 ± 0.04 GBq, respectively, as measured using a dose calibrator
with an error of 3%. Data were collected for 600 seconds. Figure 5.11 shows the sum energy
spectrum acquired from imaging the three vials for 600 seconds using DEPICT. The dashed
black lines illustrate the energy window that is used to select imaging events of 355 – 375
keV. Figure 5.12a shows the energy gated pixel map acquired. A uniformity correction was
then applied to the data and the uniformity corrected vial data are shown in Figure 5.12b.
(a) (b)
Figure 5.10: (a) Photograph of the custom Jaszczak phantom with the three 10 mm inner diameter
vials highlighted and (b) schematic of the Jaszczak phantom orientation above the collimated detector.
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Figure 5.11: Energy spectrum summed for all pixels produced for data acquired with three 131I vials.
The dashed black lines show energy gate that is applied to Figures 5.12a and 5.12b.
The uniformity corrected, energy gated pixel map produced with the DEPICT system shown
in Figure 5.12b is a direct projection of the three vials with three distinct areas of higher
counts with respect to the background. The positions of the three vials have been accurately
reconstructed. Vial 2 is known to have slightly reduced activity with respect to the other two
vials. The total counts from the pixels at the known position of vial 2 are 2.23 x 104. The
counts for vials 1 and 3 were 2.64 x 104 and 2.68 x 104, respectively, demonstrating that the
counts reflect the activity differences between the vials.
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Figure 5.12: (a) Energy gated pixel map acquired with DEPICT from imaging three 10 mm inner
diameter vials of 131I and (b) uniformity corrected, energy gated pixel map acquired from imaging
three 10 mm inner diameter vials of 131I. The white line highlights the slice taken for Figure 5.15.
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Data were subsequently acquired with the three vials of 131I and a commercial gamma camera
for comparison. The Siemens gamma camera was coupled to a high-energy general purpose
(HEGP) collimator with hexagonal holes of L = 59.7 mm, d = 4.0 mm and t = 2.0 mm.
The energy window was set between 337 – 392 (15%) as this is typically the energy window
set in clinical imaging. The data acquired with the clinical gamma camera were in Digital
Imaging and Communications in Medicine (DICOM) format, which is the international stan-
dard to transmit, store, retrieve, process and display clinical medical imaging information
[111]. Examples of information that can be read out from DICOM files is shown in Appendix
B.4. The medical imaging software OsiriX [112] was used to analyse the DICOM files. The
gamma camera had a FOV of 614 mm2, a matrix size n of 512 x 512 and zoom factor Z of
2. A zoom factor is sometimes applied during acquisition to further decrease pixel size. The
size of a pixel d in mm was therefore calculated to be 0.6 mm, using Equation 5.1 [113].
d =
FOV
Z × n (5.1)
The centre of the vials were positioned 10 cm from the HEGP collimator for 600 seconds.
The image obtained with the gamma camera is shown in Figure 5.13. Although the data
were originally binned into a 512 x 512 matrix, the axis was scaled given the 0.6 mm size and
is therefore shown as a function of pixel size in mm.
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Figure 5.13: Pixel map acquired from imaging three 10 mm inner diameter vials of 131I with a Siemens
Intevo gamma camera. The white line highlights the slice taken for Figure 5.15.
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The image acquired with clinical gamma camera does not have three distinct higher count
rate areas corresponding to the vial cross-sections, as is seen in the DEPICT image, but
instead shows multiple circular patterns. Imaging of high-energy γ rays requires collimators
to have thicker septa and larger holes, however this causes hole-pattern artefacts within the
image [114, 115]. The diameter of one of the small circles was measured using OsiriX to be
approximately 4.2 mm in size, which is consistent with the size of the 4 mm Siemens collimator
holes. If a γ ray penetrates the collimator septa without first undergoing a scatter interaction,
it cannot be distinguished from a desired event that passes straight through a collimator hole.
This cannot be compensated for using techniques that are based on differences in energy
spectra and degrades the spatial resolution. Often, collimators used with clinical gamma
camera have hexagonal holes. This shape is desirable as many holes can be packed together,
increasing the sensitivity. However, the system suffers from septal penetration if the septa
are not sufficiently thick for the γ rays that are being imaged, illustrated by the black solid
lines in Figure 5.14a. This produces an effect in the acquired image that is know as a ‘star
artefact’ due to the effect producing an image that looks like a star, resulting in a loss of
image contrast. This effect is exacerbated when there is a high-energy radionuclide within
a small volume and is regularly seen in 131I images of the thyroid, increasing the difficulty
of performing area delineation. This star artefact can be seen in Figure 5.14b. This image
shows the data from Figure 5.13 with a lower maximum value set in the colour map.
t = Septal Thickness
t
(a) (b)
Figure 5.14: (a) Schematic illustrating the star artefact caused by septal penetration of γ rays through
the collimator septa. (b) Jaszczak phantom image acquired with a clinical gamma camera and 131I
showing star artefact.
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Improving area delineation in planar gamma camera imaging, and subsequently volume de-
lineation in SPECT images, is an important aim of the DEPICT project. This allows for
better identification of the spatial distribution of 131I uptake to diseased areas of the thyroid,
and subsequently extraction of dosimetric values. In order to determine if accurate area de-
lineation is possible with the DEPICT system, analysis was performed to ascertain if the size
of a vial from the image in Figure 5.12b could be quantified. This methodology was repeated
and compared with the gamma camera image from Figure 5.13. To analyse these data sets,
a slice was taken through the centre of one of the vials. The ideal slice would have no counts
outside the known vial position, with a step function of maximum normalised counts of 1
within the vial location. The width of the step function should correspond to the known
diameter of the vial. The white lines through vial 2 in Figure 5.12b and Figure 5.13 illustrate
the chosen slice, corresponding to y = 17 pixels in the DEPICT data and y = 146 mm in
the Siemens gamma camera data. The slices were both 22 mm in length in the x-direction.
Figure 5.15 shows the slices produced from the images with the maximum counts from both
the DEPICT and Siemens gamma camera images normalised to 1 and plotted as a function
of x position (mm). The DEPICT pixel numbers were multiplied by 2, given the pixel size of
2 mm, to calibrate into mm for direct comparison with the Siemens data. The blue dashed
line shows the Siemens gamma camera data and the black solid line shows the DEPICT
data. The red dashed lines indicate the known position of the vial from the DEPICT image,
between x = 7 and x = 17 mm.
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Figure 5.15: Slice through vial 2 from DEPICT (black solid line) and Siemens gamma camera data
(blue dashed line). The dashed red lines show the true diameter of the vial.
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The DEPICT slice begins at background level increasing to a maximum between the red
dashed lines, before falling back to background. The background intensity of the DEPICT
data is ∼5% of the maximum. The variation in the DEPICT slice counts within the known
vial position can be attributed to pixel-to-pixel fluctuations due to Poisson statistics. The
gamma camera data however, has 3 local maxima which are centred at approximately x = 3,
10 and 18 mm. It is clear from visual inspection that the counts for the Siemens data are not
well constrained within the known region of the vial. There is also increased background of
30% of the maximum signal amplitude. The DEPICT system therefore clearly offers enhanced
spatial resolution and signal-to-noise over the Siemens system, which cannot delineate the vial
region. False hot spots in the Siemens data would correspond to inaccurate regions of localised
activity in a medical image, which could lead to incorrect diagnosis or false verification of
treatment.
In order to quantify how the DEPICT data varies from being an ideal step function, the
data was plotted against a step function of width 10 mm in Figure 5.16. The red dashed
line shows the diameter of the vial represented by an ideal step function, the solid black line
shows the DEPICT slice data and the grey dashed line through 0.5 normalised slice counts
shows the FWHM of the step function. This FWHM line was found to intercept the DEPICT
data at x = 7.4 and 16.8 mm. If the data were a true step function, it would intercept x = 7
and 17. The deviations from x = 7 and 17 are within one pixel width. This is a satisfactory
deviation as the limitation of the DEPICT system is the 2 mm pixel size.
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Figure 5.16: Slice through vial 2 from DEPICT data. Red dashed line shows the ideal step function.
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Taking a slice through a region of interest in an image is useful for looking at the signal-to-
noise ratio and for an approximate calculation of the vial size, but statistical fluctuations in
the pixel count may mean this is not a good way to determine the size of features. Therefore,
the cumulative frequency of the slices has been calculated. The cumulative frequency distri-
bution gives a running total of the counts in each pixel along the slice, therefore reducing the
statistical variation with each summed pixel count. The cumulative frequency distributions
of the slices through the middle of vial 2 from Figures 5.12b and 5.13 have been plotted as a
function of pixel size in mm. These are shown in Figure 5.17. The dashed black lines show
the apparent diameter of the vial from the pixel map images.
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Figure 5.17: Cumulative frequency plots for (a) the DEPICT system and (b) the clinical Siemens
Intevo gamma camera. The black dashed lines show the apparent diameter of the vial from each
image.
In Figure 5.17a, there are three distinct regions of the cumulative frequency plot that can be
fit with three straight lines of differing gradient, shown by the blue dashed lines. A straight
line was plotted through 2 – 6 mm with a gradient of 97 counts/mm. This increased to 1323
counts/mm between 6 – 16 and reduces to 55 counts/mm between 16 – 20 mm. The gradient
of the lines corresponding to areas of background in Figure 5.17a (2 – 6 mm and 16 – 20
mm) are less than 7.5% of gradient through the vial region (6 to 16 mm). The gradient is
expected to be low in regions of background, as not many counts are being accumulated.
In the vial, lots of counts are accumulating so the cumulative frequency increases rapidly
and uniformly if the activity is homogeneous. The point at which the gradient first deviates
from background, indicated by the first dashed line at 6 mm in Figure 5.17a, is taken as
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the start of the vial. The end of the vial is found when the gradient of the line deviates
back to background, shown by the second dashed black line at 16 mm. The width of the
lines is 10 mm, which is consistent with the known size of the vials. Comparatively, in the
cumulative frequency plot shown in Figure 5.17b, acquired from the gamma camera data in
Figure 5.13, there are no clear increase or decreases in gradient. Between 136 – 140, there is
a small bump, corresponding to the hot spot seen in the middle of the slice, but the gradient
remains relatively steady. It therefore is not practical to apply straight line fits to this data.
From Figure 5.13, the start and end point of the vial appear to be between 130 – 148 mm
which is indicated by the dashed lines in Figure 5.17b. This corresponds to a vial diameter of
18 mm, which is larger than the known vial diameter of 10 mm due to septal penetration and
poor spatial resolution. As the vial shape is not well defined, it is difficult from the image to
ascertain the shape and diameter of the vial. If this were an organ and dosimetry were being
performed by multiple operators, it is likely a variety of organ sizes would be measured giving
a range of calculated absorbed doses. The DEPICT system with improved spatial resolution,
energy resolution and custom-designed collimator successfully facilitates area delineation and
will reduce inter-operator variability in dose measurements when performing dosimetry.
5.5 Thyroid Phantom
To evaluate the system performance for imaging the uptake of radioiodine in the case of thy-
roid disease, a perspex anthropomorphic thyroid phantom based on a clinical Picker phantom
[116] was developed, shown in the photographs in Figures 5.18a and 5.18b. This is a very
important test case as ultimately the aim of the DEPICT project is to be able to perform
quantitative dosimetry for radioiodine treatment. The phantom has a thyroid shaped cavity
with 2 lobes and dimensions of 75 x 65 x 17.5 mm. In the human body, a healthy thyroid
gland would show similar uptake of radioiodine in both lobes. However, in patients with thy-
roid cancer or benign disease, there will be variable uptake in the thyroid resulting in areas
of higher or lower uptake with respect to the rest of the volume. These areas are referred to
as ‘hot’ and ‘cold’ regions, respectively. Hot spots are not often cancerous, however between
5 – 15 % of cold nodules may become malignant [117]. This expected non-uniform uptake
has been taken into account when designing the phantom. The phantom was designed to
have 3 solid rods in the thyroid cavity with diameters of 6, 9 and 12 mm to mimic three
cold spots. The height of the solid rods were equal to the lobe thickness. The right lobe also
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(a)
17.5 mm
35 mm
87.5 mm
32.5 mm
50 mm
(b)
Figure 5.18: Custom thyroid phantom (a) top and (b) side views.
contained a section that was twice the depth of the rest of the cavity and therefore contained
twice the activity, mimicking a hot spot. The hot spot had a depth of 35 mm. Between the
normal lobe and the base of the phantom is a 50 mm section of perspex (32.5 mm below
the hot spot). This attenuating material replicates the attenuating properties of the human
body. The thyroid phantom was filled with 2.7 GBq 131I and imaged at a distance of 10 cm
from the DEPICT collimator. In a clinical setting, the gamma camera FOV would be larger
than that of the thyroid being imaged. However, the DEPICT CZT detector is a prototype
system, which has a FOV limited to 44 mm2 (22 x 22 pixels). The active region of the thyroid
phantom is 75 x 65 mm and therefore larger than the detector FOV. Consequently, data were
acquired with DEPICT at four x,y positions in a 2 x 2 grid for 600 seconds each, as shown in
Figure 5.19. The pixel maps produced at each position were normalised with respect to the
uniformity map shown in Figure 5.4b and aligned with one another, obtaining an image of
the total thyroid active area. The final image is shown in Figure 5.20a. This multiple data
collection and merging of the data sets would not be required with a final clinical DEPICT
detector as it would be designed with a larger FOV by tiling multiple CZT modules. For
comparison, an image of the thyroid phantom was also acquired for 600 seconds with the
clinical gamma camera and is shown in Figure 5.20b.
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Figure 5.19: Schematic showing the four x,y positions of the thyroid phantom. The pixel maps
acquired at each position with the DEPICT system were normalised and merged together to create
one image of the total thyroid active area.
Qualitatively, the DEPICT image demonstrates significantly improved image quality com-
pared to the gamma camera image. The three cold spots are evident in the DEPICT image
with three regions at the known cold spot positions with approximately background counts
(∼30 counts). The 6 and 9 mm diameter cold spots are not evident in the Siemens gamma
camera image and although there is a slightly reduced region of counts at the known position
of the 12 mm cold spot, it is not well defined. Overall, there are increased statistics in the
Siemens image because of the large collimator hole size compared to the DEPICT collimator,
increasing sensitivity. As a reminder, this high sensitivity is undesirable in dosimetric imag-
ing following MRT, because it leads to high dead time in the detector system, which induces
large uncertainties on dosimetric calculations.
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Figure 5.20: Thyroid phantom imaged with (a) DEPICT CZT detector and high-energy parallel-hole
collimator and (b) Siemens gamma camera with high-energy general purpose collimator. The white
lines in (a) and (b) correspond to the slices used in Figure 5.21. The dashed square in (a) highlight
the subset of pixels used to acquire background counts for Figure 5.21.
To quantitatively analyse the cold spots, slices were taken through the 6, 9 and 12 mm cold
spot locations in the y-direction, shown by the white lines in Figures 5.20a and 5.20b. The
maximum counts of the three slices for both the DEPICT data and the Siemens gamma
camera data were normalised to 1 and plotted as a function of mm in the y-direction, shown
in Figure 5.21. The red dashed lines show the known location and width of each cold spot.
The black solid line shows the DEPICT data and the blue dashed lines show the Siemens
data, for each of the 6, 9 and 12 mm cold spots. Ideally, the slices would show normalised
counts of 1 outside the known cold spot region, with a reduction to background levels within
the region. For the 6, 9 and 12 mm cold spots, the DEPICT data follows this trend with a
reduction in counts within the known cold spot region. The data plotted through all three
cold spots begins at a maximum, decreases rapidly within the cold spot location and increases
again. The DEPICT 9 mm data looks slightly less like a step function because the diameter
of the cold spot is not divisible by the 2 mm pixel size, therefore it will cover 5 pixels. This
is due to the partial volume effect described in Section 3.6 where objects smaller than the
system resolution (2 mm for DEPICT) will have all their counts detected, but over a larger
volume than their true size. The slices through the cold spots in the Siemens data have a
very irregular pattern, caused by the hole-pattern artefacts within the image due to the large
collimator holes. The 6 mm Siemens data generally increase over 12 mm. The 9 mm data
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Figure 5.21: Normalised slices through the 6, 9 and 12 mm cold spot locations from data acquired
with DEPICT and Siemens gamma camera.
have a small dip in the middle but this likely due to statistical fluctuations as is not lower
than the data between 2 – 4 mm. The 12 mm data do decrease between the cold spot loca-
tions, however the overall slice tends to decrease rather than just between the dashed lines.
Qualitatively, the cold spots were not visible in Figure 5.20b when the thyroid phantom was
imaged with the Siemens gamma camera, however these results prove there are no significant
reduction in counts at the known cold spot positions. This indicates that cold spots caused
by malignancy in a thyroid image acquired with a clinical gamma camera may be missed,
but can be detected with the DEPICT system.
The DEPICT slices were subsequently accessed to ascertain whether counts within the cold
spots returned to background levels. The average background count from a subset of 77 pixels
outside the thyroid cavity shape, illustrated by the dashed white lines in Figure 5.20a, was
calculated as it would be expected that the counts from pixels within the cold spot were the
same as background. The average background from multiple pixels was calculated to reduce
the statistical errors that would arise from taking one slice through an area of background
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Figure 5.22: Normalised slices through the 6, 9 and 12 mm cold spot locations in DEPICT, with red
dashed lines indicating the ideal step function with the base at background level.
with only ∼20 counts per pixel. This average background value was then normalised to the
maximum count through each slice at 6, 9 and 12 mm. An ideal step function was plotted
with the base of the step function at the average background level. These background values
were 0.19, 0.15 and 0.15 normalised counts respectively for the 6 mm, 9 mm and 12 mm
data. The average background count remains the same but is normalised to different maxi-
mum values. As there are statistical variations within the slice counts through the DEPICT
cold spots, the average minima of each slice were calculated. This was achieved by summing
the normalised counts of each pixel value that lay within the step function, between the red
dashed lines, and diving by the number of pixels within that region. For the 6 mm data, the
counts from 6 and 8 mm were averaged, giving a normalised minimum slice count of 0.15.
For the 9 mm cold spot, the average normalised minimum slice count from summing counts
at 6, 8, 10 and 12 mm and was calculated as 0.24. Finally, summing the normalised counts
at 6, 8, 10, 12 and 14 mm gave a value of 0.23 for the 12 mm slice. The 6 mm cold spot
data appears to drop below the background level. The slice through the cold spot contains
only a small number of counts from a few pixels, compared to the average of 77 pixels for the
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background data, therefore this may be due to a particularly low counting pixel. The pixel
counts at the 9 mm and 12 mm cold spots do not completely fall to background level. The
DEPICT data however, are much improved on Siemens data where the cold spots are not
quantifiable.
The cumulative frequency method for obtaining the sizes of artefacts within an image was
investigated with the data acquired with the thyroid phantom, as this is a much more complex
test case than the individual vials in Figure 5.12b. For the slices illustrated through the 6
mm, 9 mm and 12 mm cold spots show in Figure 5.20a, the cumulative frequency of the
slice counts were calculated and are plotted in Figures 5.23a, 5.23b and 5.23c, respectively.
In addition, the cumulative frequency from a slice through the hot spot was also calculated.
The slice selected was y = 24, from x = 19 – 40 and the cumulative frequency plot is shown
in Figure 5.23d. For the slice through a cold spot, it is expected that the gradient of a line
through pixels outside the cold spot will be relatively steep, with the gradient being shallow
within the cold spot due to only a very small number of counts being summed from pixel-
to-pixel. Conversely, through the hot spot it is expected the gradient of the line will begin
shallow, increase through the known hot spot position as a high number of counts are being
summed, before levelling off outside the hot spot.
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Figure 5.23: Cumulative frequency plots for slices through (a) 6 mm cold spot, (b) 9 mm cold spot,
(c) 12 mm cold spot and (d) the hot spot from Figure 5.20a. The black dashed lines in each figure
correspond to three straight lines fit to regions of varying gradients.
For each of the data sets in Figures 5.23a - 5.23d, there are three distinct areas to each plot
that can be fitted with three straight lines of differing gradient, shown by the black dashed
lines. For the 6 mm cold spot data in Figure 5.23a the gradient of the line between 2 and
4 mm is 45 counts/mm, decreasing to 7 counts/mm from 4 to 8 mm and increasing to 38
counts/mm from 8 to 12 mm. The gradient between 4 and 8 mm is less than 20% of that of
the lines from 2 – 4 and 8 – 12 mm. This would indicate a cold spot of 4 mm in size. It is
known that the cold spot is 6 mm in diameter, therefore the cumulative frequency method
does not accurately reconstruct the known cold spot diameter. For the 9 mm cold spot data,
this trend is reproduced with a gradient of 44 counts/mm between 2 – 4 mm, 14 counts/mm
from 4 – 12 mm and 45 counts/mm from 12 – 16 mm. This would suggest the cold spot is
8 mm in diameter, which is smaller than the known diameter of 9 mm. For the 12 mm cold
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spot data the gradient is 51 counts/mm from 2 – 4 mm, 14 counts/mm from 4 – 16 mm and
56 counts/mm from 16 – 18 mm. This indicates a cold spot of diameter 12 mm, which is
consistent with the known cold spot size. Finally, for the hot spot cumulative frequency, the
gradient is 24 counts/mm from 2 to 8 mm, increasing to 124 counts/mm from 8 to 38 mm and
decreasing to 19 counts/mm from 38 to 48 mm. This suggests there is an area of increased
counts or a hot spot of 30 mm. This is consistent with the known area of increased counts
along this slice of 15 pixels in width. The cumulative frequency method for determining sizes
of areas of interest within an image was found to be successful for cold spots of at least 12
mm in size and for hot spots. However, for cold spots of 6 and 9 mm in diameter, this method
did not accurately reconstruct the known vial size. When the contrast within an area of an
image is degraded, the cumulative frequency method has difficulty in accurately ascertaining
the diameter of a region of interest.
5.6 Summary of Phantom Imaging Measurements
One of the key aims of the DEPICT project is to develop a system that can accurately
delineate areas of interest. This was tested with the DEPICT system and compared to
the Siemens gamma camera with vials of 131I. Methods such as determining the cumulative
frequency of a counts through a slice within an image have been established to quantify sizes
of features in an image. It was accurately found to calculate the sizes of 10 mm inner diameter
vials and cold spots greater than 12 mm in diameter. The DEPICT system has been shown
to have improved image quality when imaging clinical activities of 131I due to the superior
spatial and energy resolution. The system spatial resolution at 10 cm was determined to be 2
mm, compared to 13.8 mm for a clinical gamma camera. The spatial resolution of DEPICT
is ultimately limited by pixel size, but there is a compromise however, between decreasing
pixel size to improve the spatial resolution and suffering from charge sharing. In addition, an
increased number of smaller pixels leads to increased electronics for read out of more channels,
that requiring increased cooling. A smaller number of counts would also be acquired per each
pixel, increasing statistical error. Therefore, the DEPICT pixel size of 2 mm is a sufficient
compromise. Finally, images acquired with a thyroid phantom were compared with DEPICT
and a Siemens gamma camera. Cold spots that were visible in the DEPICT image were not
distinguishable by the clinical system, highlighting the improved image quality.
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Activity Quantification and
Tomography
Accurately quantifying the uptake of radioactivity within patients undergoing MRT is essen-
tial for personalised dosimetry. This requires the conversion of detected counts (in cps) in
a region of interest into a value of activity (e.g. MBq). Image quantification, however, is
regarded as the largest cause of inaccuracy in dosimetry. Firstly, there are camera limita-
tions such as the spatial resolution, energy resolution and dead time. Secondly, degradation
of the images from attenuation and scatter will cause errors in the quantification of activity.
This chapter will investigate the feasibility of using DEPICT to obtain quantitative activity
information from both planar and 3D images.
6.1 Relative Activity Quantification
To begin with, quantifying the relative activity of various regions of interest within an im-
age was investigated using the thyroid phantom detailed in Chapter 5 and shown in Figures
5.18a and 5.18b. As the hot spot is twice the depth of the normal lobe, it should have twice
the activity and hence twice the number of counts should be detected in comparison to the
normal lobe. To investigate this, the ratio of counts in 1.44 cm2 regions of interest within
the normal lobe and the hot spot were compared to each other, using data acquired with
both the DEPICT and the Siemens Intevo gamma camera; the expected ratio being 50%.
The regions of interest were equidistant from the centre of the phantom, as highlighted by
the white squares in Figures 6.1a and 6.1b. There is a section of perspex between the base
of the thyroid cavity and the base of the phantom, therefore an attenuation correction needs
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Figure 6.1: Thyroid phantom imaged with (a) DEPICT CZT detector and high-energy parallel-hole
collimator and (b) Siemens gamma camera with high-energy general purpose collimator. The left
hand square in each image highlights the data selected from the normal lobe; the right hand square
shows the hot spot.
to be applied. The thickness of perspex between the normal lobe and the base of the phan-
tom is 50 mm, whilst there is 32.5 mm between the hot spot and the base. An attenuation
correction was performed using Equation 3.5, where the linear attenuation coefficient µ of
perspex is 0.126 cm−1 [54]. As discussed in Section 3.6 attenuation correction is essential for
accurate activity quantification measurements. The raw and attenuation corrected counts
for the normal and hot spot regions for both images are shown in Table 6.1, along with the
calculated ratios of both the uncorrected and corrected normal lobe counts to hot spot counts.
The ratio of uncorrected normal/hot lobe counts is 36.19 ± 0.73% for DEPICT and 37.86
± 0.05% for the Siemens clinical gamma camera. The ratios increase to 45.12 ± 0.91% for
DEPICT, and for the Siemens camera to 47.19 ± 0.07%, highlighting the importance of
attenuation correction for quantifying activity. The ratios are consistent with one another,
calculated using the consistency relationship |x1 − x2| < 3
√
∆x21 + ∆x
2
2 and within reason-
able agreement of the known ratio of 50%. Corrections for self absorption have not been
implemented. The statistical error calculated for the Siemens data is much smaller because
there are significantly increased counts due to the higher throughput of γ rays through the
clinical collimator. In clinical gamma camera imaging of the body, it would be necessary to
use multiple attenuation coefficients for tissues of differing densities.
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DEPICT Siemens
Uncorrected normal lobe counts (x103) 3.34 695.39
Uncorrected hot spot counts (x103) 9.24 1836.98
Ratio of normal/hot uncorrected counts (%) 36.19 37.86
Error on ratio (%) 0.73 0.05
Corrected normal lobe counts (x103) 6.28 1305.67
Corrected hot spot counts (x103) 13.91 2766.61
Ratio of normal/hot corrected counts (%) 45.12 47.19
Error on ratio (%) 0.91 0.07
Table 6.1: Raw and attenuation corrected counts for normal lobe and hot spot for the DEPICT and
gamma camera images.
6.2 Distance Dependence
Although it is useful to extract the relative activity uptaken to different regions of interest,
the absolute activity is a more valuable measurement for dosimetry and treatment verifica-
tion. To be able to determine the calibration factor for converting measured count rate (cps)
into absolute activity (GBq), it is necessary to determine if there is a geometrical dependence
on the detected count rate. If this was the case, the calibration factor that is required to
convert counts into an activity would also need to vary as a function of distance between the
thyroid and DEPICT. It is expected in clinical implementation that the distance between the
thyroid and DEPICT will be approximately 10 cm [118], however this could vary according to
the patient geometry. In order to investigate the geometrical relationship between measured
counts and distance, data were acquired with a dose calibrator reference vial of 133Ba, shown
in Figure 6.2 [119]. The vial was manufactured by distributing the active element in 20 ml of
epoxy, comprising a density of approximately 1.0 g/cm3 and supplied in a 27 ml polyethylene
vial. A distributed source, rather than a point-like source, was selected for this measurement
as it mimics the scenario of imaging activity contained in the thyroid. The diameter of the
base of the vial is 31.2 mm, as shown in Figure 6.2a. The 133Ba vial was mounted onto a me-
chanical scanning arm, shown schematically in Figure 6.2b, which accurately positioned the
vial at distances of 2, 4, 6, 8 and 10 cm from the face of the collimator. The scanning arm is
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(a) (b)
Source-to-collimator 
distance
Mechanical scanning arm
Collimator
Detector
3.19 in [81 mm]
Active element
[20 ml resin matrix]
Capsule
  1.23 in
[31.2 mm]
Cap
133Ba vial
Figure 6.2: (a) Image of the 133Ba vial and (b) a schematic of the experimental setup with the 133Ba
vial on mechanical scanning arm at a distance from collimator face.
controlled by a Velmex VXM Stepper Motor Controller [120] that has the capability to drive
and control precise linear movement and was selected to minimise any errors in positioning
the source as the only variable is the distance to the collimator. Although 133Ba provides an
excellent analogue to 131I γ emissions, the activity of the vial at the time of measurement
(8.39 MBq) was several magnitudes lower than that used in therapy (a few GBq). A data
collection time of 20 hours for each distance was therefore selected to minimise statistical
uncertainties. An energy gate of 340 to 360 keV was applied when using the 133Ba source,
which removes contribution from scattered γ rays and maximises signal to noise in the image.
This energy window is shown in the 133Ba spectrum in Figure 6.3.
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Figure 6.3: Energy spectrum acquired with the distributed 133Ba source. The dashed black lines
highlight the 340 – 360 keV energy window.
The average counts per pixel at each distance was calculated by summing the counts from all
pixels and dividing by the total number of pixels. Known noisy pixels were manually switched
off and not included in the analysis, which left 478 useful pixels. The results are shown in
Table 6.2. The average pixel counts obtained for the source at each measurement position
are all directly comparable as the collection time was the same (20 hours) and activity loss
over the total 100 hour data collection is negligible for 133Ba (t1/2phys = 10.51 years).
Source-to-collimator distance (cm) Total counts Average counts per pixel Error on average pixel count
2 34227 71.61 8.46
4 33688 70.48 8.39
6 34119 71.38 8.44
8 34004 71.14 8.43
10 34758 72.72 8.53
Table 6.2: Counts as a function of source-to-collimator distance for all pixels.
The average number of counts per pixel range from 70.48 to 72.72 and do not appear to follow
a direct relationship with distance. Instead, the fluctuations can be attributed to statistical
uncertainties and all average pixel counts are within
√
N of one another. This is an expected
result as it is known parallel hole collimators have a count rate that is independent of distance
[55] which is ideal for clinical measurements as distance dependent calibration factors are not
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required. Measurements can now be undertaken to determine a suitable calibration factor
and investigate the feasibility of absolute activity quantification.
6.3 Planar Absolute Activity Quantification
In order to perform absolute measurement of the activity in regions of interest, the calibra-
tion factor, or planar sensitivity (cps/GBq) of the system must be known. To determine
the DEPICT system sensitivity, the National Electrical Manufacturers Association (NEMA)
System Planar Sensitivity test for discrete pixel detectors was followed [108]. NEMA stan-
dard tests were developed to provide a uniform criterion for the measurement and reporting
of performance parameters for gamma cameras. Planar sensitivity corresponds to the sensi-
tivity in one acquisition plane to a specifically defined planar source placed parallel to that
plane and are dependent on collimator type, energy window width, γ-ray energy, source con-
figuration and other factors. The NEMA test states a dose calibrator for accurate activity
measurements and flat plastic dish (e.g. petri dish) are required. A petri dish with a small
enough diameter for the DEPICT CZT detector was not available, therefore a vial with a
base diameter of 30 mm was used. The system sensitivity must be determined for the energy
window used with a particular radionuclide therefore the energy window was set at 355 –
375 keV, which is the energy window used with 131I (∼ 5%). The vial was filled with 3.45
GBq of 131I and placed 10 cm from the face of the collimator, which is expected to be the
approximate distance between the thyroid and DEPICT in future clinical implementation.
The uncertainty on the calibrator used to measure the activity is 3%. As only events within
the photopeak window are considered, the activity needs to be multiplied by the emission
probability of the 364.5 keV γ rays emitted from 131I, which is 81.7%. Therefore, the 364.5
keV photopeak activity was 2.82 GBq. Data were collected for 120 seconds and the number
of counts within the photopeak was measured. A background measurement was also collected
without the vial for 120 seconds.
The total number counts within the 355 – 375 keV energy window was 18522 ± 136, after
background subtraction. The energy gated pixel map image acquired is shown in Figure
6.5a, without any uniformity or scatter corrections applied. The data acquisition time of
120 seconds gives a sensitivity, or number of detected photopeak counts per unit time per
unit source activity, of 54.73 cps/GBq. To increase the accuracy of the calculated sensitivity
88
CHAPTER 6. Activity Quantification and Tomography
value, two corrections can be applied to each pixel; a uniformity correction and a scatter
correction. The uniformity correction was applied using the uniformity factors matrix shown
in Figure 5.4b. It is known that a portion of the counts within the photopeak may arise
from Compton scattered events, due to 131I emitting γ rays higher in energy than 364.5 keV.
Therefore, the Triple Energy Window (TEW) scatter correction method was used [121] to
remove scatter events. The true primary γ-ray emissions Cprim are given by:
Cprim = Ctotal − Cscat, (6.1)
where Ctotal and Cscat are the total photopeak counts and counts arising from scattering
events, respectively. The subtraction is carried out using two sets of data: the counts acquired
within a main window centred on the photopeak energy, and the counts from two sub-
windows, positioned either side of the the main window. The scattered γ rays included in
the main window are estimated from the counts acquired within the sub-windows. Figure 6.4
illustrates the main photopeak window and the sub-windows to the left and the right of the
photopeak window. The TEW correction method is more suitable with 131I than the dual
window correction method [122] (where there is only a left window and main window) as the
right window will account for scatter from emissions above 364.5 keV.
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Figure 6.4: 131I sum spectrum acquired for planar sensitivity measurement showing left, main and
right windows for Triple Energy Window (TEW) scatter correction.
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The width of the main window is defined as Wm and that of the sub-windows as Ws. The
scattered counts in the photopeak Cscat can be estimated from a linear interpolation between
the two sub-windows, following a trapezoidal approximation of scatter counts:
Cscat ∼=
(
Cleft
Ws
+
Cright
Ws
)
∗ Wm
2
(6.2)
where Cleft and Cright are the counts in the left and right windows, respectively. The left
scatter window was defined between 345 – 355 keV and right scatter window between 375 –
385 keV. To obtain the total counts Ctotal, the uniformity corrected counts from each pixel
were summed and the value of Cscat was acquired by summing the scatter correction to
each pixel. The planar system sensitivity (cps/GBq) was then determined by dividing the
true counts of the planar scan (photopeak minus scatter counts) by the known activity and
acquisition time. Figure 6.5b shows the pixel map following the application of uniformity
and scatter corrections applied to each pixel. Table 6.3 lists the values of Ctotal, Cscat, Cprim,
acquisition time, Cprim (cps), source activity and calculated sensitivity.
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Figure 6.5: Energy gated pixel maps of (a) raw counts acquired from imaging the 30 mm diameter
vial and (b) with uniformity and scatter correction applied to each pixel. Note the difference in scales.
Although the pixel counts in Figure 6.5b are expected to become more uniform with the
application of a uniformity correction, it is known from the previous measurements that the
correction is suboptimal. In addition, the small number of counts per pixel mean the counts
in the sub-windows Ws are large, relative to the main window Wm giving large statistical
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Figure 6.6: Raw (uncorrected) data acquired using DEPICT for (a) 1 vial and (b) 3 vials containing
131I.
fluctuations in pixel counts. It is expected this effect would improve with a longer data
collection time.
Ctotal Cscat Cprim Time (s) Cprim (cps) Activity (GBq) Sensitivity (cps/GBq)
47563 26967 20597 120 171.6 2.82 60.87
Table 6.3: Values for calculation of scatter correction and sensitivity. All values are uniformity
corrected.
The new value for sensitivity, calculated following the application of uniformity and scatter
corrections is 60.87 cps/GBq, shown in Table 6.3. Data were subsequently acquired to de-
termine the feasibility of using both system sensitivity values for activity quantification. For
this, data were acquired with a single vial and 3 vials filled with 131I. Figures 6.6a and 6.6b
show the energy gated pixel maps acquired for these two data sets. The single vial had a
total activity of 1.14 ± 0.03 GBq as measured by a dose calibrator with an error of 3% and
the three vials had a total sum activity of 3.37 ± 0.06 GBq. The total error on the three
vial sum activity is found by adding the errors of each individual vial in quadrature due to
the propagation of errors. Both data sets were acquired for 600 seconds and each vial had an
inner diameter of 10 mm. Before the total counts could be calibrated into an activity, three
corrections needed to be applied:
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• Attenuation Correction
Unlike the calculations for the sensitivity values where there was no attenuating material
between the vial and the collimator, the 1 and 3 131I vial data sets were acquired with the
vials placed in the Jaszczak phantom shown in Figure 5.10a. Therefore, an attenuation
correction (AC) needed to be applied to each pixel to account for the 2 cm perspex
material at the base of phantom using Equation 3.5.
• Uniformity Correction
As with previous data sets, a uniformity correction (UC) was performed using the
uniformity matrix shown in Figure 5.4b.
• Scatter Correction
A TEW scatter correction (SC) was applied to each pixel for the data acquired with 1
and 3 vials.
The AC and UC were applied to the main energy window and two sub-windows for each
pixel in each data set. This meant that when using Equation 6.2 to determine the scatter
contribution, the sub-window counts were also corrected for attenuation and uniformity to
make the counts comparable. Table 6.4 shows the total photopeak counts following the
application of attenuation, uniformity and scatter corrections. Following AC, the total counts
for each vial increases, due to the recovery of counts that were lost by attenuation in the
perspex. The UC increases total counts by about 40% as it is known there is a reduction in
counts at the edges of each of the four modules and the SC reduces the counts as scattered
counts within the photopeak window have been removed.
Total raw counts After AC After AC + UC After AC + UC + SC
1 vial 2366 3044 8683 3627
3 vials 70881 91195 232881 96711
Table 6.4: Total counts before and after attenuation AC, uniformity UC and scatter SC corrections.
The total counts acquired for the single vial data after the application of the three corrections
was 3627. Since the data collection time was 60 seconds, this gives a value of counts per second
(cps) of 60.54. The total counts acquired over a 600 second period for the 3 vial data was
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96711, giving a cps value of 161.19. These values were divided by each sensitivity value to
give a value of activity in GBq and are shown in Table 6.5.
1 vial activity (GBq) 3 vial activity (GBq)
Sensitivity value 1 (54.73 cps/GBq) 1.11 2.95
Sensitivity value 2 (60.87 cps/GBq) 0.99 2.65
Table 6.5: Calculated activities for 1 and 3 vials of 131I using sensitivity values.
The calculated activities of the single vial were 1.11 ± 0.16 GBq and 0.99 ± 0.14 GBq,
respectively, using sensitivity values 1 and 2. The photopeak activity of the single vial was
0.91 ± 0.03 GBq. The calculated value for activity using sensitivity value 2 is within errors of
the known vial activity, whilst that calculated using sensitivity value 1 is not. The calculated
activities for the 3 vial data were 2.95 ± 0.28 GBq and 2.65 ± 0.26 GBq, using sensitivity
values 1 and 2, respectively. Although the calculated activity using sensitivity value 2 is
closer to the know total photopeak activity of the 3 vials of 2.73 ± 0.05 GBq, both calculated
activities are within errors of the known activity value and were calculated to be consistent
with the using the consistency relationship |x1 − x2| < 3
√
∆x21 + ∆x
2
2. These results show
planar activity quantification with DEPICT is feasible, with improved values calculated when
corrections are implemented for the image degrading factors such as attenuation and scatter.
6.4 Tomographic Reconstruction
The results obtained for planar imaging with DEPICT have been shown as superior to those
obtained with a clinical gamma camera. However, a further challenge for the device will be
producing 3D images of the 3D volumes of interest, by acquiring data at multiple angles to
be input to tomography algorithms. This results in a SPECT image, rather than a planar
gamma camera image. The feasibility of obtaining 3D images with the DEPICT system was
investigated. For tomographic reconstruction, the open-source software NiftyRec [123] was
utilised in Matlab to reconstruct data using an Ordered Subset Expectation Maximisation
(OSEM) algorithm. The 133Ba vial source shown in Figure 6.2 was mounted onto a rotating
scanning table and data were collected for the vial at various angles to the DEPICT gamma
camera, shown in Figure 6.7a. The scanning table was a Velmex Rotating Table [124] designed
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to allow motorised continuous 360◦ rotational motion. Data were collected over 360◦, at 10◦
increments, with the data collection time for each step set at 28,800 seconds (8 hours). The
long counting times were necessary due to the low source activity of 8.59 MBq and would be
decreased significantly in clinical implementation for GBq activities. The distributed 133Ba
source shown in Figure 6.2a was used for data collection. With the vial mounted vertically,
the middle of the resin was 6.5 cm from the face of the collimator. Data were recorded at
every 10◦ increment as a csv file, containing list-mode data which was input to the NiftyRec
Matlab code. The first process performed by the code was calibration of the raw data using a
calibration file, and the application of an energy gate to veto events arising from outside the
photopeak. A planar image is produced for each angle of rotation θ and all the planar images
are saved into a 3D matrix of x, y, θ, where x and y are the 22 x 22 pixels. A common way
of presenting this information is in the form of a 2D matrix, known as a sinogram [125]. A
sinogram produces a 2D cross-sectional image of the activity from a slice within the object at
each angle θ. A slice was taken through the 3D matrix to create a sinogram for y pixel number
= 18 and is shown in Figure 6.7b. Each column represents a single row in the projection
image arranged in increasing angular order. The goal of an iterative reconstruction algorithm
such as OSEM is to estimate the object from a measured sinogram.
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Figure 6.7: (a) 133Ba vial mounted onto the rotating scanning table above the DEPICT collimator
and (b) a sinogram produced from a slice through the data acquired at each angle.
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The second process within the code applies the OSEM algorithm to the 3D data. It is possible
to optimise the output of the reconstruction by varying user inputs. The most important
of these is the iteration number, which corresponds to the number of OSEM iterations. For
each iteration, a closer estimate of the true counts distribution is achieved, however too many
iterations can generate unwanted noise. The output of the code following application of the
algorithm is a text file with four columns of the format x, y, z and intensity, where the x, y,
z values give the coordinates of reconstructed counts (intensity) in 3-dimensions. The pro-
gramme TopCat [126] (Tool for Operations on Catalogues and Tables), which is an interactive
graphical viewer and editor for tabular data, was then utilised to view the contents of the
text file. It has the functionality of 3D plotting using cartesian coordinates where points in
3D are coloured according to their intensities.
Initially, one iteration was used with 2 OSEM subsets. The reconstruction produced is shown
in Figure 6.8a. The reconstructed 3D cylindrical volume is expected to have a base diameter
and height of 16 pixels. This reconstructed image has counts in every voxel (3D pixel) and
does not resemble the 133Ba vial, however it is known that OSEM algorithms generate a
very simple initial image estimate for one iteration. The number of iterations was therefore
increased to 5 and the subsequent reconstructed image is shown in Figure 6.8b. Figure 6.8b
appears to show a concentrated region of counts within the centre of the image where the
vial is known to be, indicated by an increase of purple coloured voxels of 50 – 70 counts, but
it still does not resemble a reconstruction of the 133Ba vial. For each planar image obtained
at each reconstruction angle, counts are acquired in every pixel. These counts are either true
photopeak counts, as an energy gate was applied, or background. Hence, all the background
counts will also undesirably get reconstructed and these counts will be masking the true vial
shape. Therefore, the data were reprocessed with a suitable threshold was applied to the
reconstructed counts to attempt to clean up the image. A threshold was selected that visi-
bly removed unwanted counts from the image, whilst retaining the counts at the known vial
position. Example reconstructed images, following the application of a threshold are shown
in Figures 6.9, 6.10 and 6.11 for 1, 15 and 150 iterations.
Figure 6.9 shows that applying a threshold with the simple initial condition of one itera-
tion removes unwanted background counts, and a reconstructed image that resembles a the
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(a) (b)
Figure 6.8: 3D reconstructed 133Ba vial following (a) 1 iteration and (b) 5 iterations.
cylindrical shape of the 133Ba distribution is evident. The size of the reconstructed volume
however, is much larger than the known vial size. Increasing the number of iterations to 15
for example, shown in Figure 6.10, produces a much more accurate 3D representation of the
133Ba vial. It does appear that the activity is not evenly distributed within the epoxy resin
as the counts are not constant across the reconstructed volume. There are counts of approx-
imately 100 towards to centre of the volume, with regions of around 200 counts towards the
vial edge. At the maximum iteration number used for this analysis of 150, the volume does
not resemble the known shape and it appears to be suffering from edge enhancement [127].
This edge artefact can occur at high iteration number near edges where the radioactivity
concentration level changes appreciably within a small distance, such as the edge of a vial,
enhancing edge activity whilst underestimating the activity at the centre of the vial.
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Figure 6.9: 3D reconstructed 133Ba vial after 1 iteration, with a threshold of 30 reconstructed counts.
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Figure 6.10: 3D reconstructed 133Ba vial after 15 iterations, with a threshold of 30 reconstructed
counts.
Figure 6.11: 3d reconstructed 133Ba vial after 150 iterations, with a threshold of 30 reconstructed
counts.
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Following the application of a threshold, an investigation into the optimum number of itera-
tions for this data was conducted. It is known that the total reconstructed counts within an
image will remain constant with increasing iteration number. However, for the reconstructed
counts within a volume of interest in an image, such as the vial in this data analysis, the
reconstructed counts will increase with increasing iteration number as the algorithm produces
better estimates of the actual distribution of the counts. However, above a certain iteration
number (that will vary for every data analysis with OSEM algorithms) the counts will satu-
rate. This means the iterative code has converged to the maximum likelihood estimate of the
count distribution and further iterations do not improved the estimate, but increase noise.
Due to the probabilistic nature of the reconstruction algorithm, every time it is applied to
the data a unique 3D count distribution is produced. Therefore, for the investigation into
the optimum iteration number, the data has been processed by the reconstruction code three
times to obtain an average total number of reconstructed counts at each iteration number
over a range from 1 to 150 iterations. The average total reconstructed counts within the
volume of interest have been plotted as a function of iteration number and is shown in Figure
6.12.
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Figure 6.12: Total average reconstructed counts within the volume of interest as a function of the
number of iterations for the NiftyRec OSEM algorithm.
98
CHAPTER 6. Activity Quantification and Tomography
A fit has been applied to these data, which follows a second order exponential y = aebx+cedx
where a = 1.43e+5, b = 3.64e-5, c = -2.88e+4 and d = -0.13. The shape of this plot
is as described above and is typical for increasing iteration number in OSEM algorithms
[128, 129, 130]. For this data, the total reconstructed counts saturate above approximately
30 iterations. The total reconstructed counts at 50 iterations appears to be anomalous as it
does not follow the fit to the data. Ideally, an iteration number would be selected that lies
on the area of the graph that curves just before the plateau, giving a compromise between
increased image noise and optimum estimate of reconstructed counts. For this data, an iter-
ation number of 15, 20 or 30 would satisfy this criteria.
To further investigate the optimum iteration number, the reconstructed 3D images produced
at each iteration number were compared to see if they resembled the true dimensions of
the 133Ba vial. A histogram was plotted showing the total reconstructed counts integrated
over the y-direction for each value along the x-axis. This would indicate the reconstructed
diameter of the base of the vial and was used as a measure of how accurately the reconstructed
image resembled the true volume. An example histogram of 15 iterations is shown in Figure
6.13.
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Figure 6.13: Histogram showing total reconstructed counts in the y-direction for each x value. Data
shown is for 15 iterations.
The known vial diameter is 31.2 mm therefore due to the DEPICT pixel size of 2 mm, the vial
should produce counts across 16 pixels because of partial volume effects. For the histogram
shown in Figure 6.13, counts are distributed in the x-axis from 4 – 20. As counts are acquired
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Figure 6.14: Vial diameter determined from histograms as a function of iteration number. Dashed
line shows real vial diameter.
over 16 pixels and these counts are known to be attributed to the reeconstructed vial volume
at that iteration number, the reconstructed vial diameter was taken as 16 pixels (32 mm),
accurately reconstructing the known diameter. The vial diameters acquired from histograms
at various iteration numbers from 1 – 150 were plotted as a function of iteration number in
Figure 6.14. In Figure 6.14, the dashed line illustrates the known vial diameter and the error
on the measured vial diameter is 2 mm as this is the smallest size the DEPICT detector can
measure. Figure 6.14 shows that for these data, there are three iteration numbers where the
vial size is accurate; 5, 10 and 15 iterations. Above this, the vial decreases in size. This is
possibly due to the edge enhancement effect skewing the size of the reconstructed vial. For
this data, 15 iterations was selected as the optimum OSEM iteration number as it gives the
best estimate of counts, reduced noise, whilst also accurately reconstructing the known vial
size.
To be able to extract quantitative activity information for the 3D reconstruction, corrections
would need to be applied within the reconstruction algorithm for scatter, attenuation, partial
volume effects and collimator-detector response [128]. In addition, calibration data would
need to be acquired for conversion of reconstructed counts to absolute activity. The extent
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and complexity of the work required to achieve accurate 3D activity quantification is beyond
the scope of this thesis. A review paper describing the different parts in the dosimetry chain
for radionuclide therapy, with emphasis on activity quantification from SPECT images to
achieved personalised dosimetry is found in [34].
6.5 Summary of Activity Quantification Measurements
Relative activity quantification was performed for regions of interest within a thyroid phantom
where the known activity ratio is 50%, highlighting the important of attenuation correction
in activity quantification. Planar quantification of the radioactivity within vials containing
131I has been achieved using DEPICT to within 9% of the known activity for data acquired
with 1 vial and 3% for data with 3 vials, using a system sensitivity value calculated to be
60.81 cps/MBq. Tomographic imaging of a 133Ba vial was successful with an OSEM itera-
tive reconstruction algorithm, with analysis undertaken to determine the optimum iteration
number. For these data, 15 iterations and 2 subsets was found to accurately reconstruct the
vial. Future work may look to implement corrections to account for factors that degrade the
quantitative accuracy of a 3D reconstructed image.
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Further Clinical Applicability of
DEPICT
As discussed in Section 2.2, 131I treatment is the most established example of MRT. Ra-
dioiodine treatment for thyroid cancer and diseases has proven so successful, treatments have
remained largely unchanged in over 70 years since it was first used. However, there appears
to be a lack of progression in MRT, relative to EBRT, and this is due to only a small number
of patients being treated with this modality, usually with rare cancers and only for palliative
intent [131]. Treatments however, are steadily increasing. For example, a large survey by the
Internal Dosimetry Users Group showed almost three times as many treatments were carried
out in 2015 compared to 2007 [132] and this trend is predicted to continue. This will be aided
by MRT entering a new era in which a number of innovative therapeutic radionuclides are
being used clinically. These radionuclides open up MRT as a treatment modality for a larger
variety of cancers and diseases. However, treatments with emerging nuclides for therapy such
as 177Lu, are much more expensive than those with radioiodine. It can cost approximately
£70,000 per treatment cycle involving six intravenous administrations of 7.4 Gq [133], com-
pared to ∼£300 for a capsule of 131I, so utilising them efficiently is crucial which can only be
achieved through dosimetry. Experimental γ-ray spectra of emerging radiotherapeutics were
acquired with DEPICT at The Royal Marsden Hospital and are presented in this chapter.
Increasingly in MRT, a combination treatment using multiple nuclides simultaneously is being
discussed [134, 135]. For example, using a high-energy β-emitter such as 90Y, suitable for
treating larger tumours, alongside the lower-energy 177Lu for smaller tumours may offer a
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more effective treatment [136]. In addition, simultaneous multi-nuclide imaging would offer
great advantages in diagnostic SPECT such as the reduction of positional errors that may be
suffered when multiple images with different nuclides have to be acquired over various days.
As the future of MRT will only progress by using new radionuclides or multiple nuclides in
combination, the feasibility of simultaneous multi-nuclide imaging has been investigated with
the DEPICT system in this chapter. The aims of this chapter are therefore to:
• Assess the spectroscopic performance of DEPICT for other radiotherapeutics.
• Evaluate the multi-nuclide imaging performance of DEPICT.
• Perform a preliminary study of collimator design for other radiotherapeutics.
7.1 Emerging Radionuclides for Therapy
Table 2.1 details the radionuclides that have been highlighted as having characteristics suit-
able for use in MRT, either purely for therapy or as a theranostic. Although there appears
to be many radionuclides with suitable decay emissions and half-lives, the radionuclides need
to be labelled to suitable pharmaceuticals with an appropriate biodistribution to target the
radiation specifically to the disease sites. The recent introduction of antibodies and small
molecules has allowed this [9]. Four of the nuclides listed in Table 2.1 that are emerging in
MRT were measured with the DEPICT CZT detector in order to acquire a γ-ray spectrum
and are shown in the following sections. Data were collected at The Royal Marsden Hospi-
tal with each source for 300 seconds. For comparison, spectra with each nuclide were also
acquired with a clinical gamma camera, with varying acquisition times. As only spectral
information was desired, the data were collected intrinsically without a collimator present
allowing a high number of statistics to be acquired within a short time.
7.1.1 177Lu
177Lu is a desirable radionuclide for MRT from a physical perspective as it has a favourable
half-life t1/2phys of 6.7 days, a concentrated energy deposition due to its low-energy β emis-
sions, and the emission of γ rays that enable imaging of the biodistribution. 177Lu can be
coupled to various pharmaceuticals for the treatment of neuroendocrine and prostate cancers.
A 177Lu spectrum was acquired with DEPICT and a 3 MBq source and is shown in Figure
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Figure 7.1: 177Lu γ-ray spectrum acquired with DEPICT and the clinical gamma camera. The γ rays
of interest are 113 keV and 208 keV.
7.1. 177Lu has two γ rays that can be used for imaging, with energies of 113 and 208 keV.
The 208 keV γ ray has a greater emission probability than the 113 keV γ ray (Pγ = 11%
compared to Pγ = 6%) and will be attenuated less by tissue making it more suitable for imag-
ing. The 113 keV peak has a greater number of counts than the 208 keV peak in Figure 7.1
(4.0 x 105 net photopeak counts compared to 1.7 x 105), however this is due to the detector
having increased efficiency at lower γ-ray energies, where photoelectric absorption is more
probable. Although the emission probabilities of these γ rays are relatively low, the high
fixed administered activity of 7.4 GBq makes imaging possible. The energy resolution at 113
keV was measured to be 6.11% and 3.90% at 208 keV, using GF3. Data were subsequently
acquired with a 13 MBq vial of 177Lu for 10 seconds with a clinical Siemens Intevo gamma
camera and the resulting spectrum is shown in Figure 7.1. The measured energy resolutions
of the 113 and 208 keV peaks are 11.78% and 9.94%, respectively.
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7.1.2 111In
As discussed in Section 2.1.6, 111In is used in the imaging/therapy pair of 111In/90Y. 90Y
decays almost exclusively via the emission of a high-energy β-particle with a maximum en-
ergy of 2.28 MeV, maximum tissue penetration of 11 mm and half-life t1/2phys of 64 hours
[137], making it amenable for a variety of MRT applications. Most commonly, these in-
clude radioembolisation, where tiny glass or resin beads filled with 90Y are placed inside
the blood vessels that feed a tumour, or in MRT where 90Y labelled pharmaceuticals treat
neuroendocrine tumours. Although imaging the bremsstrahlung radiation generated by the
interactions of the 90Y β-particles is feasible [138], image quality for 90Y bremsstrahung ra-
diation is limited by overlying tissue attenuation, scattering, variable count rates, wide range
of energies and type of collimation employed [137]. Therefore, the most practical method for
imaging it to use 111In attached to the same pharmaceutical as a surrogate γ-emitting ra-
dionuclide. 111In has a half-life t1/2phys of 67 days, comparable to
90Y, and is assumed to have
an identical biodistribution. Typically, approximately 150 MBq of 111In is administered. It
decays via the emission of 171 and 245 keV γ rays. A γ-ray spectrum acquired with DEPICT
10 MBq of 111In is shown in Figure 7.2. The energy resolution of the 171 and 245 keV γ
rays are 4.70% and 3.77%, respectively. Figure 7.2 also shows the γ-ray spectrum acquired
with the clinical gamma camera and 42 MBq of 111In for 10 seconds. The measured energy
resolutions of the 171 and 245 keV peaks are 12.24% and 11.50%, respectively.
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Figure 7.2: 111In γ-ray spectrum acquired with DEPICT and the clinical gamma camera. The γ rays
of interest are 171 keV and 245 keV.
7.1.3 223Ra
Prostate cancer is the most common male cancer in the UK and the second most common
male cancer worldwide [139]. 223Ra is an α-particle emitter and is used for treatment of
bone metastases from prostate cancer. Although other radionuclides have been used for the
same purpose, such as 153Sm and 89Sr, 223Ra is the first α-emitter to also demonstrate proof
of survival [140]. 223Ra use has increased by a factor of 100 since being approved by the
European Medicines Agency in 2013 [141]. The number of patients with bone metastases
treated with radiopharmaceuticals increased by nearly 400% from 2007 to 2015 due to 223Ra
[142]. A DEPICT γ-ray spectrum acquired with 2 MBq of 223Ra is shown in Figure 7.3. The
γ ray of interest is typically 269 keV with an emission probability of 14%. This is because a
clinical gamma camera cannot accurately resolve the low-energy peaks of 145 and 155 keV,
as seen in Figure 7.3. In addition, the emission probabilities of the two lower-energy γ rays
are reduced (Pγ = 3% and Pγ = 6%, respectively) therefore will suffer increased attenuation
through the body. However, the 145 and 155 keV photopeaks can be easily resolved with
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Figure 7.3: 223Ra spectrum acquired with DEPICT and the clinical gamma camera. The γ ray of
interest is 269 keV.
DEPICT, giving additional statistics in energy gated images. Attenuation corrections may
also be implemented by looking at the relative attenuation of different γ rays from an nuclide
if multiple γ-ray energies can be resolved. The energy resolution of the 269 keV γ ray was
measured with DEPICT as 3.8%. A vial with 6.2 MBq of 223Ra was placed in front of
the clinical gamma camera and the γ-ray spectrum acquired is shown in Figure 7.3. The
measured energy resolution of the 269 keV peak is 12.42%.
7.1.4 227Th
227Th is also an α-particle emitter and used for the treatment of Non-Hodgkin’s Lymphoma,
ovarian cancer or mesothelioma; a cancer that is almost always caused by exposure to as-
bestos. 227Th decays to 223Ra with an average α energy of 5.9 MeV and to other short-lived
radionuclides in its decay to stable 207Pb. A 227Th γ-ray spectrum was acquired with the
DEPICT system and at the time of measurement, the 227Th/223Ra ratio was 2/3 MBq.
Therefore, γ-ray emissions from 223Ra also arise in a 227Th γ-ray energy spectrum. A spec-
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trum was also acquired with a Siemens clinical gamma camera for comparison. The data for
this spectrum were acquired by The Royal Marsden as part of a clinical trial, therefore the
exact measurement details are undisclosed. The γ-ray spectrum acquired with DEPICT is of
particular interest for dosimetry applications, as the 227Th peaks at 236 keV (Pγ = 13.4%)
and 256 keV (Pγ = 8.5%) are easily resolvable, illustrated in Figure 7.4. This is not the case
in a spectrum acquired with a clinical camera spectra, as seen in Figure 7.4. The poor energy
resolution causes the 269 keV peak from 223Ra to mask the 256 keV peak, as seen in the
inset of Figure 7.4. The 236, 256 and 269 keV photopeaks have energy resolutions of 3.45%,
3.12% and 3.86%, respectively, measured with DEPICT. It was not possible to measure the
energy resolution of the photopeaks in the clinical spectra accurately.
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Figure 7.4: 227Th γ-ray spectra acquired with DEPICT and the clinical gamma camera with the data
courtesy of The Royal Marsden Hospital. The γ-ray of interest is 236 keV. Insets (a) and (b) expand
the spectra between 220 and 300 keV to show the peaks at 236 keV and 256 keV and 269 keV as
imaged by DEPICT and Siemens gamma camera.
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7.2 Monte-Carlo study of 227Th
Due to the excellent energy resolution of CZT, the photopeaks of each nuclide studied in
Section 7.1 are clearly resolvable in the γ-ray spectra acquired with DEPICT in Figures 7.1 -
7.4. However, these spectra were collected without spectral degrading scatter material that
would be present during MRT. The radionuclide this would have the greatest impact on is
227Th. The photopeak of interest is 236 keV however down scatter from the two photopeaks
with higher energies (256 and 269 keV) may be detected in an energy window set around the
236 keV photopeak, resulting in reduced image contrast and degraded quantitative accuracy.
Therefore, to assess the spectral quality in a realistic clinical setting, 227Th γ-ray spectra were
simulated using the GAMOS [102] Monte-Carlo toolkit with a 227Th source placed within
scattering material. The minimum set of commands required to run a GAMOS simulation
are those selecting a geometry, a physics list and a generator, to initialise Geant4 and run
N events. The basic GAMOS electromagnetic physics list defines the particles required for
the simulation and their physical processes. For this simulation, the physical processes of
γ rays and electrons were called. The low-energy physics model based on the Livermore
Evaluated Data Libraries [143, 144, 145] were selected. These libraries provides atomic data
for elements Z = 1 to 100, over the energy range 10 eV to 100 GeV which is appropriate
for medical simulations. The GAMOS generator provides several time, energy, position and
direction distributions that the user may combine to achieve their desired outcome. The
geometry includes the definition of materials and describes the position of the particle source
and simulated detector in space. The generation of particles and the geometry are described
below.
A distributed cylindrical source of radius 2 cm and length Z of 4 cm, with the same activity
ratio as the experimental 227Th/223Ra spectrum collected with DEPICT in Figure 7.4, was
simulated. The distributed source, shown by the white cylinder in Figure 7.5, was placed
inside a volume in which the volume material had the attenuating properties of soft tissue,
defined by the Tissue Substitutes in Radiation Dosimetry and Measurement (Report 44)
[146]. This simulated a simplified MRT situation in which a distributed source of activity is
contained with soft tissue in the body. To extract information from a GAMOS simulation,
a sensitive detector that simulates the signals (hits) in a device must be created. It creates
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Figure 7.5: Simulated GAMOS geometry viewed using view3Dscene .
hits each time a particle track transverses a sensitive volume and loses energy. Sensitive
detectors can be attributed to a user-defined volume to mimic the response of the sensitive
part of a real detector. A 44 x 44 x 5 mm volume segmented into 484 2 x 2 x 5 mm voxels
to replicate the DEPICT CZT detector was therefore created, shown in red in Figure 7.5.
The height and width of the soft tissue volume, shown in blue, were both set as 6 cm to
completely cover the face of the CZT detector. The depth was changed in order to vary the
thickness of soft tissue x between the CZT detector and the edge of the distributed source
volume nearest to the detector. as illustrated in Figure 7.5. For comparison, the simulation
was run with x set to 5 cm and 10 cm and also without the soft tissue surrounding the source.
There are a number of experimental detector effects which can be accounted for with user
commands in GAMOS, including energy resolution and minimum hit energy (threshold). The
energy resolution of the DEPICT CZT detector was therefore recreated in the simulated CZT
detector, along with the energy threshold that was set in experimental data collection. The
ability to smear the energy of the hits with a Gaussian distribution is achieved by:
/gamos/setParamSD : EnergyResol : Absorber VALUE1
In addition, a second term can be applied for energy-independent factors attributed to in-
strumental effects such as noise by:
/gamos/setParamSD : EnergyResolInstr : Absorber VALUE2
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The extent of Gaussian smearing is dictated by the width parameter of a Gaussian distribu-
tion, the standard deviation σ, and in GAMOS is the value of VALUE1. The parameter σ
is related to the FWHM through the relation FWHM = 2.35σ [47]. Therefore, to calculate
the result of VALUE1 required to accurately simulate the DEPICT CZT energy resolution,
the FWHM of various nuclides with γ-ray energies 59 – 364.5 keV were measured and a plot
of FWHM versus energy was produced. A straight line was fit to the data with the equation
y = mx+c. The gradient m of the graph was then divided by 2.35 to obtain the value of σ as
FWHM = 2.35σ, which was calculated to be 0.0097. VALUE2 corresponds to the intercept
of the FWHM versus energy graph, as it is the contribution to the energy resolution that is
independent of γ-ray energy. This was calculated as 0.0019. In GAMOS, charge transport
properties cannot be simulated, therefore the low-energy photopeak tailing characteristic of
CZT detectors is not reproduced.
Simulations with no scatter material and 5 cm and 10 cm of scatter material were run with
10 million events each, where the number of events is the number of initial particles. Each
particle will then collide and generate a set of secondary particles. ROOT [147], a scientific
toolkit developed by CERN that allows data processing, statistical analysis and visualisa-
tion, was used to display the reconstructed hits as a histogram. Figure 7.6 shows the three
histograms acquired, with no scatter and 5 and 10 cm of scatter material. Figure 7.7 displays
the events from Figure 7.6 that have an energy from 220 – 300 keV. This energy regions
contains the 236, 256 and 269 keV γ rays that are of interest in 227Th imaging.
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Figure 7.6: 227Th energy spectra simulated with no scatter material (black dashed line), 5 cm (solid
black line) and 10 cm (solid blue line) of scatter material between the source and the detector.
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Figure 7.7: Shown is the data from Figure 7.6 but only events with energy between 220 and 300 keV.
Figure 7.6 shows three 227Th spectra, with decreasing counts as the thickness of scatter
material increases. The position and width of the photopeaks replicate those seen in the
experimentally collected 227Th spectrum in Figure 7.4a. Following a simulation, GAMOS
can output information about the interactions of ‘original’ γ rays in the sensitive detector.
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For this energy range, only photoelectric absorption and Compton scattering are possible.
Table 7.1 highlights the number of original γ rays reaching the sensitive detector N γ in SD,
the number of original γ rays undergoing photoelectric interactions in the sensitive detector N
PE and the number of original γ rays with Compton interactions N Comp for the histograms
seen in Figure 7.6 with no scatter material, 5 cm and 10 cm.
No scatter (x105) 5 cm scatter (x105) 10 cm scatter (x105)
N γ in SD 3.94 2.04 0.43
N PE 3.23 (81.85%) 1.60 (78.11%) 0.33 (76.20%)
N Comp 0.29 (7.23%) 0.19 (9.42%) 0.04 (9.82%)
Table 7.1: Comparison of photopeak to Compton scatter events. The percentage in brackets shows the
relative photoelectric or Compton scattered events compared to the total γ-ray events in the sensitive
detector.
As the thickness of scatter material increases, the number of photoelectric events decreases,
while the number of Compton events increases, as expected. The peak-to-Compton ratio,
defined here as the ratio of N PE / N Comp, is 11.32 for no scatter, 8.29 for 5 cm of scatter and
7.76 for 10 cm of scatter. A reduced peak-to-Compton ratio will cause a reduction in contrast
within a medical image, increasing the difficulty of performing dosimetry. It is expected the
presence of a collimator would induce further scatter. The three photopeaks of interest are
still resolvable, and due to the excellent energy resolution of DEPICT it is possible to energy
gate individual emissions to accurately suppress scattered events for activity quantification.
7.3 Multi-nuclide Imaging
99mTc and 123I are two common medical imaging nuclides that emit γ rays of very similar
energies; 140.5 keV and 159 keV, respectively. Although not used for therapeutic purposes,
these nuclides and can be used simultaneously to study two physiological processes to eluci-
date the disease status as part of an MRT treatment plan [148]. Thus, experimental planar
images were acquired with 99mTc and 123I for the investigation of multi-nuclide imaging with
DEPICT. A collimator optimised for low-energy γ rays is required for imaging these nu-
clides. Therefore, a prototype low-energy parallel-hole collimator, manufactured by Kromek,
was coupled to the DEPICT CZT detector. The lead collimator was designed with hexagonal
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Figure 7.8: A photograph of the perspex phantom placed on top of the low-energy collimator. Red
circles show the position of the three 123I vials; blue circles show the position of the 99mTc vials. In
the photograph the phantom is offset from the position in which it was placed during data collection
in order to be able to view the low-energy collimator.
holes of length L = 23 mm, hole diameter d = 1.2 mm and septa thickness t = 0.2 mm. Unlike
the DEPICT collimator, the low-energy collimator was not designed to be pixel matched to
the CZT detector. Data were acquired simultaneously with six 8 mm inner diameter vials of
length 4.5 cm; three filled with aqueous 123I (t1/2phys = 13.22 hours) and three with
99mTc
(t1/2phys = 6.01 hours). The
123I vials each contained an activity of ∼300 kBq, with ∼200
kBq in each 99mTc vial. The activities of the 123I and 99mTc sources were calibrated at The
Royal Liverpool University Hospital on the morning of the measurement, and uncertainties
arise due to the calibration and dispensing methods. The vials were placed into a perspex
phantom in the orientation shown in Figure 7.8 and data acquired for 30 minutes.
The associated sum spectra acquired with the six vials simultaneously is shown in Figure
7.9a. The two peaks at approximately 75 and 85 keV correspond to lead x-rays produced in
fluorescence from the collimator. The peaks at 140.5 and 159 keV are the photopeak events
from the 99mTc and 123I sources, respectively. The black dashed lines encompass γ-ray events
with energy between 130 – 175 keV and indicate the energy gate applied to the the pixel map
shown in Figure 7.9b. Six areas of high counts are evident in the pixel map corresponding to
114
CHAPTER 7. Further Clinical Applicability of DEPICT
0 20 40 60 80 100 120 140 160 180
Energy (keV)
0
0.5
1
1.5
2
2.5
Co
un
ts
#104
(a)
2 4 6 8 10 12 14 16 18 20 22
x pixel number
2
4
6
8
10
12
14
16
18
20
22
 
y 
pi
xe
l n
um
er
0
200
400
600
800
1000
1200
1400
1600
1800
(b)
Figure 7.9: (a) Sum spectra acquired with three 123I and three 99mTc vials. The dashed black
lines encompass both photopeaks, the blue solid lines and the red dotted lines encompass the 99mTc
photopeak and the 123I photopeak, respectively and (b) the energy gated pixel map obtained, with
γ-ray events with energy 130 – 175 keV.
the six vials. The hot spots at the known 123I vial positions have increased counts compared
to the hot spots for the 99mTc vials. This is consistent with the increased activity in the
123I vials, although it appears that the vials did not contain exactly equal activities. As the
energy gate applied encompasses the photopeak energy of each nuclide, it is not possible in
this image to distinguish the 99mTc and 123I vials from one another.
Due to the excellent energy resolution of the CZT detector, it is possible to apply very
narrow energy windows around the individual photopeaks. An energy window around 5% was
applied around each photopeak, corresponding to 137 – 144 keV around the 140.5 keV 99mTc
photopeak and 155 – 163 keV around the 159 keV 123I photopeak. These energy windows
are shown in Figure 7.9a with the blue solid line showing the 99mTc energy window, and red
dotted lines indicating the 123I window. Two energy gated pixel maps corresponding to the
data encompassed in each energy window are shown in Figures 7.10a and 7.10b. With the
energy gate applied between 137 – 144 keV in Figure 7.10a, three regions of higher intensity
are visible at the known 99mTc vial positions. There are three areas of approximately 150
counts visible in the 99mTc gated pixel map where the 123I vials are known to be. Although
the energy gate is applied around the 99mTc photopeak, it sits on the Compton background of
123I. Therefore some events in the 99mTc pixel map will arise from 123I emissions. The triple
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Figure 7.10: Energy gated pixel maps showing vials containing (a) 99mTc only and (b) 123I only.
energy window scatter correction method could be applied to remove these scattered events
from the image [149]. Figure 7.10b shows three high count areas at the known position of the
123I vial positions in the pixel map created with γ-ray events between 155 – 163 keV. These
images show that it is possible to apply an energy gate around one photopeak and be able to
observe the vials with that energy only and prove multi-nuclide imaging with radionuclides of
similar γ-ray energy is achieveable with the DEPICT system. This technique is not feasible
with a NaI(Tl) detector typically used in clinical gamma cameras. For comparison, Figure
7.11 shows a γ-ray spectrum obtained from imaging two 16.4 mm diameter vials containing
0.11 MBq 99mTc and 0.55 MBq 123I [150]. The photopeaks are not easily resolvable, and
complex corrections would have to be applied to deconvolve an image acquired with 99mTc
and 123I with a clinical gamma camera.
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Figure 7.11: 123I and 99mTc energy spectrum acquired with NaI(Tl) detector. Data courtesy of A.
Patel [150].
7.3.1 Energy Optimised Collimator
Sections 7.1.1 - 7.1.4 show the DEPICT CZT detector can be used to acquire high quality
spectroscopic data for a variety of medical radionuclides. In order to acquire medical images
with these nuclides, a collimator optimised for the energy of their emitted γ rays is required.
The choice of collimator is a trade-off between high sensitivity, good signal-to-noise ratio, spa-
tial resolution and septal penetration. It was not within the remit of this thesis to produce
multiple collimators so as a preliminary study to allow recommendations for future work,
experimental data were acquired using existing collimators with other designs later studied
using GAMOS. 177Lu is classed as a medium-energy γ-emitter. Medium-energy collimators
are therefore preferable over low-energy collimators for 177Lu imaging because of the lower
septal penetration of the emitted γ rays. In addition, although high-energy collimators have
thicker septa than medium-energy collimators that would further reduce septal penetration,
they have inferior spatial resolution due to larger collimator holes. In order to study the
effects that arise due to imaging with an unoptimised collimator, data were acquired with a
22 mm inner diameter vial of 108 MBq 177Lu, with both the low-energy prototype Kromek
collimator described in Section 7.3 and the DEPICT high-energy collimator. Data were ac-
quired for 15 minutes with the low-energy collimator and 20 minutes with the high-energy
collimator and an energy window of 200 – 220 keV was applied. Figure 7.12a and Figure 7.12b
show the energy gated pixel maps acquired with the low-energy and high-energy collimators,
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Figure 7.12: 177Lu vial positioned on top of (a) low-energy Kromek collimator and (b) the custom-
designed high-energy collimator. Both images are energy gated on the 208 keV peak with an energy
window of 200 – 220 keV.
respectively. Figure 7.12a has an area of 5000 – 6000 counts per pixel towards the centre
of the image, with the counts decreasing with increasing radial distance from the centre.
Ideally, a distinct circular pattern would be visible at the position of the vial with the known
diameter of 22 mm, however there is blurring of the vial edges caused by septal penetration.
The exact position or edges of the vial cannot be determined accurately from this image.
Figure 7.12b shows a distinct circular region of ∼175 counts per pixel, corresponding to a
direct projection of the vial that is 11 pixels in diameter. Although typically high-energy
collimators have larger holes to increase the sensitivity, the DEPICT high-energy collimator
was developed with small holes for decreased sensitivity (due to imaging high activities) and
high resolution. Therefore a clear outline of the base of the vial is seen in the image, but
with highly reduced counts compared to the low-energy collimator. Due to difficulties that
occurred in the acquisition of the high-energy collimator data, the collimator was not posi-
tioned in its ideal position above the detector. This error in positioning caused a large amount
of scatter, manifesting as a high (100 count) background in the pixel map. It is expected
that the background counts would be would be dramatically reduced if the collimator was
positioned correctly. Due to the cost and availability of the radionuclide, it was not possible
to repeat this experiment.
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A DEPICT imaging system for employment across the energy range of the radionuclides
discussed in this chapter requires a custom-designed medium-energy collimator. GAMOS
was therefore used for the preliminary design of a medium-energy collimator. Firstly, to
validate the GAMOS geometry, simulations of the experimental setup used for acquiring
Figure 7.12a and 7.12b were undertaken, and pixel maps compared. Figure 7.13a shows the
simulated low-energy collimator with 23 mm length and 1.2 diameter holes and Figure 7.13b
shows that of the high-energy collimator with 55 mm length and 0.6 mm diameter holes. In
both figures, the simulated pixelated CZT detector is shown in red, the collimator holes are
white and the edge of the collimator that is physically positioned above the detector casing
in shown in blue. The white cylinder is a simulated glass vial, with a 177Lu source distributed
within the volume. There is a 2.1 mm gap between the base of the collimator holes and the
CZT detector face. In Figures 5.1a and 5.1b, 50 γ-ray events were simulated and their paths
are illustrated by the green lines.
(a) (b)
Figure 7.13: Images showing the geometry of the GAMOS simulations of (a) low-energy Kromek
prototype collimator and (b) custom-designed DEPICT high-energy collimator. The coloured volumes
are defined in the text.
The simulations to acquire data for validation ran 100 million events for the low-energy col-
limator and 2100 million events for the high-energy collimator. 177Lu 208 keV γ rays were
simulated for comparison to the experimentally acquired pixel maps shown in Figures 7.12a
and Figure 7.12b, as only events arising from photoelectric absorption were included. Figures
7.14a and 7.14b show the simulated pixel maps that were binned into 22 bins across 44 mm
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Figure 7.14: Plots showing GAMOS simulated pixels maps of the (a) low-energy and (b) high-energy
collimators and 177Lu vial.
in the x- and y-directions (-20 to 20 mm) to simulate the CZT pixels. Figure 7.14a shows an
area of ∼400 counts in the centre of the image, corresponding the simulated vial, with a back-
ground ∼15 counts. The large amount of septal penetration seen in Figure 7.12a is not well
replicated as for simplicity, the low-energy collimator was simulated with circular holes rather
than hexagonal. However, there are a small number of pixels with approximately 50 counts
surrounding the hot spot due to a small amount of septal penetration. Transmission (%) is
defined as the number of original γ rays that interacted within the sensitive detector N γ in
SD divided by the number of original simulated events, multiplied by 100. For the simulated
low-energy collimator N γ in SD was 17578, giving a transmission of 1.76 x 10−2 %. Figure
7.14b shows the pixel map acquired from simulating the DEPICT high-energy collimator. The
collimator was designed to have a very low efficiency for imaging the high-activities in MRT
therefore a reduced transmission compared to the low-energy collimator would be expected.
For the high-energy collimator, N γ in SD was 1420, giving a transmission of 6.76 x 10−5 %.
The maximum possible number of GAMOS simulated events were run, however due to the
extremely low transmission, a pixel map that would be representative of an experimentally
acquired pixel map was not produced. The centre pixels of the image that corresponding
to the vial position, have approximately 40 counts, with mostly zero counts in surrounding
pixels and a small number ∼5 in the edge pixels. The relative differences however, in pixel
counts and calculated transmission values between the low-energy collimator and high-energy
collimator simulated data were as expected.
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As the simulated images adequately represent the experimental pixel maps, a medium-energy
collimator could be designed by modifying the high-energy, pixel matched tungsten collimator
geometry. Although a higher activity of 177Lu is typically administered in MRT compared to
that of 131I (7.4 GBq to 3.7 GBq), the γ rays emitted from 177Lu are lower in both energy and
intensity. The emission probability of 364.5 keV γ rays from 131I is 82%, compared to 11%
for 208 keV γ rays from 177Lu. Additionally, the linear attenuation coefficient of soft tissue is
0.13 cm−1 at 208 keV compared to 0.11 cm−1 at 364% [54]. Equation 3.5 shows that for soft
tissue of thickness 5 cm, 52% of 208 keV γ rays would pass through the material compared
to 58% for 364.5 keV γ rays. If a 208 keV γ ray is emitted for a given disintegration, it is
more likely to be attenuated, therefore dead time effects are less likely to be as severe and
the collimator does not have to be as low-efficiency as the high-energy DEPICT collimator.
Typically the hole diameter and length for a medium-energy collimator are greater than those
for a low-energy collimator and less than those of a high-energy collimator. However, as the
DEPICT high-energy collimator is designed for low-efficiency, high-resolution measurements
to improve image quality and improve count rate saturation, it has a much smaller hole
diameter than that of the low-energy collimator. To facilitate high-resolution imaging with
increased efficiency, collimator geometries were simulated with the hole diameter ranging from
0.6 (low-energy collimator hole diameter) to 1.2 mm (high-energy collimator hole diameter),
in 0.1 mm increments. The hole length was set at 40 mm for each hole diameter. The length
of the holes are required to be longer than those of a low-energy collimator, to reduce septal
penetration, but shorter than those of the high-energy collimator to allow more γ rays to
reach the detector. Therefore, the hole length was varied from 25 – 50 mm, with the hole
diameter set at 1 mm. For each hole diameter and hole length, 50 million events were ran.
Figures 7.15a and 7.15b show the measured transmission as a function of diameter and length,
respectively. The transmission is also known as collimator efficiency g and is defined by
g ≈ K2
(
d
L
)2[ d2
(d+ t)2
]
, (7.1)
where K is a constant that depends on hole shape (∼0.24 for round holes) and d, L, and t are
hole diameter, length and septal thickness. Therefore, Equation 7.1 shows the transmission
is proportional to d2, assuming t = 0, and also to 1/L2. This relationship is replicated in the
data shown in Figures 7.15a and 7.15b.
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Figure 7.15: Plots showing the transmission (%) of events as a function of (a) hole diameter d and
(b) hole length L. For (a) the length was set at 40 mm and for (b) the diameter was set at 1 mm.
For this rudimentary medium-energy collimator design, 40 mm was chosen as the hole length
as this was the mid-length between the low- and high-energy collimators. This length is also
comparable to the length of commercial medium-energy collimators at 40.64 mm. The hole
diameter of 1 mm was chosen, giving both increased sensitivity and high-resolution imaging.
A small amount of septal penetration is often accepted in gamma cameras; usually 5%. For
septal penetration of less than 5%, the septal thickness t, hole diameter d and hole length l
are related by
t ≥ 6d/µ
l − (3/µ) , (7.2)
where µ is the linear attenuation coefficient of the septal material [55]. For the chosen hole
length l of 40 mm, hole diameter d of 1 mm and linear attenuation coefficient µ for tungsten
of 12.93 cm−1 at 208 keV, the septal thickness required for less than 5% setpal penetration
is ≥ 0.01 mm, which is far surpassed in this design with a septal thickness of 1 mm. As
the DEPICT collimator is pixel matched, there is the constraint that d + t must equal the
pixel pitch of 2 mm. The expected system spatial resolution Rsys can be determined using
Equations 3.3 and 3.4 to calculate the values of collimator resolution Rcoll and Rsys. Rcoll is
1.25 mm for a source-to-collimator of 10 cm giving a value for system spatial resolution Rsys
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of 2.36 mm. Although this is degraded compared to the 2 mm resolution of the DEPICT
high-energy collimator, it is much improved on the system spatial resolution of a clinical
gamma camera coupled to a medium-energy collimator of 12.5 mm at 10 cm. Figure 7.16
shows a simulated pixel map acquired with the medium-energy collimator with 2100 million
simulated events.
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Figure 7.16: Medium-energy collimator simulation with hole length L = 40 mm and hole
rdiameter d = 1 mm.
The simulated pixel map shows a high ∼550 count area towards the centre of the of the
image with approximately 20 counts in the background pixels. The simulated transmission
of the medium-energy collimator was calculated as 9.10 x 10−4, which is intermediate to the
transmissions calculated for the low- and high-energy collimators, as expected. From the
image, the diameter of the vial is calculated as 12 mm, including the pixels at the edge of the
high count area of approximately 200 counts, however the spatial resolution is expected to be
degraded compared to the high-energy collimator due to the shorter and larger diameter holes.
The design of a collimator is complex as hole length and diameter are not totally independent
of one another, therefore it is not possible to ascertain their effects on an image individually.
As the DEPICT CZT has a very small FOV, it is likely that future work will involved a scaled
up version of the detector used in this thesis. Therefore, the design of the medium-energy
collimator may change as detector is scaled up in size. In addition, the sensitivity of the
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system will depend on the organ being imaged, as deeper-seated organs will induce more
scatter and attenuation
7.4 Summary of Further Clinical Applicability of DEPICT
In this chapter, the feasibility of multi-nuclide imaging with DEPICT has been investigated as
simultaneous imaging of 123I and 99mTc can be used in brain and cardiac imaging [151, 152].
The excellent energy resolution of CZT was found to successfully permit simultaneous imaging
of these two nuclides. Energy spectra of the γ rays emitted from emerging radionuclides in the
field of MRT were acquired with the DEPICT CZT detector. These were 177Lu, 111In, 223Ra
and 227Th. A comparison of 227Th γ-ray spectra acquired with and without scatter material
was undertaken with simulations using GAMOS. The peak-to-Compton ratio decreased with
increasing scatter material as expected, but the peaks of interest were still resolvable. Medical
imaging of the emerging radionuclides that emit medium-energy γ rays requires a medium-
energy collimator. GAMOS was used for the preliminary design of a DEPICT medium-energy
collimator to facilitate this. The final design was circular holes of length l = 40 mm, diameter
d = 1 mm and septal thickness t of 1 mm.
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Conclusions
The methods used to develop and evaluate the DEPICT system for imaging the γ rays emitted
following MRT have been discussed in this thesis. The DEPICT project was based at the
University of Liverpool with collaborators from The Royal Liverpool University Hospital, The
Royal Marsden Hospital and Kromek. Data were acquired across both hospital sites to allow
measurements with high activity medical radionuclides in order to provide realistic clinical
test scenarios. The project focussed on radioiodine treatment of thyroid cancer and benign
diseases, such as hyperthyroidism.
The motivation for this project was the need for the routine clinical implementation of
dosimetry in MRT. Accurate calculation of the absorbed dose will enable therapies to be
tailored to give maximum tumour absorbed dose, whilst minimising the dose to organs at
risk. In EBRT, the process of patient-specific dosimetry has been standard practise for years
providing individualised radiotherapy treatments to patients with accurately delivered ab-
sorbed tumour doses. In MRT, it is rare for a patient to have their absorbed doses calculated
and therapy is based on administering standard amounts of activity. Failing to calculate dose
leads to some patients receiving more radiation than is necessary to treat their disease, and
some receiving a sub-optimal dose. The EU Directive 2013/59/Euratom of 5 December 2013
required that by February 2018 ‘all medical exposures of patients for radiotherapy purposes,
exposures of target volumes shall be individually planned and their delivery appropriately
verified’. However, most centres still employ a ‘one-size-fits-all’ approach rather than calculat-
ing individualised internal dose values, even though increasing evidence shows that treatment
outcomes correlate with the absorbed doses delivered to tumours and healthy organs [153]. In
addition to the patient benefit of potentially increased rates of successful cancer treatment,
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progressing from generic treatments to the routine application of patient-specific dosimetry
will save NHS funds by MRT becoming a more effective and efficient treatment modality.
The cost savings become even more important when emerging radiopharmaceuticals are con-
sidered as the cost of these for treatment is significant.
Limitations in current clinical gamma cameras hinder the progression of dosimetry in MRT
due to uncertainties that arise from outlining organs of interest from poor quality images. To
overcome issues faced in imaging, such as limited energy resolution and spatial resolution, a
pixelated CZT detector was chosen for use in the DEPICT project. CZT is a room temper-
ature semiconductor detector that is known to have superior energy resolution and excellent
spatial resolution, if developed with small pixels. In the work of this thesis, a DMatrix CZT
detector manufactured by eV Products [92] was optimised for MRT applications that require
good energy resolution and high-throughput of γ rays, given the high activities administered.
A custom-designed high-energy parallel-hole collimator was developed to couple to the CZT
detector to create a γ-ray imaging system. The collimator had a high resolution and low
efficiency and was found not to enter dead time when imaging therapeutic activity levels
(at least 3.5 GBq). The measured energy resolution of 3% at 364.5 keV and system spatial
resolution at 10 cm of 2 mm are far superior to the same parameters in scintillator gamma
cameras. These are 9 – 10% and 13.4 mm for energy resolution and system spatial resolution
with a high-energy collimator, respectively. Improved energy resolution allows narrow energy
windows to be set around a photopeak reducing unwanted scatter contributions within an
image, which would otherwise degrade the signal-to-noise. The CZT detectors are also cou-
pled to custom ASICs to process and readout the signals, which reduce the size and cost of
readout electronics compared to clinical gamma cameras that require bulky PMTs.
Images produced using the DEPICT system for data acquired with 131I and a variety of
clinical phantoms have been shown to be both qualitatively and quantitatively superior when
compared to a Siemens Intevo gamma camera. The DEPICT system could easily resolve
vials of 10 mm diameter, whereas the large collimator holes of the Siemens system degraded
the image. Cold spots in a thyroid phantom that were visible in the DEPICT image were not
seen in an image acquired with the Siemens gamma camera. These cold spots were 6, 9 and
12 mm in diameter meaning the clinical system would not pick up an artefact with reduced
counts with respect to the background in a clinical image of this size. Identifying features
of this size is important to accurately represent the physiological non-uniformities within a
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diseased thyroid.
Planar activity quantification of data acquired from a single vial and three vials of 131I was
achieved to facilitate calibration of detected counts into an activity. Two sensitivity values
(cps/Gbq) for the collimated DEPICT system with 131I were acquired. The first was simply
calculated from placing a 131I vial above the detector and measuring the counts per second
per unit photopeak activity. The second had appropriate uniformity, scatter and attenuation
corrections applied. This factor of 60.87 cps/GBq reconstructed the known activity of the
single vial to within 9% and 3% for the three vials. Although these values of activity were well
reconstructed this study was carried out without the presence of background activity, which
is always present in clinical studies and would complicate activity quantification. Attenuation
correction would also be further complicated in a patient due to areas with different attenu-
ation coefficients. Successful 3D reconstruction of a 133Ba vial was achieved using an OSEM
reconstruction algorithm, with an investigation performed into optimum iteration number.
It was found that 15 iterations with 2 subsets and a threshold of 30 reconstructed counts was
optimum for reconstruction of the vial volume in 3D.
An area where CZT may have a significant impact is in 227Th therapy. The Royal Marsden
Hospital in Sutton is currently the only UK centre to be taking part in a first-in-human
study to evaluate the safety, maximum tolerated dose, pharmacokinetics and recommended
dose for further clinical developement with this nuclide [154]. Imaging is extremely difficult
due to the poor energy resolution of scintillator gamma cameras and the extremely low
administered activities, starting at 1.5 MBq. Complicated deconvolution techniques have
to be employed to separate the 227Th photopeak from those arising from 223Ra emissions
for activity quantification. 227Th γ-ray spectra acquired with the DEPICT system and a
clinical gamma camera have shown the significant impact the superior energy resolution
has on resolving photopeaks and will aid dosimetry measurements. Imaging of emerging
radionuclides in MRT with DEPICT however, such as 227Th, requires an energy optimised
collimator. For γ rays with energy above approximately 140 keV and below 260 keV, a
medium-energy collimator is required. The preliminary design of a medium-energy collimator
was presented with collimator holes of length L = 40 mm, diameter d = 1 mm and septal
thickess t = 1 mm were selected.
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8.1 Recommendations
The following recommendations for further work have been made in order to develop a fully
clinical DEPICT system:
• Determine if planar activity quantification is feasible with different radionuclides and/or
geometries. It is likely this would require calculation of different sensitivity factors
because the sensitivity is energy-dependent, due to the energy dependence of interaction
mechanisms.
• If personalised dosimetry was implemented and shown some patients would benefit from
lower administered activities of 131I, a high-energy collimator with larger or shorter holes
to increase the sensitivity may be required as the DEPICT collimator was developed
for activities on the order of several GBq. In addition, a CZT crystal that is thicker
than 5 mm may be desired for greater detection efficiency if administered activities
were lower.
• Produce pixel-matched parallel-hole collimators for a detector system where multiple
CZT detectors are tiled up for larger FOV.
• Investigate the feasibility of activity quantification from 3D reconstructed images. This
will require implementation of appropriate corrections within the reconstruction algo-
rithm and acquisition of data for calibration from counts to activity.
8.2 Clinical DEPICT Design
A mock-up of a potential clinical DEPICT system is shown in Figure 8.1. The system shown is
designed specifically for imaging of the thyroid. The collimator, CZT detector and associated
electronics would be encased and positioned onto a rotating arm to acquire multiple images
at various angles around the patient. If a clinical DEPICT system was developed, there are
currently 23 131I treatment centres in the UK this could be supplied to. These centres deliver
∼2000 131I treatments and ∼100 131I-mIBG neuroblastoma treatments per year. Whilst this
is small compared to EBRT, it has been suggested that 131I-mIBG would be used far more
extensively if personalised treatment is adopted and shows patient benefits and reduced costs
[155]. More than £5 million per year is currently spent on 131I MRT in the UK.
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Figure 8.1: Mock-up of potential clinical DEPICT detector system.
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A.1 Full 131I Decay Chain
131I decays via the emission of multiple β particles and γ rays to 131Xe, shown in Figure A.1.
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Figure A.1: 131I decay chain to 131Xe. Reproduced from [99].
130
SUPPLEMENTARY MATERIAL FOR CHAPTER 4
A.2 Charge Sharing
Pixelated CZT detectors allow increased spatial resolution compared to unsegmented detec-
tors, and this effect improves as the pixel size decreases due to the small pixel effect [61].
However, when the pixel size is decreased to be comparable to the size of the electron charge
cloud created when the γ ray interacts, the charge may be shared between multiple pixels or
lost in the gap between the pixels and degrade the spatial resolution. Multiple pixel events
can occur either due to the charge sharing phenomena, or because the γ ray Compton scatters
from one pixel into another, where it deposits its remaining energy. To quantify the amount
of charge sharing in the DEPICT CZT detector, the response of the detector as a function
of known γ ray position was measured. A 1.64 GBq 241Am source collimated into a 1 mm
beam was mounted on a x-y positioning table, controlled by a Velmex VXM Stepper Motor
Controller [120], 1.5 cm above the carbon fibre window. The collimated source was moved
across the face of the detector in an x-y grid with the step between positions set at 1 mm
and data collected for 1 second at each step. For this data collection, the detector readout
mode was changed from the ‘basic sparsified photon collection’ mode used thus far, that only
read out triggered channels above a threshold, to ‘readout all’ mode. This meant that any
interaction would trigger the read out of all events in the individual CZT detector module.
It was necessary to read out all data from all pixels, in order to observe low energy Compton
scattering or charge shared events that occur.
(a) (b)
Figure A.2: Figures (a) and (b) show the collimated 241Am source mounted onto the scanning arm,
and placed 1.5 cm above the carbon fibre window.
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To discriminate between charge shared and Compton scattered events, the Compton scatter-
ing formula given in Equation 3.2 was used. This allowed the range of possible energies of
the scattered γ ray Ef and recoil electron to be calculated. Figure A.3 plots the energies of
a 59.5 keV γ ray and an electron after Compton scattering, given the incident γ-ray energy
E0 = 59.5 keV and the rest mass equivalent energy of the electron m0c
2 = 511 keV.
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Figure A.3: Energies of a 241Am 59.5 keV γ ray and electron after Compton scattering.
The range of possible energies was calculated to be 0 – 11.3 keV for the energy absorbed by
the recoil electron and 48.3 – 59.5 keV for the scattered γ ray, for values of θ between 0 and
180◦. Any multi-pixel event with deposited energies of 11.3 - 48.3 keV could then be tagged
as a charge shared event, not a Compton scattered event. Since the detector was in readout
all mode, all pixels will output a signal corresponding to the collection of real charge or due to
electronic or background noise. Figure A.4 shows an example energy spectrum acquired with
the 241Am source for this data collection. As a result of the readout mode, a large amount
of low energy noise below ∼10 keV is exhibited in the spectrum. This is due to events from
all pixels being summed each time a γ ray interacts. Therefore, a threshold of 5 keV was
set in post processing when quantifying the charge shared events, to discriminate some noise
events. It is known that this threshold will also remove a proportion of Compton scattered
and charged shared events, with an energy less than 5 keV.
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Figure A.4: 241Am energy spectrum acquired in readout all mode, illustrating energy regions corre-
sponding to low energy noise and Compton events, charge shared events and events due to photoelectric
absorption.
The final criteria for a multi-pixel event to be classed as a charge shared event is as follows:
• Energy deposited is outside Compton scatter limits defined in Figure A.3.
• Energy is deposited in directly neighbouring pixels, denoted pixel 1 and pixel 2.
• Energy is deposited in the same time stamp.
• Sum of energy deposited in pixel 1 and pixel 2 is less than or equal to 65 keV, accounting
for the imperfect detector resolution when detecting photoelectric events.
A 2D energy spectrum is shown in Figure A.5, which depicts the energy recorded in each
pixel, for events in which 2 pixels pass the threshold in the same time stamp. The threshold
is evident where there are no counts between 0 and 5 keV on each axis. The red areas of
16,000 counts at 59.5 keV for both pixels corresponds to a 59.5 keV γ ray being detected in
one pixel in coincidence with noise of energy between ∼5 – 8 keV in another pixel.
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Figure A.5: 2D energy spectrum depicting the energy recorded in each pixel, for events in which 2
pixels pass the threshold in the same time stamp. Only data below 70 keV are included.
Following the application of the charge shared selection criteria, the ratio of charge shared
events to all γ-ray interactions for this data was determined to be 0.79%. This is the mini-
mum contribution of charge sharing as some events have been lost with the post processing
threshold. This methodology for quantifying charge sharing is not applicable with 131I, as
the possible energies for the recoil electron and scattered γ ray are 0 – 214.3 keV and 150.2 –
364.5 keV, respectively. The energies of the electron and scattered γ ray overlap as seen in
Figure A.6, therefore the charge shared events cannot be distinguished from Compton scatter
events, however it would be expected that the contribution of charge shared events would
increase for 131I. The relative cross sections for Compton scattering and photoelectric ab-
sorption interactions by a 59.5 keV γ ray are 0.116 cm2/g (2.13%) and 5.315 cm2/g (97.86%)
respectively, for a total attenuation cross section of 5.431 cm2. There is a large increase in
Compton scattering cross section for 131I 364.5 keV γ ray at 0.083 cm2/g (72.81%), with
0.031 cm2/g (27.16 %) for photoelectric absorption for a total attenuation cross section of
0.114 cm2/g [54].
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Figure A.6: Energies of a 131I 364.5 keV γ ray and electron after Compton scattering.
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B.1 DEPICT Collimator
Figures B.1a - c show CAD drawings of the top, cross section and bottom view of the custom-
designed high-energy parallel-hole collimator for DEPICT.
(a) (b) (c)
Figure B.1: (a) Top (b) cross section slice and (c) bottom view of the high-energy parallel-hole
tungsten collimator.
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B.2 Misalignment of Detector Modules
Figure B.2 shows the four individual CZT detector modules that make up the DMatrix
detector. The upper right module appears to be slightly misaligned with respect to the
other three modules. As the collimator was designed to have 484 holes, each matched to an
individual pixel, this misalignment means the collimator holes do not lie exactly above the
detector pixels and cause reduced counts in a portion of the pixels. The physical gap between
the modules is also evident.
Figure B.2: Slight misalignment of CZT detector modules.
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B.3 Uniformity Phantom
Figure B.3 shows a photograph of the uniformity phantom above the uncollimated DEPICT
system.
Figure B.3: A photograph of the uniformity phantom above the DEPICT detector.
B.4 Digital Imaging and Communications in Medicine
Digital Imaging and Communications in Medicine (DICOM) files are the standard for the
communication and management of medical imaging information and related data. Figure
B.4 shows an example of the information that is transmitted alongside medical images. It
includes information such as date and time, and smallest and largest pixel values.
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Figure B.4: MATLAB DICOM information of thyroid phantom measurement taken with Siemens
gamma camera.
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B.5 System Spatial Resolution with Scatter Setup
Figure B.5 shows a photograph of the 1 mm inner diameter line phantoms (capillary tubes)
placed on top of a 10 cm acrylic scattering block to measure the system spatial resolution
with scatter material.
Figure B.5: A photograph showing the DEPICT system with line phantoms placed on top of 10 cm
acrylic scattering block.
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